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1. summAry of performAnce of 
rApId dIAgnostIc tests for mAlArIA: 
wHo product testIng rounds 1–7 
1.1.  Introduction
WHO estimates that 3.2 billion people are at risk for malaria. 
In 2015, there were an estimated 212 million new cases (with 
an uncertainty range of 148 million to 304 million) and an 
estimated 429 000 deaths (with an uncertainty range of 
235 000 to 639 000). Approximately 90% of these deaths 
occurred in sub-Saharan Africa and just over 70% were 
of children under 5 years. Malaria remains endemic in 91 
countries and territories and while parasite-based diagnosis 
is increasing, national surveys between 2013 and 2015 
suggest approximately 31% of suspected malaria cases in 
sub-Saharan Africa were not confirmed with a diagnostic 
test, resulting in over-use of antimalarial drugs and poor 
disease monitoring (1). 
WHO recommends that malaria case management be based 
on parasite diagnosis in all cases (2). The use of antigen-
detecting rapid diagnostic tests (RDTs) is a vital part of this 
strategy, forming the basis for extending access to malaria 
diagnosis by providing parasite-based diagnosis in areas 
where good-quality microscopy cannot be maintained. The 
number of RDTs available and the scale of their use have 
increased rapidly over the past few years. However, limita-
tions of field trials and the heterogeneous nature of malaria 
transmission have limited the availability of the good-quality 
data on performance that national malaria programmes 
require to make informed decisions on procurement and 
implementation, and it is difficult to extrapolate the results 
of field trials to different populations and times. Therefore, 
in 2006, the WHO Special Programme for Research and 
Training in Tropical Diseases (TDR) and the Foundation for 
Innovative New Diagnostics (FIND) launched a programme 
to systematically evaluate and compare the performance of 
commercially available malaria RDTs. 
The results of WHO’s malaria RDT product testing have been 
published annually since 2009 and form the basis of the 
procurement criteria of WHO, other United Nations agencies, 
the Global Fund to Fight AIDS, Tuberculosis and Malaria, 
national governments and non-governmental organiza-
tions. The data have guided procurement decisions, which, 
in turn, have shifted markets towards better-performing 
tests (1) and are driving overall improvements in the quality 
of manufacturing. 
WHO’s malaria RDT product testing constitutes the laboratory 
evaluation component of WHO malaria RDT prequalification, 
but meeting WHO prequalification criteria has not previ-
ously been a requirement for a WHO recommendation on 
procurement. As of 1 January 2018, WHO prequalification, 
comprising a dossier and inspections of manufacturing 
sites as well as a laboratory evaluation, will determine the 
eligibility of malaria RDTs for procurement. Therefore, all 
manufacturers that submit products to Round 8 and future 
rounds will be required also to submit applications for WHO 
prequalification. 
RDT sales increased from 46 million in 2008 (before imple-
mentation of the product testing programme) to 320 million 
in 2013 (according to manufacturer sales data). In 2014, the 
number of diagnostic tests provided (RDTs and microscopy 
combined) in Africa exceeded the total number of courses 
of artemisinin-based combination therapy administered in 
Africa for only the second time. Since 2013, decreasing RDT 
sales in Asia have led to an overall decrease in global sales 
(270 million were sold globally in 2015); however, sales in 
Africa have continued to rise each year since 2008. By 2014, 
it was confirmed that all 91 countries with ongoing malaria 
transmission had adopted the WHO policy of testing before 
administering treatment. Despite these achievements, a 
large number of cases remain undiagnosed, particularly in 
the private sector, indicating that some gains are still to be 
made (1).
This summary presents an overview of the results of rounds 
4–7 of malaria RDT product testing and key concepts for 
understanding and using the results. It is published in 
conjunction with the release of the full report on round 7. 
With the exception of products that are no longer manu-
factured and/or are de-listed because of failure to comply 
with compulsory resubmission requirements, the results of 
all rounds of testing should be considered as a single data 
set. The separate, full reports of each round (3–8) should be 
consulted for further details of methods, product performance 
and interpretation of the results.
1.2.  the wHo product testing 
programme
The RDT evaluations summarized here were performed in 
collaboration by WHO, TDR, FIND, the United States Centers 
for Disease Control and Prevention (CDC) and other partners1. 
All companies that manufacture RDTs according to the ISO 
13485:2003 quality system standard were invited to submit 
1 See full reports of rounds 1–7 for lists of collaborating partners.
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products for evaluation. In each round of testing, products 
were evaluated against geographically diverse, cryopreserved 
Plasmodium falciparum and P. vivax clinical samples diluted 
to 200 and 2000 parasites/µL with consistently comparable 
concentration ranges of histidine-rich protein II (HRP2), 
Plasmodium lactate dehydrogenase (pLDH) and aldolase 
determined by quantitative enzyme-linked immunosorbent 
assay (ELISA) (Annex S1). In the first round of testing, 41 
products from 21 manufacturers were evaluated against 
prepared blood panels of cultured P. falciparum parasites, 
while 29, 50, 48, 42, 41 and 46 products from 13, 23, 27, 34, 
22 and 27 manufacturers were evaluated in rounds 2, 3, 4, 5, 
6 and 7, respectively. Of these 297 products, 293 progressed 
to testing against panels of patient-derived P. falciparum and 
P. vivax parasites and a parasite-negative panel. Thermal 
stability was assessed after 2 months of storage at elevated 
temperature and humidity, and a rudimentary assessment of 
ease of use was made. In round 6 and 7, specific observations 
of RDT anomalies were also systematically recorded. Many 
manufacturers have decided voluntarily to submit products to 
one or more rounds of testing, and, in round 5, a requirement 
was instituted to resubmit products for re-evaluation within 5 
years of original testing (Table S1). Of the 293 fully evaluated 
products in rounds 1–7, 31 have been evaluated twice, 21 
have been evaluated three times, two evaluated four times 
and three evaluated five times. Of the 202 unique products 
tested in the programme, 65 detect P. falciparum alone, 143 
detect and differentiate P. falciparum from non-P. falciparum 
malaria (either pan-specific or species-specific for P. vivax 
or P. vivax, ovale and malariae), 10 detect P. falciparum and 
non-P. falciparum malaria without distinguishing between 
them, and one product was designed to detect P. vivax 
only. Manufacturers submitted two lots of each product for 
evaluation. When the same products (9) were resubmitted 
in subsequent rounds of testing, the second set of results 
replaced those from the earlier round. Thus, the performance 
of some tests in the results below differs from that reported 
in rounds 1–6.
Of the 30 products due for compulsory retesting in round 7, 
five were submitted (Table S1). Round 3 products that were 
not resubmitted have been removed from the figures and 
tables in this summary performance document.
Product testing is part of a continuing programme of work 
to improve the quality of RDTs in use and to ensure reliable 
malaria diagnosis in areas where malaria is prevalent. The 
aim of the evaluation is to provide comparative data on 
the performance of the submitted production lots of each 
product. Since 2009, these data have guided procurement 
decisions by WHO, other United Nations agencies and national 
governments. 
WHO product testing has constituted the laboratory evalu-
ation component of the WHO prequalification process for 
malaria RDTs (10), which additionally includes a standard-
ized dossier review and a manufacturing site inspection to 
ensure safety, quality and performance comprehensively. 
WHO prequalification of in vitro diagnostics, established in 
2008, is used in all United Nations agencies to determine 
the eligibility for procurement of tests for HIV, hepatitis B 
and C and syphilis and by national authorities to complement 
their national regulatory approvals. WHO prequalification will 
determine the eligibility of malaria RDTs for procurement as 
of 1 January 20181. 
To facilitate this transition, manufacturers with products that 
currently meet procurement criteria and those submitting 
to future rounds of lab evaluations are required to submit 
applications to WHO prequalification. Only those products 
that meet WHO prequalification requirements by 31 December 
2017 will be eligible for WHO procurement. An eigth round 
of product testing started in February 2017. 
1.3.  panel detection score and 
other results of the evaluation
The results (summarized in Figs S1–S3 and Tables S2 and S3) 
provide comparative data on two lots of products against a 
panel of parasite samples diluted in blood to a low density 
(200 parasites/µL) and a higher density (2000 parasites/µL). 
The former is well below the mean parasite density found in 
many populations with endemic malaria and is considered 
close to the threshold that must be detected in order to 
reliably identify clinical malaria in many settings (11). For the 
purposes of this report, the main measure of performance 
is the panel detection score (PDS); for each RDT evaluated, 
the PDS is measured separately at the lower and the higher 
parasite densities. The summary figures also show the false-
positive rates against blood samples containing no malaria 
parasites or known markers of other diseases and the rate 
of invalid results. 
The PDS is the percentage of malaria samples in the panel 
that give a positive result in two RDTs per lot at the lower 
parasite density or by a single RDT per lot at the higher 
parasite density. As each sample is tested with RDTs from 
two lots, for a sample to be positive at the lower parasite 
density, it must show a positive result in four tests (two RDTs 
per lot for two lots); at the higher parasite density, it must 
show a positive result in two tests (one RDT per lot for two 
lots). Thus, the PDS is a combined measure of positivity rate 
incorporating inter-test and inter-lot consistency. As all tests 
performed on each sample must show a positive result for 
the sample to be considered positive, the PDS for a given RDT 
will usually be lower than a simple positivity rate per panel, 
measured by comparing the number of positive tests among 
all tests performed per panel. The PDS is also different from 
clinical sensitivity, which is the ability of the test to detect 
malaria infection in a given population of infected patients. 
Boxes 1 and 2 illustrate how the PDS is calculated and how 
it differs from a simple positivity rate for all samples tested 
and from clinical sensitivity in a population. 
The PDS for a given RDT is different from the clinical sensi-
tivity of that RDT (also called the true positive rate), which 
is a measure of the proportion of people known to have the 
disease who test positive for it. The sensitivity of malaria 
RDTs is highly dependent on local conditions, including the 
parasite density in the population; it therefore varies among 
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Box 1: Example calculation of panel detection score and positivity rate for product A against a sample density  
of 200 parasites/µL
The first reading was at the minimum time specified by the manufacturer; the second reading was up to 30 min latera. A sample is 























Test 1 Test 2
Detected if  
4 positive  
first readings
a second reading results are for internal use only
P. falciparum  
sample a b c d
1 + - + + Sample  NOT detected
2 + - - + Sample  NOT detected
3 + + + + Sample  detected
In this example, only one of three samples was positive all four times  
it was tested; the PDS is therefore 1/3 = 33%. 
The positivity rate is calculated as the percentage of all tests of a particular product that returned a positive test result at the 
manufacturers’ recommended minimum reading time when tested against a P. falciparum or P. vivax sample.
In the above example, the positivity rate is: 9/12 = 75%. 
The positivity rate is always greater than the PDS, except when the PDS and the positivity rate are both 100%.
Box 2: Performance measures in WHO product testing and in field settings: PDS versus clinical sensitivity
WHO Malaria RDT Product Testing
Primary performance measure: PDS indicates which 
products are likely to be more sensitive in the field, 
particularly in populations with low‐density infections.
200 parasites/μL
2000 parasites/μL
Reference panels: two fixed parasite densities allows 
discrimination in RDT performance. 
Malaria endemic setting
Performance measure: sensitivity is the proportion of the popu-
lation studied who have malaria for whom the test is positive.
- high, moderate, low transmission
- immune, non-immune
- vulnerable groups
Patients have varying parasite density. Most RDTs for 
P. falciparum and P. vivax perform well for a parasite density 
> 2000 parasites/μL, but clinically significant densities 
< 200 parasites/μL may be missed. The “overall” test performance 
will nevertheless be classified as very good in a field evaluation. 
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of immunity affects the parasite density at which they exhibit 
symptoms that warrant a diagnostic test. Where transmission 
rates are low, the parasite densities in people with symptoms 
of malaria are likely to be low, and tests will be less sensitive. 
Test performance at 200 parasites/µL is therefore particularly 
important. The results in this report show the comparative 
performance of RDTs and indicate which products are likely 
to be more sensitive in the field, particularly in populations 
with low-density infections. 
In general, as countries reduce the prevalence of malaria 
and even move towards malaria elimination, detection of 
low parasite densities becomes increasingly important in 
case management. As the high PDS at 2000 parasites/µL 
indicates, the sensitivity of many of these products is similar 
in populations with higher parasite densities; therefore, it is 
not possible to discriminate RDTs with superior performance.
An important caveat to estimating field sensitivity from the 
PDS provided in this report is that the panels used include 
only parasites known to express the target antigens. While 
non-expression of the target antigens has not been recorded 
for aldolase or pLDH, it is known that parasites that infect 
people in some areas of South America (Peru, Colombia, 
Brazil), India and Africa (Eritrea, Ghana, Rwanda) do not 
express HRP2 (12–13 , 33-34). In areas where HRP2-deleted 
parasites exist, tests for HRP2 will have greatly reduced 
sensitivity or be incapable of detecting P. falciparum. In such 
populations, only tests for pLDH or aldolase in P. falciparum 
parasites will be effective.
Heat stability (summarized in Table S3) is vital to maintaining 
the sensitivity of tests in the field. As a result, for procure-
ment, careful consideration must be given to ensure that 
the products to be used in areas with high temperatures 
of transport and storage have demonstrated stability in 
the product testing programme. Requirements vary among 
countries; for example, if tests are to be deployed in areas 
where temperatures rarely rise above 30°C, less emphasis 
is needed on stability at high temperatures than on other 
aspects of quality. 
Ease-of-use requirements depend on the extent of training 
and the work environment of the users. Particularly in 
primary health care settings, the simpler the test, the easier 
it will be to avoid errors in preparation and interpretation. 
Certain anomalies resulting from defects in production lots 
or RDT degradation may affect the running of the test or 
interpretation and may warrant a field safety notice and 
corrective action.
To encourage manufacturers to meet international standards 
and best practice in the packaging and labelling of malaria 
RDTs, with the goal of ensuring better, more consistent ease 
of use, WHO and partners have made recommendations 
for the instructions for use and labelling of malaria RDTs 
(14). Evaluation of adherence to the recommendations was 
introduced in round 7. 
Detailed results can be found in the report of each evalua-
tion (3–8) and at http://www.who.int/malaria/publications/
diagnostic_testing/en/ (accessed 8 March 2017). 
1.4.  summary of outcomes
Laboratory-based evaluation provides a comparative, stand-
ardized measure of RDT performance for distinguishing 
between well and poorly performing tests to serve as a basis 
for procurement decisions by malaria control programmes 
and to guide United Nations procurement policy.
In round 7, the proportion of tests that achieved a PDS ≥ 75% 
at a density of 200 parasites/µL is slightly lower than in round 
6 for both P. falciparum (87.0%%) and P. vivax (70.0%).
Several RDTs in the seven rounds of testing consistently 
detected malaria at a low parasite density (200 parasites/µL), 
had low false-positive rates, are stable at tropical tempera-
tures, are relatively easy to use and can detect P. falciparum 
or P. vivax infections or both. 
Although the performance of the products varied widely 
at low parasite density (200 parasites/µL) in round 7, all 
products had a high rate of detection of P. falciparum at 
2000 parasites/µL (PDS of 100%), as did the majority of 
products for P. vivax at 2000 parasites/µL. 
In all except two of the RDTs submitted to round 7, the HRP2 
antigen was used to detect P. falciparum, either alone (41 
products) or with Pf-pLDH (3 products). In the two exceptions, 
Pf-pLDH was used alone. Of the five products that detected 
Pf-pLDH, two combined Pf-pLDH with HRP2 in the same test 
line, one had dual test lines for detecting P. falciparum (one 
HPR2 and one Pf-pLDH test line), and two had only Pf-pLDH. 
While the dual test line product performed well overall, the 
line for detecting Pf-pLDH performed considerably less well 
than the HPR2-detecting test line at 200 µL, with a PDS 
of 38%. The PDS of the two products with Pf-pLDH alone 
for detecting P. falciparum at 200 parasites/µL were 75% 
and 73%. Thus, after seven rounds of testing, the choice 
of well-performing pLDH-based P. falciparum tests and of 
pan-only tests remains limited. 
The test performance of lots in round 7 varied only 
slightly, with an average difference in positivity rates of 
1.5 percentage point (range, 0–4.5%) and 1.0 percentage 
point (range, 0–3.5%) when tested against 200 parasites/µL 
wildtype P. falciparum and P. vivax, respectively (Tables 
A3.1 and A4.1), a pattern also seen in round 6. In previous 
rounds, however, wide variation was found, indicating the 
advisability of testing lots after purchase and before use in 
the field. The frequency of anomalies that can interfere with 
test interpretation was recorded for the first time in round 6. 
In round 7, one to five anomalies were found with 33 of the 
46 products (Annex S2, Table 8, Fig. 30). Incomplete clearing 
and a red background were the most common anomalies, 
seen in 48% and 24% of products, respectively. The next 
most common anomalies were incomplete migration, failed 
migration and a red background obscuring the test lines, in 
15%, 11% and 11% of products, respectively. Most products 
(44/46) had anomalies in < 1% of the tests; two products 
had anomalies in 1.4% of products (Table 8). Overall, fewer 
types and a lower frequency of anomalies were seen in round 
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All except one of the RDTs evaluated in round 7 were in 
cassette format; the exception was in dipstick format. 
Only 5 of the 30 RDTs due for compulsory resubmission 
were submitted for retesting. All met the WHO procurement 
criteria on initial testing. Two products (one for P. falciparum 
only and one combination RDT) scored higher in re-testing, 
with percentage point increases of 7 and 6, respectively, in 
the PDS at 200 µL against P. falciparum and an increase of 
6 percentage points against P. vivax for the combination 
RDT. Three re-tested products (one P. falciparum only, two 
combination RDTs) scored lower than in their initial testing, 
with percentage point decreases of 7, 8 and 16 in the PDS at 
200 µL against P. falciparum and a decrease of 91 percentage 
points (to a score of zero) in the PDS against P. vivax for the 
combination RDT. Of these three products with diminished 
performance, two no longer meet the criteria for procure-
ment. Four products showed decreased false-positive rates 
on re-testing, whereas one had an increase from 0% to 5% 
at 200 µL. 
1.5.  de-listing of products in 
summary report
Products that are due for compulsory resubmission (every 
5 years) but are not resubmitted are removed from the 
summary results listing (Tables S2 and S3) and the online 
interactive database (15) and are featured only in the full 
round-specific product testing report. They are also not 
eligible for WHO procurement. Furthermore, a product is 
de-listed if WHO is notified by the manufacturer that its 
production has been discontinued. To date, 72 products have 
been delisted (Table S4). 
1.6.  How product testing results 
can inform rdt procurement 
and use
Accurate diagnosis is vital to good malaria case manage-
ment, whether based on microscopy or on RDTs. The results 
of this report should be used to make a short list of RDTs 
for procurement for use in settings where good microscopy 
is not available or appropriate. Box 3 lists WHO’s minimum 
criteria for RDT selection, and Annex S3 provides a step-by-
step approach to selecting an RDT, taking into consideration 
local malaria transmission and illness where the tests will be 
used (e.g. Plasmodium spp., target antigen, parasite densities, 
climate) and other important considerations, including ease 
of use in the field (Annex S2), training or retraining require-
ments and lot testing.1
The results in Table S2 indicate WHO prequalification status 
and are colour-coded to reflect achievement of WHO perfor-
mance requirements for RDT procurement. A web-based tool 
that allows filtering of product testing results by various 
parameters to assist in selecting products with the perfor-
mance characteristics most suitable for a country’s health 
programme is available and is maintained by FIND (15). 
This online database has been updated to allow filtering 
of results by RDT procedural characteristics, such as blood 
volume requirements, number of buffer drops and time to a 
result. This will allow identification of products with similar 
procedures so that, when product replacement is required, 
another product can be selected with the same or a similar 
protocol. Use of similar products may reduce the need for 
user retraining and reduce user error. 
The results in the product testing reports are presented by 
product, which are described by their name and “product 
code”. The same RDT may be sold in a variety of product 
configurations, such as single or multi-kits, the number of 
tests per box, with or without certain accessories, and they 
are assigned a series of distinct product codes on this basis. 
The reports lists the precise name and product code as 
provided by the manufacturer for testing. Procurers should 
contact the manufacturer for a list of product configurations 
before purchase.
Comprehensive guidance on several aspects of procure-
ment can be found in Recommended selection criteria for 
procurement of malaria rapid diagnostic tests (16), published 
as a WHO information note in 20162 and Good practices for 
selecting and procuring rapid diagnostic tests for malaria (16). 
Guidance on implementation is provided in Universal access 
to malaria diagnosis (17). 
1  The WHO-FIND malaria RDT evaluation programme provides lot-testing 
capacity in two regional laboratories free of charge. Information on 
the programme and how to access it can be found at: https://www.
finddx.org/malaria-rdt-qa/ (accessed 8 March 2017).
2  http://www.who.int/malaria/publications/atoz/rdt-selection-criteria.
pdf (accessed 3 April)
Box 3: WHO selection criteria for the procurement of RDTs
Products should be selected in line with the following set of criteria, based on the results of the assessment of the WHO Malaria 
RDT Product Testing Programme:
(A) For the detection of Plasmodium falciparum (Pf) in all transmission settings the panel detection score (PDS) against Pf samples 
should be at least 75% at 200 parasites/μl.
(B) For the detection of Plasmodium vivax (Pv) in all transmission settings the panel detection score (PDS) against Pv samples 
should be at least 75% at 200 parasites/μl.
(C) The false positive rate should be less than 10%.
(D) The invalid rate should be less than 5%.
Only products meeting performance criteria outlined in A,B,C and D are recommended for procurement
As of 1 January, 2018 WHO procurement recommendations for malaria RDTs will change to require WHO prequalification designation1.
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1.7.  product testing and wHo programme for prequalification of 
diagnostics and medical devices
In the WHO programme for prequalification of diagnostics 
and medical devices, the results of product testing are used 
as the laboratory evaluation component of the prequalifica-
tion process for malaria RDTs. These data are used to set 
priorities for dossier review and inspection. As of 1 January 
2018, WHO prequalification will become a requirement for 
WHO procurement. Therefore, manufacturers are strongly 
encouraged to apply.1 Prequalified RDTs are listed in summary 
tables and at http://www.who.int/diagnostics_laboratory/
evaluations/PQ_list/en/ (accessed 8 March 2017).
1 http://www.who.int/malaria/news/2016/rdt-procurement-criteria/en/
Figure S1: Malaria RDT performance in phase 2 of rounds 4–7 against wild-type (clinical) samples containing P. falciparum  
at low (200) and high (2000) parasite density (parasites/µL) and clean-negative samples
a Panel detection score - A sample is considered detected only if all RDTs from both lots read by the first technician, at minimum specified reading time, are positive. 
b Clean-negative - blood samples from healthy volunteers with no known current illness or blood abnormality. 
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Figure S1: Malaria RDT performance in phase 2 of rounds 4–7 against wild-type (clinical) samples containing P. falciparum  
at low (200) and high (2000) parasite density (parasites/µL) and clean-negative samples
a Panel detection score - A sample is considered detected only if all RDTs from both lots read by the first technician, at minimum specified reading time, are positive. 
b Clean-negative - blood samples from healthy volunteers with no known current illness or blood abnormality. 
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Figure S2: Malaria RDT performance in phase 2 of rounds 4–7 against wild-type (clinical) samples containing  
P. vivax at low (200) and high (2000) parasite density (parasites/µL) and clean-negative samples
a Panel detection score - A sample is considered detected only if all RDTs from both lots read by the first technician, at minimum specified reading time, are positive. 
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Figure S2: Malaria RDT performance in phase 2 of rounds 4–7 against wild-type (clinical) samples containing  
P. vivax at low (200) and high (2000) parasite density (parasites/µL) and clean-negative samples
a Panel detection score - A sample is considered detected only if all RDTs from both lots read by the first technician, at minimum specified reading time, are positive. 
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Figure S3: Panel detection score of malaria combination RDTs meeting WHO procurement criteria for false-positive 
and invalid rates, in phase 2 of rounds 4–7 against wild-type (clinical) samples containing P. falciparum and P. vivax 
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  1 Core™ Malaria Pan Pf - MAL - 190024
  2 BioTracer™ Malaria P.f/PAN Rapid Card - 17012
  3 SD BIOLINE Malaria Ag P.f/Pan - 05FK60
  4 Is It... Malaria Pf PAN - MPFPAN050
  5 CareStart ™ Malaria Screen RDT - RMAM-05071
  6 Aspen® Malaria Ag Pf/Pv - AS0060
  7 careUS™ Malaria Combo Pf/Pv (HRP2/pLDH) Ag - RMV-M05082
  8 NanoSign Malaria pf/pan Ag 3.0 - RMAP10
  9 Humasis Malaria P.f/P.v Antigen Test - AMFV-7025
10 RAPID 1-2-3® HEMA CASSETTE MALARIA PF/PV TEST - MAL-PFV-CAS/25(100)
11 Rapid 1-2-3 HEMA® CASSETTE MALARIA PF/PAN - MAL-PF/Pan-CAS/25
12 One Step Malaria P.F/P.V Test (Cassette) - 523352
13 ADVANCED QUALITY™ ONE STEP Malaria (p.f/p.v.) Tri-line Test - ITP11003-TC25
14 SD Bioline Malaria Ag P.f/P.v - 05FK80
15 RapiGEN BIOCREDIT Malaria Ag Pf/Pv (HRPII/pLDH) - C40RHA25
16 One Step Malaria HRP2/pLDH (P.f/P.v) Test - W056-C
17 NG-Test MALARIA Pf/Pan (pLDH) - NGB-MAL-W23-005
18 BIOCREDIT Malaria Ag Pf/Pan (HRPII/pLDH) - C32RHA25
19 CareStart ™ Malaria Pf/Pv (HRP2/pLDH) Ag Combo RDT - RMVM-03091
20 BioTracer™ Malaria P.f/P.v Rapid Card - 17412
21 PALUTOP +4 optima® - 5499
22 KHB® Malaria Ag P.f/P.v Rapid Test - KH-R-07-50
23 SD BIOLINE Malaria Ag Pf/ Pan - 05FK66
24 CareStart ™ Malaria Pf/PAN (HRP2/pLDH) Ag COMBO RDT - RMRM(U)-XXX7X
25 Humasis Malaria P.f/Pan Antigen Test - AMAL-7025
26 DIAQUICK Malaria P.f/Pan Cassette - Z11200CE
27 NG-Test MALARIA Pf/Pan (pLDH) - NG-MAL-W23-001
28 Malaria PV/PF (pLDH/HRP2) Antigen Test- Inf-72
29 ATOMORAPID™ MALARIA (PF/PAN) - MMAL01
30 HiSens Malaria Ag P.f/P.v Combo Card - HR3123
31 HiSens Malaria Ag P.f/VOM Combo Card - HR3323
32 CareStart ™ Malaria Pf/Pv (HRP2/pLDH) Ag. Combo RDT - RMVM-05072
33 Malaria Pf/Pan One Step Rapid Test - RT 20222
34 Humasis Malaria P.f/Pan Antigen Test - ANMAL-7025
35 Malaria Pf/Pv Rapid Test - GCMAL(pf/pv)-402a
36 Trusty™ Malaria Antigen P.f./p.v. test - A03-12-322
37 Asan Easy Test® Malaria Pf/Pan Ag - AM4650-K
38 Is ItÖ Malaria Pf/Pv Device - AL030
39 Humasis Malaria P.f/P.v Antigen Test - ANMIV-7025
40 Advanced Quality™ Rapid Malaria Test (Pf/Pan) - ITP11005
41 FirstSign™ ParaView (Pan+Pf) - 2101CB-25
42 Vikia® Malaria Ag Pf/Pan - 412499
43 Malaria Pf/PAN Test - PROMALPFV001
44 ABON™ Plus Malaria P.f/Pan Rapid Test Device (Whole Blood) - IMA-T402
45 Alere Trueline™ - Rapid test kit for Malaria Ag Pf/Pan (HRP-II/pLDH) - 05FK60AI-40
46 Biosynex® Malaria Pf/Pv - 0581_K25
47 SD Bioline Malaria Ag P.f/P.f/P.v - 05FK120
48 Rapid Test Kit for Malaria Ag Pf/Pv-Alere Trueline Malaria Ag Pf/Pv - 11108191040
49 Biosynex® Malaria Pf/Pan - 0584_K25
50 First Response® Malaria Ag. pLDH/HRP2 Combo Card Test - I16FRC
51 Malaria Pf (HRPII)/ PV (PLDH) Antigen Detection Test Device - GM006
52 First Response® Malaria Ag Pf/Pv Card Test - PI19FRC
53 ICT MALARIA DUAL TEST - ML03
54 ParaHIT - Total Ver. 1.0 (Device) - 55IC204-10
55 Advantage Malaria Pan + Pf Card - IR231025
56 CareStart ™ Malaria PAN (pLDH) Ag RDT - RMNM(U)-XXX7X
57 Maleriscan® Malaria Pf/PAN (Pv, Pm, Po) 3 Line Antigen Test - MAT-PF/PAN-50
58 GenBody™ Malaria Pf/Pan Ag - MALAG100
59 BIONOTE MALARIA P.f & Pan Ag Rapid Test Kit - RG19-08
60 First Response® Malaria Ag. pLDH/HRP2 Combo Card Test - PI16FRC
61 FalciVax™ - Rapid Test for Malaria Pv/Pf - 503010025
62 Parascreen® - Rapid Test for Malaria Pan/Pf - 503030025
63 QuickProfile™ Malaria Pf/Pan Test - 71063
64 QuickProfile™ Malaria Pf/Pv Antigen Test - 71050
65 EzDx™ Malaria Pan/Pf Rapid test detection Kit - RK MAL 001
66 OnSite Malaria Pf/Pan Ag Rapid Test - R0113C
67 One Step Test for Malaria Pf/Pv Ag MERISCREEN Malaria Pf/Pv Ag - MFLRPD-02
68 Coretests® One Step Malaria Pf/Pv Ag Test Device - B42-21/B42-22
69 Advantage Pan Malaria Card - IR013025
70 Meriscreen Malaria Pf/Pan Ag - MHLRPD-01
71 One Step Malaria P.f/Pan Whole Blood Test - W62-C
72 ParaHIT - Total Ver. 1.0 (Dipstick) - 55IC203-10
73 EzDx™ Malaria Pv/Pf Rapid Malaria antigen detection test - RK MAL 003
74 BIOCREDIT Malaria Ag Pf/Pv (pLDH/pLDH) - C60RHA25
75 OnSite Malaria Pf/Pv Ag Rapid Test - R0112C
76 RightSign™ Malaria P.f./Pan Rapid Test Cassette - IMPN-C52
77 CareStart ™ Malaria Pf/PAN (pLDH) Ag RDT - RMLM-05071
78 MeDiPro Malaria Ag HRP2/pLDH Combo - IR-0051K
79 AllTest™ Malaria P.f./Pan Rapid Test Cassette - IMPN-402
80 Adv Dx™ Malaria Pan/Pf Rapid Test Detection Kit - RKMAL016
81 Genedia® Malaria P.f/Pan Ag Rapid Test- 20-0146-01
82 ACCUCARE ONE STEP MALARIA Pf/Pan Antigen Test - MAGC 25
83 Malaria pf (HRP II)/PAN (pLDH) Antigen Detection Test Device - 1-13-101-1
84 ParaHIT® fV Rapid test for P. falciparum and P. vivax Malaria - Device - 55IC402-50
85 AZOG Malaria pf (HRPII)/pf (LDH)/ (PAN-LDH) Antigen Detection Device - MFV-124F
86 AZOG hCG Malaria Detection Test Device - MPT-124
87 Malaria Pf./Pan Antigen (MAL Pf/Pan) Test Kit - A03-18-322
88 Malaria pf (HRP II) / pv (pLDH) Antigen Detection Test Device - 1-13-101-3
89 Malaria pf (pLDH) / PAN-pLDH Test Device - MFV-124
90 Malaria Pf/Pv - GM002
91 Malaria Pf/ PAN - GM004
92 Advantage Mal Card - IR221025















1110 Malaria rapid diagnostic test perforMance – summary results of WHo product testing of malaria rdts: rounds 1-7 (2008-2016)
Table S1: Product resubmissions: WHO malaria RDT product testing rounds 1—7





CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag Combo RDT RMVM-05072a 2, 4, 7
CareStart™ Malaria HRP2/PLDH (Pf/VOM) COMBO RMWM(U)-XXX7Xb 2, 4
CareStart™ Malaria Pf (HRP2) Ag RDT RMOM(U)-XXX7Xc 1 5
CareStart™ Malaria HRP2/pLDH (Pf/PAN) Combo RMRM(U)-XXX7X 1 5
CareStart™ Malaria  PAN (pLDH) Ag RDT RMNM(U)-XXX7Xe 1 5
CareStart™ Malaria Pf (HRP2/pLDH) Ag RDT RMPM(U)-XXX7Xf 2 6
CareStart™ Malaria Pf/PAN (pLDH) Ag RDT RMLM-05071g 3 7
CareStart™ Malaria Screen RDT RMAM-05071h 3 7
Advy Chemical Pvt. Ltd. (Affiliate of 
Bharat Serums & Vaccines Ltd. ) EzDx™ Malaria Pan/Pf Rapid Test Detection Kit RK MAL 001 4, 5, 6
ARKRAY Healthcare Pvt. Ltd.i
ParaHIT® - f (Device)j 551C104-50 3 7
ParaHIT® - f (Dipstick)k 551C103-50 3 7
ASAN Pharmaceutical Co., Ltd Asan Easy Test® Malaria Pf/Pan Ag AM4650-K 5, 7
AZOG
Malaria pf (HRP II) / (PAN-LDH) Antigen Detection Test Devicel MFV-124R 1, 3
Malaria pf (pLDH) / PAN-pLDH Test Device MFV-124 3, 5
Bhat Bio-Tech India (P) Ltd. Maleriscan® Malaria Pf/PAN (Pv, Pm, Po) 3 Line Antigen Test MAT-PF/PAN-50 4, 5
Bioland NanoSign Malaria Pf/Pan Ag RMAP10 3, 4
Bionote, Inc.
BIONOTE MALARIA P.f. Ag Rapid Test Kit RG19-11 3, 6
BIONOTE MALARIA P.f & Pan Ag Rapid Test Kit RG19-08 3, 6
Biosynex IMMUNOQUICK® MALARIA falciparum 0502_K25 1 5
Bio Focus Co., Ltd. BioTracerTM Malaria P.f/PAN Rapid Card 17012 5, 6, 7
Blue Cross Bio-Medical (Beijing) Co., Ltd.
One Step Malaria Pf Test (cassette) 522352 2, 3, 4
One Step Malaria P.F/P.V Test (Cassette) 523352 4, 5
CTK Biotech, Inc.
Onsite Pf Ag Rapid Test R0114C 2, 3, 6
Onsite Malaria Pf/Pan Malaria Ag Rapid Test R0113C 2, 3, 4, 5, 6
Onsite Malaria Pf/Pv Ag Rapid Test R0112C 2, 3, 4, 6
DiaMed - A Division of Bio-Rad OptiMAL-IT 710024 1, 3
Guangzhou Wondfo Biotech Co. Ltd.
Wondfo One Step Malaria Pf/Pan Whole Blood Test W56-C 1, 3
One Step Malaria P.f/P.v Whole Blood Test W056-C 5, 6, 7
One Step Malaria P.f Testm W37-C 2, 3, 4, 6, 7
Humasis Co., Ltd. Humasis Malaria Pf/Pan Antigen Test AMAL-7025 4, 5
ICT INTERNATIONAL
ICT Malaria Combo Cassette Test ML02 1, 3, 4
ICT Malaria Pf Cassette Test ML01 1, 3 7
ICT Malaria Dual Test ML03 3, 5, 7
InTec Products, Inc.
Advanced Quality™ One Step Malaria Pf Test ITP11002TC1/TC40 1, 3, 7 5
Advanced Quality ™One Step Malaria  (Pf/Pv) Tri-line Test (whole blood) ITP11003 TC40 3, 6, 7
J.Mitra & Co. Pvt. Ltd.
Advantage Pan Malaria Card IR013025 1 5
Advantage Mal Card IR221025 1 5
Advantage P.f Malaria Card IR016025 1 5
Lumiquick Diagnostics Inc. QuickProfileTM Malaria Pf/Pv Antigen Test 71050 6, 7
Orchid Biomedical Systems
Paracheck® Pf Device - Rapid test for P. falciparum Malaria (Ver. 3)n 30301025 1, 3, 4
Paracheck® Pf Dipstick - Rapid test for P. falciparum Malaria (Ver.3)n 30302025 1, 3, 4
Premier Medical Corporation Ltd. 
First Response® Malaria Ag Combo (pLDH/HRP2)o I16FRC25 1, 2, 5
First Response Malaria Ag P. falciparum(HRP2) Card Test I13FRC25 1 5
RapiGEN Inc. BIOCREDIT Malaria Ag Pf/Pan (HRPII/pLDH) C30RHA25 5, 6, 7
SSA Diagnostics & Biotech Systems diagnosticks- Malaria (Pf)Cassette WB KMFC6001 2, 5
Standard Diagnostics Inc. 
SD BIOLINE Malaria Ag 05FK40 1, 3
SD BIOLINE Malaria Ag Pf/Pan 05FK60 1, 3, 5
SD BIOLINE Malaria Antigen 05FK50 1 5
SD Bioline Malaria Ag P.f (HRP2/pLDH) 05FK90 3, 6
SD Bioline Malaria Ag P.f/P.v 05FK80 2 6
Unimed International Inc. FirstSign™ - ParaView (Pan+Pf) Malaria Test 2101 CB-25 2, 4
Vision Biotech (Pty) Ltd / Orgenics   
(Alere Healthcare (Pty) Ltd subsidaries)
Malaria Rapid Combo/Clearview® Malaria Combo VB11p 1, 3
Malaria Rapid Pf /Clearview ®Malaria Pf VB01 1, 3, 5
Malaria Rapid Dual/Clearview® Malaria Dual Test Device VB20p 1, 3, 5
Zephyr Biomedical Systems
Malascan™ Device - Rapid test for Malaria Pf/Pan 50402025 1, 3
Parabank™ Device - Rapid test for Malaria Pan 50301025 1, 3
Parascreen™ Device -Rapid test for Malaria Pan/Pf 50310025; 503030025 (rd 6) 1, 3, 4, 5, 6
Falcivax Rapid Test for Malaria Pv/Pf (device) 50300025; 503010025 (rd 6) 2, 4, 6
* The product code corresponds to a specific configuration of the RDT, kit components and accessories. Therefore, changes to this configuration including the quantity of 
tests, the contents or the manufacturing site are denoted by a different product code. Often this involves the end portion of the product code; however, the manufacturer 
should be contacted for full details.
a Previously listed with product code G0161 for the Access Bio Inc product. Previously co-listed with G0161-ET, the equivalent Access Bio Ethiopia product. Access Bio 
Ethiopia products are now listed as separate products from separate manufacturers and not considered resubmissions.
b Previously listed with product code G0171 for the Access Bio Inc product. Previously co-listed with G0171-ET, the equivalent Access Bio Ethiopia product. Access Bio 
Ethiopia products are now listed as separate products from separate manufacturers and not considered resubmissions.
c Previously listed with product code G0141 for the Access Bio Inc product. Previously co-listed with G0141-ET, the equivalent Access Bio Ethiopia product. Access Bio 
Ethiopia products are now listed as separate products from separate manufacturers and not considered resubmissions.
d Previously listed with product code G0131/G0131-ET
e Previously listed with product code G0111
f Previously listed with product code G0181/G0181-ET 
g Previously listed with product code G0121
h Previously listed with product code G0231
I Arkray Healthcare Pvt. Ltd. was formerly Span Diagnostics Ltd.
j  New product codes have been in place since round 3, the previous code was 55IC102-10.
k New product codes have been in place since round 3, the previous code was 55IC101-10.
l Round 1 product name error : published -  Malaria Pf (HRPII)/pv-LDH) Antigen Detection Test Device  Code ; corrected product name:  Malaria Pf (HRPII/PAN-LDH) 
Antigen Detection Test Device Code. No change in product code.
m In round 2, product did not pass phase 1, therefore results do not feature in summary tables. 
n Ver.3 was introduced after round 1
o Error in WHO Malaria RDT product testing: round 1 report:  product code (II6FRC30) should have been ( I16FRC ), as in round 2
p New company acquisition (Alere™), therefore change in  product branding and catalogue numbers; VB011 to VB11 and VB020 to VB20. Manufacturer confirmed compliance 
with product definition. 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2120 Malaria rapid diagnostic test perforMance – summary results of WHo product testing of malaria rdts: rounds 1-7 (2008-2016)
Table S4: Products evaluated during rounds 1-7 that have been removed from summary results listings 
Manufacturer Product name Product code
Amgenix International, Inc.
OnSight™ - Malaria Pf Test 511-25-DB
OnSight™ - ParaQuick-2 (Pv,Pf) Malaria Test 537-25-DB
OnSight™ - PanScreen (Pan) Malaria Test 539-25-DB
OnSight™ - ParaQuick (Pan, Pf) Test 536-25DB
Abon Biopharm (Hangzhou) Co. Ltd. (Iverness Medical) ABON Malaria Pan/P.f.Rapid Test Device (whole blood) IMA-B402
Access Bio, Inc. CareStart™  Malaria/Pregnancy (HRP2/pLDH/ HCG) RRHM(U)-XXX7Xa
Access Bio Ethiopia
ParaCare Malaria HRP2/pLDH (Pf/Pv) COMBO G0161
ParaCare Malaria HRP2/pLDH (Pf/VOM) COMBO G0171
ACON Biotech (Hangzhou) Co. Ltd Surestep™ Malaria Pf/Pan Rapid Test Device (Whole Blood) IMA-T402
Acon Laboratories, Inc Malaria Plasmodium falciparum Rapid Test Device (Whole Blood) IMA-402
AZOG, Inc 
Malaria pf (HRP II) / pv (pLDH) Antigen Detection Test Device MFV-124V
Malaria pf (HRP II) / (PAN-LDH) Antigen Detection Test Device MFV-124R
Bhat Bio-Tech India (P) Ltd Maleriscan® Malaria Pf/Pv MAT-50
Bioland, Ltd
Nano Sign Malaria Pf Ag RMAF10
NanoSign Malaria Pf/Pv Ag RMAD10
BioNote,Inc. BIONOTE MALARIA P.f&P.v Ag Rapid Test Kit RG19-12
Biosynex
IMMUNOQUICK CONTACT falciparum 0519K25
Immunoquick Malaria +4 0506_K25
IMMUNOQUICK CONTACT Malaria +4 0525K25
Core Diagnostics
Core™ Malaria Pf MAL-190020
Core™ Malaria Pv/Pf Mal-190022
Core™ Malaria Pan/Pv/Pf Mal-190026
CTK Biotech, Inc. OnSite Pf Ag Rapid Test R0114C
DiaMed - A Division of Bio-Rad OptiMAL-IT 710024
Dima • Gesellschaft für Diagnostika mbH Malaria Pan test MAL-W23N-001
Diagnostics Automation/Cortez Diagnostics Inc. Malaria P.F/Vivax 172110P-25
Guangzhou Wondfo Biotech Co. Ltd. One Step Malaria P.f./Pan Whole Blood Test W56-C
HBI Co., Ltd.
HiSens Malaria Ag P.f/P.v Card HR2823
HiSens Malaria Ag Pf/Pv (HRP2/pLDH) Card HR2923
HiSens Malaria Ag Pf HRP2 Card HR3023
Human GmbH
Hexagon Malaria 58051
Hexagon Malaria Combi 58024
ICT INTERNATIONAL
ICT Malaria Combo ML02
ICT MALARIA P.F. ML04
IND Diagnostic Inc.
One Step Malaria Antigen Strip 820-1
IND ONE STEP MALARIA ANTIGEN P.f/Pan TEST 535-10
IND ONE STEP MALARIA ANTIGEN P.f 535-11
Innovatek Medical Inc. Quickstick Malaria Antigen Test
Inverness Medical Innovations, Inc. Binax Now  Malaria IN660050
J. Mitra & Co. Pvt. Ltd. Advantage Malaria Card IR211025
Medical Diagnostech (Pty) Ltd MD Malaria Pf/Pan(pLDH) test MDMALLDH001
Medisensor, Inc.
Medisensor Malaria HRP2/pLDH (Pf/Pv) COMBO M161
Medisensor Malaria HRP2/pLDH (Pf/VOM) COMBO M171
Orgenics Ltd. (Inverness Innovations) Clearview®  Malaria pLDH 70884025
Orgenics Ltd.(IS) Clearview® Malaria Dual VB20
Premier Medical Corporation Ltd. First Response® Malaria Ag pLDH I12FRC30
RapiGen inc. BIOCREDIT Malaria pf(HRP II) HR0100
Real World Diagnostics Malaria Pf/PAN TestX PROMALPFV001
Span Diagnostics
ParaHIT®-f Dipstick 551C010-50/25977
ParaHIT®- f  Device 551C102-50/25975
ParaHIT - Total (Device) 55IC202-10/25989
ParaHIT Pan M (dipstick) 55IC301-10
ParaHIT total (dipstick) 55IC201-10/25988
SSA Diagnostics & Biotech Systems
diagnosticks- Malaria (Pf) Cassette KMFC6001
diagnosticks- Malaria (Pf) Dipstick  KMFD6007
diagnosticks- Malaria (Pv/Pf) Cassette KMVFC6002
diagnosticks MALARIA (Pan) Cassette MPNWBC1007.3
diagnosticks MALARIA (Pan/Pf) Cassette MPNFWBC1007.4
diagnosticks MALARIA (Pan/Pv/Pf) Cassette MPNVFC1007.5
Standard Diagnostics Inc. 
SD BIOLINE Malaria Ag 05FK40
SD BIOLINE Malaria Ag Pf/ Pf/ Pv 05FK100
SD BIOLINE Malaria Ag Pf/ Pan 05Fk66
SD BIOLINE Malaria Ag Pv 05FK70
SD BIOLINE Malaria Ag P.f/Pan 05FK63b
SD BIOLINE Malaria Ag P.f/P.v 05FK83c
SD BIOLINE Malaria Ag Pf 05FK53d
Unimed International 
FirstSign – Malaria Pf Card Test -
FirstSign – ParaView-2 (Pv + Pf) Card Test 2102CB-25
FirstSign™ - PanCheck (Pan) Malaria Test 2104 CB-25
FirstSign™ - ParaView-3 (Pan+Pv+Pf) Malaria Test 2103 CB-25
Vision Biotech (Pty) Ltd
Vision Malaria Pf VB01
Clearview® Malaria Combo VB11
Zephyr Biomedicals Paramax-3 Rapid Test for Malaria Pan/Pv/Pf (device) 50320025
Pf, P. falciparum  Pv, P. vivax  Pvom, P. vivax, ovale, malariae  HRP2, histidine-rich protein 2  pLDH, Plasmodium lactate dehydrogenase
a Previously listed with product code G0221
b Previously co-listed with 05FK60 (multi-use pack), but removed because single pack format (05FK63) not evaluated at CDC 
c Previously co-listed with 05FK80 (multi-use pack), but removed because single pack format (05FK83) not evaluated at CDC

















2120 Malaria rapid diagnostic test perforMance – results of WHo product testing of malaria rdts: round 7 (2015–2016)
2. eXecutIve summAry
2.1. Introduction
WHO estimates that 3.2 billion people are at risk for malaria. 
In 2015, there were an estimated 212 million cases (with 
an uncertainty range of 148 million to 304 million) and an 
estimated 429 000 deaths (with an uncertainty range of 
235 000 to 639 000). Approximately 90% of these deaths 
occurred in sub-Saharan Africa, and just over 70% were 
of children under 5 years. Malaria remains endemic in 91 
countries and territories, and, while parasite-based diagnosis 
is increasing, national surveys between 2013 and 2015 
suggest approximately 31% of suspected malaria cases in 
sub-Saharan Africa were not confirmed with a diagnostic 
test, resulting in over-use of antimalarial drugs and poor 
disease monitoring (1). 
WHO recommends that malaria case management be based 
on parasite diagnosis in all cases (2). The use of antigen-
detecting RDTs is a vital part of this strategy, forming the 
basis for extending access to malaria diagnosis by providing 
parasite-based diagnosis in areas where good-quality micros-
copy cannot be maintained. The data generated by the WHO 
and FIND programme to evaluate and compare the perfor-
mance of commercially available malaria RDTs are guiding 
procurement decisions, which, in turn, have shifted markets 
towards better-performing tests and helped to improve the 
quality of manufacture. Since 2009, these data have guided 
procurement decisions by WHO, other United Nations agencies 
and national governments and have formed the laboratory 
evaluation component of the WHO prequalification process 
for malaria RDTs. Meeting WHO prequalification criteria has 
not previously been a requirement for WHO procurement; 
however, as of 1 January 2018, only those products that meet 
WHO prequalification requirements will be eligible for WHO 
procurement.1 This report provides the results of round 7 of 
product testing, performed at the CDC during 2015–2016, 
with data on the performance of 46 products. This round 
adds to the evaluations of rounds 1–6 (3–8), which should 
be considered as a single evaluation, except that the results 
for products tested in previous rounds that were resubmitted 
for testing replace those reported previously. From round to 
round, the evaluation panels are essentially the same (Annex 
S1), and the same or slightly modified testing protocols 
are followed. This report extends the data from previous 
rounds and therefore increases the number of RDTs available 
for procurement for which detailed, comparative data are 
available on aspects of performance relevant to field use. The 
report provides updated data on the performance of products 
at least every 5 years, as a result of implementation of the 
compulsory resubmission policy. 
1 http://www.who.int/malaria/news/2016/rdt-procurement-criteria/
en/ (accessed 8 March 2017)
2.2.  the wHo product testing 
programme
Product testing is part of the WHO–FIND malaria RDT evalu-
ation programme, which develops methods for evaluation 
and provides data on antigen-detecting malaria RDTs. The 
programme is a collaboration among many institutions in 
malaria-endemic and non-endemic countries, with a global 
specimen bank and testing performed at the CDC (Fig. 2). 
All companies that manufacture according to ISO 13485:2003 
quality system standards were invited to submit tests for 
evaluation in the programme. The 46 products from 26 
manufacturers were evaluated with prepared blood panels 
of cultured P. falciparum parasites, patient-derived wild-
type P. falciparum and P. vivax parasites and a parasite-
negative panel. Observed anomalies were recorded. Thermal 
stability was assessed after 2 months of storage at elevated 
temperature and humidity, and a rudimentary assessment 
of ease of use was recorded. In round 7 a new assessment 
of compliance with good practices for product labelling and 
instructions for use was included. As in previous rounds, RDTs 
are grouped in the tables and figures into those designed to 
detect P. falciparum only, various combination tests and those 
that have a line only for pan-specific (or P. vivax-specific) 
malaria. Manufacturers submitted two lots of each product 
for evaluation. The 15 products that had been tested in 
previous rounds comprised five compulsory resubmissions 
and 10 voluntary resubmissions (Tables 1a,b). 
The aim of the evaluation is to provide comparative data on 
the performance of the submitted production lots of each 
product against samples containing low (200 parasites/µL) 
and high densities (2000 parasites/µL) of P. falciparum or 
P. vivax. Because the concentration of target antigens in 
samples with the same parasite density is variable, the process 
for selecting the panel is adjusted to ensure that there is 
no statistically significant difference in mean or median 
concentrations of HRP2, aldolase and pLDH antigens between 
panels used in different rounds of testing (Annex S1, Table 3). 
WHO product testing constitutes the laboratory evaluation 
component of the WHO prequalification process for malaria 
RDTs (10), which also includes a standardized dossier review 
and a manufacturing site inspection to ensure safety, quality 
and performance comprehensively. WHO prequalification 
of in vitro diagnostics, established in 2008, is used by all 
United Nations agencies to determine the eligibility of tests 
for HIV, hepatitis B and C and syphilis for procurement and 
by national authorities as a complement to their regulatory 
approvals. WHO prequalification will determine the eligibility 
of malaria RDTs for procurement as of 1 January 2018. The 
results of WHO product testing will continue to be used as 
the independent laboratory evaluation component of the 
prequalification process.
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Compulsory resubmission was introduced in round 5. Products 
that are due for resubmission (every 5 years) that are not 
submitted are removed from the summary results (Tables 
S2 and S3) and the online interactive database and appear 
only in the full round-specific product testing report. These 
products will not be eligible for WHO procurement. A product 
is also de-listed if WHO is notified by the manufacturer that 
its production has been discontinued. 
2.3.  results of the evaluation 
The results (summarized in Tables 4 and 5 and Figs 9, 10, 
11, 14 and 15) provide a comparison of two lots of products 
against a panel of parasite samples diluted to a low parasite 
density (200 parasites/µL), considered to be close to the 
threshold that tests must detect in order to identify clinical 
malaria reliably in many settings (11), and a higher parasite 
density (2000 parasites/µL). 
For the purposes of this report, the main measure of perfor-
mance is the panel detection score (PDS), the percentage 
of malaria samples in a panel that give a positive result in 
two RDTs per lot at the lower parasite density and a single 
RDT per lot at the higher parasite density. Thus, it is not a 
measure of clinical sensitivity or of the positivity rate against 
the panel but rather a combined measure of positivity rate 
and inter-test and inter-lot consistency. 
As for products evaluated in previous rounds of product 
testing, the PDS varied, although much less variation was seen 
for P. falciparum-only detecting RDTs in round 7. Generally, 
products with high performance in detecting parasites have 
low false-positive rates, good thermal stability and low 
rates of anomalies. Overall, there is no obvious trade-off 
between the PDS (or positivity rate) and the false-positive 
rate, which are surrogates for sensitivity and specificity in 
the field, respectively. 
The basis for P. falciparum detection by combination RDTs, 
particularly in samples with low parasite density, is predomi-
nantly detection of HRP2 and not pLDH. In other words, it is 
mainly the HRP2 test band that reacts with P. falciparum-
containing samples, probably reflecting poorer affinity of 
the monoclonal pLDH antibodies on the pLDH test band and 
not HRP2-persistent antigenaemia, as all samples are known 
to contain P. falciparum (and pLDH). Therefore, when using 
HRP2 and pan-pLDH (or Pf-pLDH) combination products in 
the field, it is important to remember that the presence of 
an HRP2 band combined with the absence of a pLDH band 
may reflect the lower sensitivity of the pLDH-detecting band 
in low-density samples and not persistent antigenaemia or 
successful treatment.
In round 7, the results for five products submitted for 
compulsory retesting showed an average PDS decrease of 
3.5 percentage points as compared to the previous evalu-
ation round, for detection of P. falciparum (range, –16 to 
+7; 2/5 had a better PDS). Only two of these tests also 
targeted P. vivax at 200 parasites/µL; the mean change in 
PDS was – 42.9 percentage points (range, –91 to +5). The 
mean change in the false-positive rate of clean negatives 
was – 0.4 percentage points (range, –2.5 to + 1.7%). Two of 
the five tests had improved false-positive rates (one showed 
no change, and two showed increases). Overall, most of the 
differences were decreases in PDS and improvements in 
false-positivity rates in comparison with previous testing. 
Among the voluntary resubmissions, 80% (8/10) and 75% 
(6/8) of products showed the same or better detection of 
P. falciparum and P. vivax at 200 parasites/µL, respectively. 
Specifically, in tests for P. falciparum, the mean change in 
PDS was +9.2 percentage points (range, –8 to +40; n = 10); 
8/10 had improved PDS. For P. vivax, the mean change in 
PDS was +30.7 percentage points (range, –8.6 to +65.7; 
n = 8), and 6/8 had a better PDS. The mean change in the 
false-positive rate on clean negatives was 1.9 percentage 
points (range, –7.3 to + 22.9%; n = 10), while 2/10 had a 
better false-positive rate.
In combination tests, no significant correlation was found 
between the changes in P. falciparum and P. vivax detection 
(p = 0.7), suggesting that the changes in the detection of the 
two parasite species were independent. 
In round 7, none of the products had very high false-positive 
rates when tested against clean negatives, as in round 6. 
These are an improvement from the high rates observed in 
rounds 4 and 5. In contrast, more products reacted against 
blood samples containing specific immunological abnor-
malities (and against samples containing non-Plasmodium 
infectious agents), and these false-positive rates were higher 
than those seen in round 5 (Tables A4.6–A4.9). The number 
of samples evaluated was, however, small, and the clinical 
significance of these results is limited, although they may 
be important in certain populations with very low parasite 
prevalence. 
There was no notable variation among lots in round 7 (Table 
A4.1); however, as previous rounds have shown variation 
in performance between the two lots evaluated, it is still 
recommended that products be lot-tested before field use. 
The P. falciparum HRP2 test lines in the majority of products 
showed good heat (thermal) stability after 2 months’ storage 
at 45°C and 75% humidity; however, Pf-pLDH test lines 
showed variable baseline performance and deterioration after 
incubation at 45°C. For many products, pan-pLDH perfor-
mance at baseline and after heat stress for detection of the 
P. falciparum isolate was poor, and it was nearly universally 
poor against low-parasite-density samples, making it difficult 
to assess true stability. As in round 6, products were assessed 
for heat stability against a wild-type P. vivax sample. While 
most of the products performed well, with high positivity 
rates after 2 months’ storage at 45°C and 75% humidity, 
others showed some drop in performance after storage, 
with little difference between pan-pLDH and P. vivax pLDH 
in test line stability.
The frequencies of anomalies that can interfere with test 
interpretation were recorded. In round 7, 33 of the 46 prod-
ucts had one to five different types of anomaly (Annex S2, 
Table 8, Fig. 30). Incomplete clearing and red background (not 
obscuring the test lines) were the most common anomalies, 
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migration, failed migration and a red background obscuring 
the test lines were the next most common anomalies, in 
15%, 11% and 11% of products, respectively. Most of the 
products with anomalies (31/33) had anomalies in < 1% of 
the tests, while two products had anomalies in 1.4% of tests 
(Table 8). This rate is far lower than in round 6, in which all 
products had one to six anomalies, and approximately half 
had a frequency > 2%. 
The clinical sensitivity of an RDT, i.e. the proportion of known 
cases of the disease with a positive test, is highly dependent 
on local conditions, including the parasite density in the 
target population; it therefore varies in populations with 
different levels of transmission. The comparative performance 
between RDTs shown in this report give an indication of 
which products are likely to be more sensitive in the field, 
particularly for populations with low-density infections. 
In general, as the malaria prevalence in countries falls and 
they even move towards malaria elimination, detection of 
low parasite densities will become increasingly important in 
case management. As the PDS at 2000 parasites/µL indicates, 
the sensitivity of many of these products will be similar in 
populations with higher parasite densities, although a subset 
of any population will include vulnerable individuals who may 
develop illness at low parasite densities (e.g. young children, 
pregnant women, people well protected by bed nets) and 
must always be taken into account when interpreting RDT 
results. For areas where significant non-expression of HRP2 
is known, the results in this report for HRP2-detecting tests 
should not be considered to predict sensitivity in the field. 
Only tests targeting P. falciparum by detection of pLDH or 
aldolase should be considered.
Heat stability (summarized in Tables 6a and 6b) is vital to 
maintaining the sensitivity of a test in the field. For procure-
ment, therefore, the stability results should be used to ensure 
that products to be used in areas with high temperatures 
during transport and storage have demonstrated good 
stability in the product testing programme. The requirements 
vary by country; for example, if tests are to be used in areas 
where the temperature rarely rises above 30°C, stability at 
high temperatures is less important. 
The requirements for ease of use depend on the extent of 
training and the work environment of users. Particularly in 
primary health care settings, the simpler the test, the easier 
it should be to avoid errors in preparation and interpretation.
In round 7, for the first time, adherence to a list of recom-
mendations on instructions for use and product labelling was 
assessed (Fig. 31-38). Products generally scored well in this 
assessment for labelling of the main device and labelling of 
the device packaging and of the primary product box, with 
some exceptions, especially in warnings and precautions. 
The scores for adherence to recommendations on labelling 
of buffer bottles and other accessories were lower. The 
instructions for use were highly variable, with some impor-
tant omissions, particularly on laboratory safety, product 
performance and interpretation.
2.4.  use of the results
Box 3 lists WHO’s current minimum criteria for selecting 
RDTs. With the upcoming transition to WHO prequalification 
as a requirement for malaria RDT procurement, the findings 
from dossiers and site inspections will also be considered; 
however, the performance requirements will remain the same. 
The results in Tables S2, S3 and 5 are colour-coded to reflect 
achievement of these requirements, as well as current WHO 
prequalification status (indicated in Table S2). A web-based 
tool maintained by FIND allows filtering of product testing 
results by various parameters to assist in selecting products 
with the performance characteristics most suitable for a 
country’s health programme (15). This online database has 
been updated to allow filtering of results by RDT procedural 
characteristics, such as blood volume requirements, number of 
buffer drops and time to result. This grouping, also indicated 
in Annex 1, will allow use of the same or similar protocols 
to identify products, so that, when product replacement is 
required, another product with the same or similar protocol 
may be selected. Use of similar products may reduce the need 
for user retraining and also reduce user error. 
The results of product testing are reported by product, with 
the product name and code. The same RDT may be sold in a 
variety of configurations, such as single or multi-kits, different 
numbers of tests per box, with or without certain accessories; 
and they are assigned a distinct product code on this basis. 
The reports gives the precise name and product code provided 
by the manufacturer for testing. Procurers should contact 
the manufacturer for a list of product configurations prior 
to purchase.
Annex S3 outlines a step-by-step approach to selecting an 
RDT, taking into consideration local conditions of malaria 
transmission and illness (e.g. Plasmodium spp., target antigen, 
parasite density, climate) and other important considera-
tions, such as ease of use in the field and lot testing. RDTs 
must not be procured without preparation for proper use, 
including supply chain management and training in test 
use and disposal and in patient management in response 
to results. Comprehensive guidance on several aspects 
of procurement can be found in Recommended selection 
criteria for procurement of malaria rapid diagnostic tests 
(16), published as a WHO information note in 2016,1 and 
guidance on implementation in Universal access to malaria 
diagnosis (17). 
1 http://www.who.int/malaria/publications/atoz/rdt-selection-criteria.pdf
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3. bAckground
During the past decade, new opportunities for the control 
of malaria have emerged, including use of long-lasting 
insecticidal nets, indoor residual spraying of insecticides 
and artemisinin-based combination therapy. These have 
been shown to reduce the burden of malaria infection in 
countries where they are adequately implemented. Therefore, 
the proportion of febrile episodes attributable to malaria is 
likely to decrease substantially. 
Despite WHO’s recommendation for a parasitologically 
confirmed diagnosis of malaria infection before treatment 
in all cases (2), diagnoses are still often made on clinical 
grounds (11); however, in many endemic areas, malaria 
accounts for a minority of cases of “malaria-like” febrile 
illness. Microscopy has been the cornerstone of diagnosis 
and is recommended for malaria diagnosis when its quality 
can be maintained; however, the need for trained personnel 
and adequate reagents and equipment limits its availability 
and accessibility in malaria-endemic areas. Rapid, accu-
rate, accessible diagnostic tools are increasingly required 
as programmes extend parasite-based diagnosis and the 
prevalence of malaria decreases. RDTs to detect Plasmodium-
specific antigens (proteins) in whole blood of infected people 
are an attractive alternative to microscopy. The currently 
available RDTs come in various formats (dipstick, cassette or 
hybrids) and contain antibodies bound to specific antigens, 
such as HRP2 specific to P. falciparum, pan-specific and 
species-specific pLDH or aldolase specific to all the major 
Plasmodium species most relevant to human health (P. falci-
parum, P. vivax, P. malariae, P. ovale) (Fig. 1). 
To be widely useful, an RDT must be highly sensitive to ensure 
detection of all clinically significant malaria infections, highly 
specific to allow monitoring of low malaria prevalence and 
appropriate management of non-malarial fevers and highly 
stable to allow transport and storage in ambient conditions 
in malaria-endemic areas. Published field trials of RDTs 
show highly variable performance, probably due to poor 
manufacturing quality, incorrect storage and handling, poor 
preparation and interpretation, and sometimes poor study 
methods, analysis and reporting (17–25). In general, diagnostic 
testing by microscopy or RDT to a level of 200 parasites/µL 
will reliably detect nearly all clinically relevant infections in 
malaria-endemic areas (11). 
The number of RDTs available on the market grew rapidly 
after their introduction in the late 1990s; sales reported by 
41 manufacturers showed a peak of 320 million tests sold 
in 2013. Since 2013, there has been a global decline, due to 
decreasing sales in Asia, although sales in Africa have risen 
every year since 2008 (1). Regulatory control of diagnostics 
is, however, often weak, and procurement agencies have 
had considerable difficulty in selecting appropriate RDTs 
and ensuring their quality. In view of the inconsistency in 
the results of field studies and the inherent difficulties in 
assessing large numbers of products in a standardized way 
in field trials, WHO and partners embarked on a programme 
in 2002 to evaluate RDTs for malaria, in order to ensure 
standardized assessment of performance and to guide 
procurement decisions and regulatory mechanisms. Between 
2003 and mid-2012, the programme was managed by WHO 
and TDR in partnership with FIND. After TDR withdrew its 
involvement in 2012, the WHO Global Malaria Programme 
assumed a coordinating role. A steering committee oversees 
the development of and modifications to standard operating 
procedures (26, 27). A network of specimen collection sites 
has been established to provide specimens for a global bank 
at the CDC and to facilitate local quality control (Fig. 2). 
The reports of the previous six rounds of product testing 
have been released annually since 2009 (3–8). This seventh 
report adds data on the performance of 29 new products and 
updated data on 17 resubmitted RDTs. Testing for round 7 was 
conducted against an evaluation panel with characteristics 
similar to those of previous panels in terms of overall antigen 
concentration, parasite origin and parasite-negative blood 
samples (Annex S1). Most panel samples were retained from 
previous rounds, with 19 of 100 P. falciparum, 5 of 35 P. vivax 
and 17 of 100 negative samples replaced (new) in round 7.
4. objectIve
The objective of the programme is to evaluate malaria RDTs 
for performance in order to guide procurement of RDTs for 
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Figure 2: Network of specimen collection, characterization and testing sites
Countries or areas where malaria transmission occurs
Countries or areas with limited risk of malaria transmission
No malaria
Malaria, countries or areas at risk of tran mission, 2009
This map is intended as a visual aid only and not as a definitive source of information about malaria endemicity.
Source: © WHO 2010. All rights reserved.
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Mode of action of common malaria RDT format: 
(a) Dye-labelled antibody (Ab), specific for the target 
antigen, is present on the lower end of the nitrocellulose 
strip or in a well provided with the strip. Antibody, also 
specific for the target antigen, is bound to the strip in a 
thin (test) line, and either antibody specific for the labeled 
antibody, or antigen (Ag), is bound at the control line. 
(b) Blood and buffer, which have been placed on the strip 
or in the well, are mixed with the labelled antibody and 
are drawn up the strip across the lines of bound antibody. 
(c) If antigen is present, some labelled antibody will be 
trapped on the test line. Other labelled antibody is trapped 
on the control line.
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5. mAterIAls And metHods
5.1.  test selection 
In July 2015, the WHO–FIND malaria RDT evaluation 
programme issued a call for expressions of interest to 
manufacturers of malaria RDTs with information on the 
requirements for submission of a product to round 7 and 
the conditions for participation in the evaluation programme 
(29). Manufacturers of products that had not been retested 
since round 3 were informed they must resubmit these 
products; otherwise, the performance characteristics would 
be removed from the summary results document, which is a 
compilation of the results of all previous rounds of testing. 
This rule was introduced in round 5 to ensure that all prod-
ucts were retested < 5 years after the primary submission. 
Other standard requirements included valid ISO 13485:2003 
certification of all manufacturing sites, sufficient quantities of 
products (1100 tests from each of two lots1), compliance with 
1 Manufacturers were requested to supply an additional 500 RDTs 
per lot voluntarily to support the WHO-FIND evaluation of malaria 
recombinant antigens.
Table 1a: Manufacturers and products accepted into round 7 of WHO malaria RDT product testing programme
Manufacturer Product name Product codea Target antigen(s)
Access Bio, Inc.
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag Combo RDTc RMVM-05072 V(pLDH), HRP2
CareStart™ Malaria Pf (HRP2/pLDH) Ag Combo 3-Line RMSM-05071 F(pLDH), HRP2
CareStart™ Malaria Screen RDTb RMAM-05071 pan(pLDH), HRP2/F(pLDH)
CareStart™ Malaria Pf/PAN (pLDH) Ag RDTb RMLM-05071 pan(PLDH), F(pLDH)
Access Bio Ethiopia 
CareStart™ Malaria Pf (HRP2) Ag RDT RMOM-03091 HRP2
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag Combo RDT RMVM-03091 V(pLDH), HRP2
Advy Chemical Private Limited
Adv Dx™ Malaria Pan/Pf Rapid Test Detection Kit RKMAL016 pan(pLDH), HRP2
Adv Dx™ Malaria Pf Rapid Malaria Antigen Detection Test RKMAL017 HRP2
Alere Medical Private Limited
Alere Trueline™ – Rapid test kit for Malaria Ag Pf/Pan (HRP-II/pLDH) 05FK60AI-40 pan(pLDH), HRP2
Rapid Test Kit for Malaria Ag Pf/Pv- Alere Trueline Malaria Ag Pf/Pv 11108191040 V(pLDH), HRP2
ALLDIAG SA
PALUTOP +4 optima® 5499 pan(pLDH), V(pLDH), HRP2
PALUTOP + pf® 5531 HRP2
ARKRAY Healthcare Pvt Ltd
Parahit® f Ver 1.0 - Deviceb 55IC104-50 HRP2
Parahit f® Ver 1.0 - Dipstickb 55IC103-50 HRP2
ASAN Pharmaceutical Co., Ltd Asan Easy Test® Malaria Pf/Pan Agc AM4650-K pan(pLDH), HRP2
Aspen Laboratories Pvt. Ltd.
Aspen®  Malaria Ag Pf/Pv AS0060 V(pLDH), HRP2
Aspen® Malaria Ag Pf AS0015 HRP2
Bio Focus Co., Ltd. 
BioTracer™ Malaria P.f Rapid Card 17912 HRP2
BioTracer™ Malaria P.f/PAN Rapid Cardc 17012 pan(pLDH), HRP2
Biosynex 
Biosynex® Malaria Pf/Pv 0581_K25 V(pLDH), HRP2
Biosynex® Malaria Pf/Pan 0584_K25 pan(pLDH), HRP2
DIALAB DIAQUICK Malaria P.f. Cassette W06200 HRP2
Guangzhou Wondfo Biotech Co., Ltd.
One Step Malaria  HRP2 (P.f) Testc W37-C HRP2
One Step Malaria HRP2/pLDH (P.f/P.v) Testc W056-C V(pLDH), HRP2
Hangzhou AllTest Biotech Co. Ltd. AllTest™ Malaria P.f./Pan Rapid Test Cassette IMPN-402 Aldolase, HRP2
Hema Diagnostic Systems Rapid 1-2-3 HEMA® CASSETTE MALARIA PF/PAN MAL-PF/Pan-CAS/25 HRP2, pan(pLDH)
ICT INTERNATIONAL
ICT MALARIA DUAL TESTc ML03 HRP2, pan(pLDH)
ICT MALARIA P.F. CASSETTE TESTb ML01 HRP2
InTec Products, Inc.
ADVANCED QUALITY ™ ONE STEP Malaria (p.f) Testc ITP11002-TC25 HRP2
ADVANCED QUALITY ™ ONE STEP Malaria (p.f/p.v.) Tri-line Testc ITP11003-TC25 V(pLDH), HRP2
Lumiquick Diagnostics Inc. QuickProfile™ Malaria Pf/Pv Antigen Testc 71050 V(pLDH), HRP2
Medical Diagnostech (Pty) Ltd GMD Malaria Pf test GMDMALPF001 HRP2
Real World Diagnostics Malaria Pf/PAN  Test PROMALPFV001 HRP2, V(pLDH)
Medsource Ozone Biomedicals Pvt. Ltd. Is It... Malaria Pf PAN MPFPAN050 pan(pLDH), HRP2
Meril Diagnostics Pvt. Ltd.
One Step Test for Malaria Pf/Pv Ag MERISCREEN Malaria Pf/Pv Ag MFLRPD-02 V(pLDH), HRP2
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Manufacturer Product name Product codea Target antigen(s)
NG Biotech NG-Test MALARIA Pf/Pan (pLDH) NGB-MAL-W23-005 HRP2, pan(pLDH)
RapiGEN Inc.
BIOCREDIT Malaria Ag Pf/Pan (HRPII/pLDH)c C32RHA25 pan(pLDH), HRP2
BIOCREDIT Malaria Ag Pf/Pv (pLDH/pLDH) C60RHA25 V(pLDH), F(pLDH)
Shanghai Kehua Bio-engineering Co., Ltd. KHB® Malaria Ag (HRP2) Pf Rapid Test R-409-50-C HRP2
Standard Diagnostics, Inc.d
SD BIOLINE Malaria Ag P.f. (HRP2/pLDH) 2 Lines 05FK130-40-0 HRP2/F(pLDH)
Alere™ Malaria Ag P.f 05FK140-40-0 HRP2
WELLS BIO, INC
careUS™ Malaria Pf (HRP2) Ag RMO-M05082 HRP2
careUS™ Malaria Combo Pf/Pv (HRP2/pLDH) Ag RMV-M05082 V(pLDH), HRP2
Zhejiang Orient Gene Biotech Co., Ltd.
Malaria Pf Rapid Test GCMAL(pf)-402a HRP2
Malaria Pf/Pv Rapid Test GCMAL(pf/pv)-402a HRP2, V(pLDH)
pLDH, Plasmodium lactate dehydrogenase; HRP2, histidine rich protein 2; V, P. vivax; F, P. falciparum 
a  The product code corresponds to a specific configuration of the RDT, kit components and accessories. Therefore, changes to this configuration including the  quantity 
of tests, the contents or the manufacturing site  are denoted by a different product code. Often this involves the end portion of the product code; however, the 
manufacturer should be contacted for full details. 
b Indicates previously submitted products which were submitted for compulsory restesting in round 7.
c Indicates products which have previously been submitted and were voluntarily resubmitted in round 7.
d An Alere company
Table 1a: (continued)
Table 1b: Products due for compulsory resubmission in round 7
Manufacturer Product name Product Code Participation  in round 7a
ABON Biopharm (Hangzhou) Co. Ltd ABON Malaria Pan/P.f. Rapid Test Device (Whole Blood) IMA-B402 No
Access Bio, Inc.
CareStart™ Malaria Pf/PAN (pLDH) Ag RDT RMLM-05071b Yes
CareStart™  Malaria/Pregnancy (HRP2/pLDH/ HCG) RRHM(U)-XXX7Xc No
CareStart™ Malaria Screen RDT RMAM-05071d Yes
ACON Biotech (Hangzhou) Co. Ltd Surestep™ Malaria Pf/Pan Rapid Test Device (Whole Blood) IMA-T402 No
AZOG, Inc 
Malaria pf (HRP II) / pv (pLDH) Antigen Detection Test Device MFV-124V No
Malaria pf (HRP II) / (PAN-LDH) Antigen Detection Test Device MFV-124R No
Bioland, Ltd
Nano Sign Malaria Pf Ag RMAF10 No
NanoSign Malaria Pf/Pv Ag RMAD10 No
BioNote,Inc. BIONOTE MALARIA P.f/P.v Ag Rapid Test Kit RG19-12 No
Biosynex
IMMUNOQUICK CONTACT falciparum 0519K25 No
IMMUNOQUICK CONTACT MALARIA +4 0525K25 No
Core Diagnostics
Core™ Malaria Pf MAL-190020 No
Core™ Malaria Pv/Pf Mal-190022 No
Core™ Malaria Pan/Pv/Pf Mal-190026 No
CTK Biotech, Inc. OnSite Pf Ag Rapid Test R0114C No
DiaMed - A Division of Bio-Rad OptiMAL-IT 710024 No
Dima • Gesellschaft für Diagnostika mbH Malaria Pan test MAL-W23N-001 No
ICT International ICT Diagnostics Malaria P.f ML01 Yes
J. Mitra & Co. Pvt. Ltd. Advantage Malaria Card IR211025 No
Orgenics Ltd. Clearview® Malaria pLDH 70884025 No
Standard Diagnostics Inc. SD BIOLINE Malaria Ag 05FK40 No
Span Diagnotics Ltd.e
ParaHIT® - f (Device) 55IC102-10 Yes
ParaHIT® - f (Dipstick) 55IC101-10 Yes
SSA Diagnostics & Biotech Systems
diagnosticks MALARIA (Pan) Cassette MPNWBC1007.3 No
diagnosticks MALARIA (Pan/Pf) Cassette MPNFWBC1007.4 No
diagnosticks MALARIA (Pan/Pv/Pf) Cassette MPNVFC1007.5 No
Vision Biotech (Pty) Ltd.
Clearview® Malaria Combo VB11 No
Clearview® Malaria Pf VB01 No
Guangzhou Wondfo Biotech Co. Ltd. One Step Malaria P.f./Pan Whole Blood Test W56-C No
a The results of the first testing of the products in this list that were not retested in round 7 have been removed from tables S2 and S3 and figs S1 and S2 and are listed in table S4.
b Previously listed with product code G0121
c Previously listed with product code G0221
d Previously listed with product code G0231
e Currently listed with product codes 55IC104-50 and 55IC103-50. Span Diagnostics is now ARKRAY Healthcare Pvt.Ltd. 
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the product definition1, deadlines for document submission 
and payment of fees. 
Twenty-seven manufacturers, proposing 45 products, 
responded to the call, and the products went forward for 
testing. A further product from one manufacturer was 
exceptionally accepted as a late entry, directly into phase 
2, because of the urgent need for pf-pLDH-based RDTs in 
areas with a high prevalence of HRP2 deletions. Overall, 46 
products from 27 manufacturers were tested in round 7 
(Table 1a). Catalogue numbers and verification with manu-
facturers showed that 15 of the 46 products (33%) had been 
submitted previously to one or more rounds, including five 
(11%) scheduled for compulsory resubmission (Table 1b). All 
45 products met the minimum performance requirements2 in 
the initial evaluation against the P. falciparum culture-derived 
panel (phase 1) and were therefore evaluated fully in phase 
2, with the additional product. 
Of the 46 products that were fully evaluated, 19 are designed 
to detect P. falciparum alone, 13 to detect and differentiate 
P. falciparum from non-P. falciparum malaria, 13 to differ-
entiate P. falciparum from P. vivax and one to detect and 
differentiate P. falciparum, P. vivax and other Plasmodium 
species. Of these products, five detected P. falciparum pLDH. 
Three products had separate Pf-pLDH detecting lines and 
two combined P. falciparum pLDH with HRP2 on the same 
line. Annexes 1 and 2 give a comprehensive overview of the 
product characteristics. 
1 A working definition of a product can be found in Annex 2 (http://
www.who.int/malaria/news/2015/EOI-letter-to-manufacturers-Rd7-
annex-2jul2015.pdf?ua=1, accessed 8 March 2017). 
2 PDS > 80% against high-density (2000 parasites/µL) P. falciparum 
in culture
5.2.  the product testing protocol 
The testing process is outlined in Fig. 3 and in the Methods 
manual for product testing of malaria rapid diagnostic tests, 
version 6 (28). In brief, RDTs from each of two lots of each 
product were evaluated against a panel of parasite-positive 
and parasite-negative cryopreserved blood samples. Both lots 
were also tested for heat (thermal) stability, evaluated after 
2 months’ storage at room temperature (21–24°C), 35°C and 
45°C. A description of the ease of use of the products was 
completed on a standard form, and common anomalies were 
recorded. Evaluation of adherence to recommendations on 
instructions for use and labelling was introduced in round 7. 
Products were assessed against a list of preferred and required 
recommendations on the scope, format and terms used in the 
instructions for use and on the labelling of the box, the test 
device, its primary packaging, buffer bottle, other accessories.
The testing and all the results were monitored by the WHO–
FIND steering committee, and manufacturers were given 
30 days to comment on the results for individual products 
before publication.
5.3.  evaluation panels
RDTs were evaluated against three panels: 
• P. falciparum culture lines (includes a subset, “manufac-
turer’s panel”) at low (200 parasites/µL) and high parasite 
density (2000 parasites/µL);
• wild-type Plasmodium species (P. falciparum, P. vivax) 
from naturally infected humans diluted with parasite-
negative samples to low (200 parasites/µL) and high 
Figure 3: Overview of malaria RDT product testing
RDT product testing flow chart
Panel detection score
and false-positive rate
Heat stability Ease-of-use description Labelling and instruction for use
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parasite density (20001 parasites/µL), all samples prepared 
from isolates that express HRP2; and
• a parasite-negative panel (“clean” samples and disease-
specific or blood factor-specific samples).
An overview of sample collection and characterization is 
given in the methods manuals prepared for this purpose (27, 
28). Characterization results for each round are available in 
the reports of previous rounds (3-8). Each panel specimen 
was characterized for: 
• species, by duplicate microscopy (two microscopists) 
and confirmation of mono-species infection by nested 
polymerase chain reaction (PCR);
• antigen concentration, by quantitative ELISA for HRP2, 
pLDH and aldolase; and
• the absence of malaria parasites by nested PCR and 
confirmatory testing for other diseases in the case of 
parasite-negative samples.
Some of the P. falciparum samples in the global specimen 
bank were also characterized according to HRP2 sequence by 
PCR amplification and sequencing. This was not performed 
on samples collected after 2009, as accumulated evidence 
indicates that HRP2 variation has no significant effect on 
RDT sensitivity (30). The geographical origin of all samples 
was recorded.
panel composition
P. falciparum-cultured parasites panel 
The programme selected culture-adapted strains of P. falci-
parum from various geographical locations, including 13 
strains with type B HRP2 sequence, five with type A and two 
with type C (30). All specimens were derived from the CDC 
1  Three (3%) of the 100 high-parasite-density P. falciparum dilution 
samples contained 5000 rather than 2000 parasites/µL.
culture bank and diluted in O-positive blood from donors 
in the USA (28). 
Wild-type parasite panel 
The parasite-positive wild-type (clinical) panel consisted of 
samples from 100 cases of P. falciparum and 35 cases of 
P. vivax malaria, from 11 collection sites in Africa, Asia and 
South America (Figs 2, 4a and 4b). Samples were collected 
from febrile patients and processed by standard methods 
designed to preserve the target antigen concentration 
(27). After dilution and cryopreservation, the samples were 
transferred to the global bank (WHO specimen bank) at CDC 
for further characterization. The concentrations of sample 
antigens (HRP2, pLDH, aldolase) determined by quantitative 
ELISA are shown in Table 3. The results are based on 98 
P. falciparum samples for pLDH, 99 P. falciparum samples 
for HRP2 and 100 for aldolase, 34 P. vivax samples for pLDH 
and 35 P. vivax samples for aldolase. This panel is closely 
comparable to those of previous rounds (Annex S1). 
Negative blood sample panel
The negative panel consisted of 52 “clean” parasite-negative 
samples from donor-derived blood obtained in banks or 
from volunteers in non-endemic (USA) and endemic areas 
(Cambodia, Kenya, Madagascar, the Philippines and Senegal) 
that had been confirmed to be malaria-negative by micros-
copy and PCR. The negative sample panel also contained 
48 parasite-negative samples from donors with diseases 
that might be used in the differential diagnoses of malaria, 
that contained blood factors known to be common in the 
community or that could result in false-positive reactions in 
immunochromatographic tests (Table 2). All negative control 
samples were confirmed to be free of Plasmodium parasites 
by nested-PCR.
Figure 4a: Origin of phase 2 P. falciparum wild-type  
(clinical) samples (n=100)
Figure 4b: Origin of phase 2 P. vivax  
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5.4.  product registration
Receipt of each shipment of RDTs at the CDC was recorded 
in a dedicated RDT register. Temperature monitoring devices 
were offered to manufacturers free of charge to accompany 
RDT shipments to the CDC. All RDTs were stored at room 
temperature (21–24°C) immediately, and temperature moni-
tors were labelled with the date of receipt and forwarded for 
data extraction and analysis, when applicable.
5.5.  specimen panel registration
All panel specimens were assigned unique identification 
numbers at the collection sites and stored in aliquots of 
50 µL at –70°C until testing. All data pertaining to specimen 
identification, storage location and characterization are 
stored in a secure, dedicated database.
5.6.  test phases
The evaluation is divided into two phases. Each lot of RDTs 
was evaluated independently. Lots 1 and 2 of each product 
were tested alternately against defined sample sets1, testing 
1 A sample set usually consists of 13 P. falciparum specimens and 5 
P. vivax specimens at 200 parasites/µL and 2000 parasites/µL and 
13 malaria-negative samples.
of a set of lot 1 of all products was completed, then a set 
of lot 2 was tested, until both lots of all products had been 
tested against all panel samples.
Phase 1. A screening step is used to allow selection of RDTs 
that meet the minimal quality requirements. Products from 
two lots were evaluated against a panel of 20 culture-derived 
P. falciparum samples at high (2000 parasites/µL) and low 
(200 parasites/µL) parasite density, and against 20 clean 
negative samples. To progress to the full evaluation (phase 2), 
a product evaluated in phase 1 must achieve a minimum PDS 
of 80% against the samples containing 2000 parasites/µL 
and <50% false positive rate against clean negative samples.
Phase 2. Products from two lots are evaluated against a 
panel of diluted clinical blood samples containing wild-type 
parasites and a parasite-negative panel, evaluated for heat 
(thermal) stability and assessed for ease of use. Because 
the number of aliquots were smaller, fewer replicate RDTs 
were performed.
• Performance assessment: The mixed parasite-positive and 
parasite-negative panel comprised 100 P. falciparum, 35 
P. vivax at two parasite densities (200 parasites/µL and 
2000 parasites/µL2) and 100 parasite-negative samples. 
• Evaluation of heat stability for P. falciparum-detecting 
products: 15 RDTs from each of two lots were tested 
against a single culture-derived P. falciparum isolate 
(Nigeria XII strain, P. falciparum HRP2 sequence type B) 
with a typical antigen concentration3 at 200 parasites/µL, 
five RDTs from each lot against P. falciparum Nigeria XII 
strain at 2000 parasites/µL and four RDTs from each 
lot against a negative sample, which were all tested at 
baseline and after RDTs were maintained for 60 days 
at room temperature (< 25°C), 35°C and 45°C, at 75% 
humidity. 
 Evaluation of heat stability for P. vivax-detecting prod-
ucts: Four RDTs from each of the two lots were tested 
against a single wild-type P. vivax sample4 (from Ethiopia) 
at 200 parasites/µL, two RDTs from each lot against 
P. vivax at 2000 parasites/µL and four RDTs from each lot 
against a negative sample, at baseline and after RDTs were 
2 Three (3%) of the 100 P. falciparum high parasite density dilution 
samples contained 5000 parasites/µL rather than 2000.
3 The P. falciparum sample had 18.8 ng/mL of HRP2, 21.1 ng/mL of 
pLDH and 0.49 ng/mL of aldolase.
4 The P. vivax sample had 143.9 ng/mL of pLDH and 44.4 ng/mL of 
aldolase.
Table 3: Malaria antigen concentrations (ng/mL) in round 7 wild-type, low parasite density (200 parasites/µL) samples 
pLDH HRP2 Aldolase
P. falciparum P. vivax P. falciparum P. falciparum P. vivax
Mean 15.9 16.9 11.8 1.4 8.2
Median 13.0 16.6 6.8 1.3 8.0
Maximum 53.5 44.8 62.5 9.1 15.1
Minimum 0.2 1.6 0.7 0.0 3.2
Standard deviation 11.6 11.2 13.0 1.3 3.6
Table 2: Characteristics of Plasmodium spp. negative samples
Nature of negative samplea No.
Clean-negativeb 52
Anti-nuclear antibody positive (sera) 12
Anti-mouse antibody positive (plasma) 3
Rheumatoid factor positive (whole blood and sera) 6
Rapid plasma reagin positive (sera) 6
Chagas' disease antibody positive (plasma) 2
Dengue antibody positive (whole blood sera) 7
Leishmaniasis antibody positive (sera) 4
Schistosomiasis antibody positive (whole blood and sera) 8
a Whole blood unless indicated. Sera and plasma samples were reconstituted 
packed cells
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maintained for 60 days at room temperature (21-24°C), 
35°C and 45°C, at 75% humidity. The pLDH concentrations 
in the samples chosen were above average in order to 
increase the probability of good RDT baseline reactivity, 
thereby allowing an interpretable assessment of stability 
or degradation. 
• Ease-of-use assessment: After technicians had become 
familiar with the test device, they jointly described its 
blood safety characteristics, the quality of the instructions, 
the number of timed steps and the total time to a result, 
using a standard reference guide (28). 
•  Assessment of labelling, packaging and instructions for 
use: Technicians assessed the product components to 
determine whether they met each of the recommended 
or preferred criteria, assessed in the following categories: 
• labelling of the RDT box (58 criteria assessed); 
• labelling of the primary cassette packaging (16 criteria 
assessed);
• labelling of the cassette (11 criteria assessed);
• labelling of the buffer bottle (15 criteria assessed);
• labelling of the accessories (transfer devices, lancets, 
alcohol swabs and desiccant) (19 criteria assessed); 
and
• content and format of the instructions for use (119 
criteria assessed). See supplemental files for full details.
Figure 5: Testing procedure and calculation of panel detection score and band intensity for product A against a sample 
density of 200 parasites/µL
The first reading was at the minimum time specified by the manufacturer; the second reading was up to 30 min latera. A sample is 























Test 1 Test 2
Detected if  
4 positive  
first readings
Based on the positive results of first test reading (2 tests per lot), the mean band intensity score =a+b+c+d/4  
(excluding negative results).
a Second reading results are for internal use only
Figure 6: Testing procedure and calculation of panel detection score and band intensity for product A against a sample 
density of 2000 parasites/µL 
The first reading was at the minimum time specified by the manufacturer; the second reading was up to 30 min latera. A sample is 

















Detected if  
2 positive  
first readings
Based on positive results of first test reading (2 tests per lot), in each lot, the mean band intensity score =a+b/2
a Second reading results are for internal use only
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• RDT anomalies: During testing, technicians regularly 
reported the RDT anomalies listed below (not all of which 
were observed in round 7) and in Fig. AS2.1. When anoma-
lies were noted frequently, a photograph was taken of at 
least one example.
• red background
• red background obscuring test line(s)
• incomplete clearing 
• incomplete migration
• failed migration
• ghost test line(s)
• patchy, broken test line(s)
• diffuse test line(s)
• strip misplaced in cassette (shift)
• specimen pad not seen in sample window
• buffer remains pooled in buffer well
5.7.  performing rapid tests
All RDTs were maintained at room temperature (21–24 °C) 
until first use. When applicable, the desiccant was inspected 
for colour change, and products were discarded if they 
were present. Technicians were rotated and blinded to the 
sample type and to each other’s results. RDTs were labelled 
with a sample identification number and the date on which 
test was performed. The tests were used according to the 
manufacturer’s instructions, except that the recommended 
volume of blood was transferred by micropipette from the 
sample tube; co-packaged blood transfer devices were not 
used. The result was recorded by a technician at the minimum 
specified reading time, and a second technician re-read the 
result within 30 min for internal monitoring and to obtain 
information for the manufacturer. Annexes 1 and 2 give a 
descriptive, illustrated summary of the test characteristics 
and steps and a guide to interpretation of results.
5.8.  Interpreting the results
The results of control and test lines were recorded as negative 
or positive by each technician. Each test line was read against 
a standard colour chart and the band intensity graded as 0 
(no visible band), 1, 2, 3 or 4 (1 being the weakest colour 
intensity and 4 being the strongest). If the control line was 
recorded as “0” (no visible band) by either technician, the 
test was recorded as invalid. 
Figs 5 and 6 illustrate the testing sequence at low and high 
parasite density.
5.9.  recording anomalies
Anomalies are defined as unexpected features that appear 
during performance of an RDT. Anomalies have been observed 
since round 1. After the appearance of each, technicians 
agreed on terms with which to identify them. During earlier 
rounds of testing, their presence was recorded informally 
(and reported to manufacturers), but, since round 6, the 
frequency of anomalies has been recorded. Some anomalies 
do not interfere with the interpretation of results, while 
others may obscure test or control lines and therefore affect 
the interpretation and create confusion. Manufacturers 
are encouraged to reduce or eliminate anomalies and to 
acknowledge them in their instructions for use.
6. dAtA mAnAgement 
Receipt of products was hand-recorded in a RDT register 
at the CDC as per standard operating procedures. Data 
associated with specimen collection and characterization 
were recorded, first on hard-copy report forms as per the 
standard operating procedure at the collection sites (Fig. 2), 
the Hospital of Tropical Diseases (quantitative ELISA results) 
and the CDC (PCR results), then entered directly into Excel, 
followed by importation into a specially developed database. 
The results of product panel testing and heat stability testing 
conducted at the CDC were recorded on report forms by 
each technician individually, as per the standard operating 
procedure. The results were entered in duplicate and analysed 
for discrepancies. 
All source documents and electronic records of the study 
data are maintained in secure storage until the conclusion 
of the evaluation, data analysis and publication of the report. 
Individual product testing reports and raw data were sent to 
manufacturers in December 2016 for a 30-day review period 
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7. QuAlIty AssurAnce 
Product testing follows standard operating procedures 
developed during previous testing rounds, which are based 
on recommendations by expert consultants, with minor 
modifications by the steering committee before round 7 
(28). Overall, the quality of critical steps was controlled as 
described below.
7.1.  Quality of malaria rdts and 
their use
All RDTs were stored in a controlled environment at room 
temperature (21–24 °C). The pouch was opened, and, if 
applicable, the desiccant was checked for colour change 
immediately before use. The manufacturer’s instructions 
were followed, except for use of the blood transfer device 
provided by the manufacturer: a micropipette was used to 
ensure the correct blood volume.
A temperature monitoring device was offered to manufac-
turers to be shipped with the RDTs to the testing site (CDC). 
Lots were analysed at temperatures above and below the 
manufacturer’s recommended storage conditions. 
7.2.  Quality and objectivity of rdt 
readings
The results were read under good lighting, using standard 
colour charts by trained technicians tested for visual acuity 
and were doubly entered into the database. Technicians 
were rotated, and the readings of a second technician were 
used for internal monitoring. The summarized results were 
reviewed in detail, and potential discrepancies were identified 
and cross-checked against source laboratory report forms.
All wild-type parasite samples used in phase 2 were rand-
omized with parasite-negative samples and re-labelled. 
Reading of the RDT results by the first and second technician 
is blinded. 
7.3.  Quality of wHo specimen bank 
samples
Standard operating procedures were established for the 
preparation of all specimen bank samples (26). Culture lines 
of parasites and wild-type samples were selected on the 
basis of previous evidence and data from specific studies. All 
diluted parasite sample aliquots were stored and transported 
at –70°C and were used only once within 8 hours of thawing.
7.4.  Quality of the product testing 
site 
The Division of Parasitic Diseases and Malaria, Center for 
Global Health, CDC, is the main operating component of 
the Department of Health and Human Services of the USA 
for malaria control and prevention. Laboratories within the 
Division are accredited by Clinical Laboratory Improvement 
Amendments and are monitored by an internal quality 
management system.
8. etHIcAl consIderAtIons
Each specimen collection site obtained approval from a WHO 
research ethics review committee and/or a local institutional 
review board for specimen collection, transport and archiving 
of blood samples for the purpose of RDT product testing, lot 
testing and quality assurance.
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9. dAtA AnAlysIs 
9.1.  measures of parasite 
detection: panel detection 
score and positivity rates
As shown in Fig. 5, a product must return four positive test 
results at the manufacturers’ recommended minimum reading 
time (two from lot 1, two from lot 2 at the initial reading time) 
when tested against a parasite density of 200 parasites/µL to 
contribute to its PDS. When tested against 2000 parasites/µL 
(Fig. 6), the product must return two positive tests at the 
manufacturers’ recommended minimum reading time (one 
from each lot). Thus, the PDS is a measure of inter-test and 
inter-lot consistency, as well as the ability of the test to 
detect antigen. The PDS for P. falciparum indicates an RDT 
result that confirms the presence of P. falciparum when tested 
against cultured and wild-type P. falciparum samples, while 
the P. vivax PDS indicates Plasmodium-positive/P. falciparum-
negative results when tested with wild-type P. vivax samples.
The positivity rate is the percentage of all tests of a particular 
product that returned a positive result at the manufacturers’ 
recommended minimum reading time when tested against a 
P. falciparum or P. vivax sample.
9.2.  false-positive results
False-positive results are analysed and reported as two 
groups: those with incorrect species identification and those 
that returned a positive result for samples that do not contain 
Plasmodium spp. Specifically, the false-positive rate is the 
percentage of all tests of a particular product that returned 
a positive test result when it should not have been obtained, 
when read at the manufacturer’s recommended minimum 
reading time.
9.2.1 Incorrect species identification
A test is considered to have returned an incorrect species 
result if a positive P. falciparum test line appears when 
testing a sample containing non-P. falciparum (P. vivax) 
parasites. Fig. 7 illustrates the various possibilities for incor-
rect species identification in combination tests. For example, 
if P. falciparum samples result in only a visible pan-specific 
(or non-P. falciparum-specific) test line in combination 
tests, the result is considered to be a false-positive for 
non-P. falciparum parasites.
9.2.2 false-positive results for Plasmodium-
negative samples
Any positive reading of samples with no Plasmodium parasites 
is considered a false positive. In phase 2, parasite-negative 
samples are clean negative samples and samples containing 
other infectious agents (dengue, leishmania, Chagas, schisto-
soma and rapid plasma reagin, which is indicative of syphilis 
infection) and immunological factors (rheumatoid factor, 
anti-nuclear antibodies, anti-mouse antibodies) (Table 2).
9.3.  band intensity
All positive test results were recorded with their band inten-
sity against a standard reference chart, matched closely to 
Figure 7: Classification of incorrect species identification with combination malaria RDTs 
Pf/pan combination tests
Panel sample Pf + / Pan - Pf + / Pan + Pf - / Pan + Pf - / Pan -
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line colour. On the basis of the results of the first reader, the 
distribution of band intensity results is presented as the mean 
band intensity of positive results. In addition, the intensity 
was expressed for each possible result (0, 1, 2, 3 or 4) as the 
percentage recorded at that level1.
9.4.  lot agreement 
Agreement between test lots is calculated from the number 
of samples that return a positive result on both RDTs tested in 
that lot against parasite-positive samples at 200 parasites/µL, 
and on the single RDT from each lot tested against samples 
at 2000 parasites/µL. High inter-lot agreement indicates 
consistency in detecting malaria parasites. When one test is 
invalid and the other positive, positive agreement is recorded. 
Fig. 8 shows sample calculations for lot agreement.
9.5.  Invalid tests
Invalid tests are those deemed invalid during testing of both 
lots, with samples at 200 parasites/µL and 2000 parasites/µL.
9.6.  Heat (thermal) stability 
The results of heat stability testing are reported as the 
number of positive tests against one cultured P. falciparum 
or one wild-type P. vivax parasite sample at 200 and 
2000 parasites/µL based on the first reading of two lots at 
each parasite density (maximum score is 30 (P. falciparum) 
or eight (P. vivax) against 200 parasites/µL samples and 10 
(P. falciparum) or four (P. vivax) against 2000 parasites/µL 
1 A standard intensity comparison chart is used, which allows matching 
to the closest of four common colour variants of labelled antibodies 
used in RDTs, each at four levels of intensity.
samples)2 and mean band intensity (for positive tests only 
based on the first reading) after the lots were stored at room 
temperature (21–25°C) and at 35°C and 45°C for 2 months. At 
some point during the 60-day incubation period for the late 
entry test (CareStart™ Malaria Pf/PAN (pLDH)- RMLM-05071), 
the humidity regulator in the 45°C  stability chamber  was 
compromised leading to water-soaking of all test boxes. The 
precise timing of this event and the effect on temperature and 
humidity are unknown. Testing was still performed because 
all cassette packaging was intact. 
9.7.  Anomalies 
The presence and frequency of commonly observed anoma-
lies – red background, red background obscuring test line(s), 
incomplete clearing, incomplete migration, failed migration, 
strip misplaced in cassette (shift), specimen pad not seen in 
the sample window, ghost test line(s), diffuse test line(s), 
patchy broken line(s) and buffer remains pooled in buffer 
well – were routinely recorded for all round-7 products. 
Photographs and descriptions are shown in Fig. AS2.1. 
9.8.  labelling and instructions 
for use
For each product, technicians recorded whether the product 
met each of the recommended criteria. The results were 
pooled for analysis. The proportions of products that met a 
selection of recommended criteria is presented graphically 
in Figs 31–38.
2 Fifteen tests per lot against 200 parasites/µL samples, five tests 
per lot against 2000 parasites/µL for P. falciparum samples, four 
tests per lot against 200 parasites/µL samples and two tests per lot 
against 2000 parasites/µL for P. vivax samples. Invalid results were 
excluded from the analysis.
Figure 8: Explanation of lot agreement calculation 
Test results  
(1= positive, 0 = negative)
Derived values  
(1= both positive, 0 = both negative)













Sample 1 1 1 1 1 1 1 1 1
Sample 2 1 0 0 0 Disagree 0 Can’t compare 0
Sample 3 0 1 0 1 Disagree Disagree Can’t compare 0
Sample 4 0 0 0 0 0 0 0 0
Sample 5 1 1 1 1 1 1 1 1
PDS = sum (f) / number of samples = 2/5 = 40
Lot 1 PDS = sum (a) / number of samples = 2 / 5 = 40
Lot 2 PDS = sum (b) / number of samples = 2 / 5 = 40 
Positivity = number of positive results / total number of tests = 11 / 20 = 55% 
Agreement between tests = (count number of 0 and 1s in (a) and (b)) / (number of samples x 2 lots) = 7 / 10 = 70% 
Agreement between lots = (count number of 0 and 1s in (d)) / (number of samples - ‐ number of “can’t compare” in (d)) = 3 /3 = 100% 
Note: reader 1 = Technician 1 in raw data files
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10. AssocIAtIon between pArAsIte 
densIty And AntIgen concentrAtIon 
Malaria RDTs detect parasite-derived antigen. The relation 
of the concentration of antigen available from the blood 
sample (after lysis of red cells and parasites) to the peripheral 
parasite density varies widely because of a series of host and 
parasite factors (Box 4).
In establishing panels for the product testing programme 
that reflect possible variations in antigen concentration for 
parasitaemia of 200 parasites/µL, a large number (> 300) of 
wild-type parasite samples from clinical cases in different 
geographical areas were analysed by quantitative ELISA for 
HRP2, pLDH and aldolase. Only samples with antigen values 
within the 90th percentile for HRP2, pLDH and aldolase 
were selected for the performance panels. Furthermore, the 
distribution of antigen levels for HRP2, pLDH and aldolase was 
compared with that in previous rounds to ensure consistency. 
No statistically significant differences in average antigen 
levels between the panels for rounds 1–7 were detected for 
any of the antigens (p > 0.5, Kruskal-Wallis test). Therefore, 
the panels used for the product testing rounds can be consid-
ered comparable (Annex S1).
11. evAluAtIon of mAlArIA rApId 
dIAgnostIc tests In tHe lAborAtory 
And In tHe fIeld 
Despite the strengths of the product testing programme, the 
evaluations are not completely analogous to field testing 
of malaria RDTs. In order to compose a panel that could be 
used to evaluate RDTs reproducibly, blood samples must be 
diluted, frozen and stored below −70°C; however, blood that 
has undergone freezing and thawing is lysed and may not 
have exactly the same characteristics as fresh blood. Another 
difference from field evaluation is use of a micro-pipette to 
place blood in the RDT device rather than the blood transfer 
device provided by the manufacturer. This is necessary because 
blood is collected from a cryo-tube rather than a finger-prick 
and because the blood transfer devices provided with the 
different products vary (31). This technique also ensures the 
consistency of testing by reducing the likelihood of operator 
error. As all samples in the panel used for the evaluation are 
prepared from parasites that express HRP2, the results will 
not be predictive of field trial results of parasite populations 
with significant levels of HRP2 deletion (12–13). In addition, 
the population frequency of blood immunological factors or 
infectious diseases, which can result in false-positive results, 
may vary. Therefore, the sensitivity and specificity of an 
RDT in the field depends on the epidemiological situation. 
The evaluation reported here does not predict sensitivity or 
specificity in a given field situation but the rates of detection 
of target antigens and false-positive results of RDTs against a 
standardized panel in a controlled, repeatable manner. As the 
panel is meant to be a close approximation to field samples, 
the detection rates of different products will be reflected 
in similar differences in the field. The panel is designed to 
include a large number of samples that are close to the limit 
of detection of RDTs (200 parasites/µL) and is therefore likely 
to discriminate between them more clearly than a field trial. 
It follows that, in settings where the parasite density is very 
high, no differences in the PDS or positivity rates of tests or 
much smaller differences will be observed than those reported 
against the WHO evaluation panel. Furthermore, where the 
parasite density is very low, the detection rates may be lower 
than those reported here.
Box 4. Explanations for variable antigen concentrations in samples with the same parasite density
• variation in antigen expression among isolates
• different durations of infections (accumulating antigens)
• different parasite growth stages at the time of collection (expressing different levels of antigens)
• presence of circulating HRP2 from previous cycles of growth
• HRP2 produced by parasites sequestered in the host’s vascular tissues that cannot be accounted for in the estimate of parasite 
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Field trials have a place in product selection, particularly 
in determining which of a short-list of products is most 
appropriate for the technicians and situation of its intended 
use in a programme (e.g. ease-of-use characteristics). Such 
trials should have carefully defined objectives and procedures 
designed to achieve them. Trials to determine the probable 
field sensitivity and specificity of a product also have a 
place but require large samples and populations with low 
parasite densities if significant differences are to be found 
between well-performing products; they must also be closely 
controlled and are therefore expensive. Such trials do not 
allow comparison of a large number of products. WHO has 
published recommendations for good practice in malaria 
field trials (32), which should be followed to improve the 
reproducibility and quality of the results.
12. results 
12.1.  summary
Round 7 of WHO malaria RDT product testing provided 
results for 46 products evaluated against P. falciparum 
culture samples, and all the products proceeded to evalu-
ation against wild-type samples collected from parasi-
taemic patients on three continents and a large panel of 
parasite-negative samples. Heat stability was assessed at 
the temperatures commonly encountered in malaria-endemic 
countries. Thirteen research institutes were engaged in either 
sample collection or sample characterization to establish 
the evaluation panels. Between February 2016 and August 
2016, approximately 65 000 RDTs were tested at the CDC. 
The main results are presented in Tables 4 and 5, which 
group the RDTs by the species they are designed to detect, 
i.e. P. falciparum only, P. falciparum and all species or P. falci-
parum and P. vivax. Note that only tests against P. falciparum 
and P. vivax were evaluated, and the evaluation therefore 
does not indicate whether a product intended to detect other 
species, i.e. P. malariae, P. ovale, could do so. 
PDS values at both high and low parasite concentrations are 
presented, as are false-positive rates and the percentages 
of invalid test results. Tests in each category are listed 
alphabetically, but the results are colour-coded according 
to WHO-recommended RDT procurement selection criteria 
(Box 3); WHO prequalification status is also indicated. When 
choosing an appropriate product, it is important also to 
review its thermal stability (Tables 6a and 6b) according to 
the expected conditions of transport and storage in the field. 
The results of the evaluation are listed below. 
• The overall range of results against wild-type P. falciparum 
and negative samples, including P. falciparum PDS, P. falci-
parum positivity rate and heat stability, were similar to 
those in rounds 1–6 (3–8), the false-positivity rates and 
P. vivax PDS and P. vivax positivity rates were similar to 
those in round 6, and better than in previous rounds.
  The median PDS for P. falciparum at low parasite densities 
in round 7 (89.5%) was slightly higher than in rounds 5 
and 6 (both 86%) and similar to that seen in round 4 
(89.3%). No products in round 7 scored a PDS of 100% 
for the P. falciparum detecting line. The PDS for P. vivax 
at low densities has improved consistently since round 1 
(median, 30%), the results for rounds 2, 3, 4, 5, 6 and 7 
being 75.0%, 51.4%, 61.8%, 65.7%, 82.9% and 90.0%, 
respectively. Six products achieved 100% PDS on their 
pan-pLDH and P. vivax pLDH lines when tested against 
P. vivax but had lower scores for their P. falciparum 
detecting lines. The median false-positive rate on clean 
negative samples and samples containing other infectious 
agents was 0%, while samples containing immunological 
factors had a median overall false-positive rate of 2.8%. 
• A number of RDTs consistently detected malaria at a low 
parasite density (200 parasites/µL), had low false-positive 
rates, were stable at tropical temperatures, are relatively 
easy to use and can detect P. falciparum, P. vivax or both. 
This increases the number of well-performing tests from 
that in rounds 1–6.
• The one P. falciparum-only test detecting pf-pLDH did 
not meet procurement criteria; however, one combination 
non-HRP2 detecting RDT met criteria for P. falciparum and 
P. vivax targeting pf-pLDH and pan-pLDH, respectively.
• The performance of products varied at low parasite density 
(200 parasites/µL), but most showed high detection rates 
for P. falciparum and P. vivax at 2000 parasites/µL. 
• All, except two, round-7 products had an HRP2 detecting 
line, and most of these products achieved a high PDS for 
P. falciparum detection at low parasite density. 
• Several combination tests achieved PDS at the upper end 
of the range for both P. falciparum and P. vivax. (Fig. S3).
• There was minimal lot-to-lot variation in the test perfor-
mance of round-7 products. 
• Overall, approximately half of the combination tests with 
Pf and Pan lines in which HRP2 was used for detection of 
P. falciparum, returned positive results only on the HRP2 
band at lower densities of P. falciparum. Results were 
product-specific, with values ranging from 5% to 89%. 
Manufacturers’ instructions should therefore classify 
P. falciparum infections as positive in either the HRP2 
test line alone or in combination with the pan-pLDH line.















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4342 Malaria rapid diagnostic test perforMance – results of WHo product testing of malaria rdts: round 7 (2015–2016)
• Only one of two tests met the WHO procurement criterion 
for detection of P. falciparum with Pf-pLDH alone. This 
test had a PDS of 75%, a false-positive rate of 0% and 
an invalid rate of 0.6%. However, the test had diminished 
performance after incubation at 35°C and 45°C (Figs. 22, 
23). The PDS in other Pf-pLDH tests in which HRP2 was 
used to detect Pf on the same test line, ranged from 
90% to 94%, however it cannot be distinguished if this 
performance results from detection of HRP2, Pf-pLDH 
or both. Tests that can detect pfhrp2-deleted para-
sites are a high priority in malaria-endemic countries 
with a high prevalence of such parasites (12, 13, 33, 34). 
• No consistent pattern was seen in the changing perfor-
mance of the five compulsorily resubmitted products. The 
PDS of some of the P. falciparum and P. vivax tests improved 
over their results in round 3, while that of others decreased. 
Tables 4 and 5 summarize the performance of malaria RDTs 
against cultured P. falciparum parasites, blood containing 
wild-type P. falciparum and P. vivax parasites and Plasmodium 
spp.-negative samples. Detailed phase-1 and phase-2 results 
of product testing are given in Annexes 3 and 4, respectively. 
The data are shown graphically in Figs. 9–19.






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































a All but 2 RDTs target HRP2 for falciparum detection. Two products target only pf-pLDH for falciparum detection (RMLM-05071 and C60RHA25). Two products 
(RMAM-05071 and 05FK130-40-0) target both HRP2 and pf-pLDH on the same line. One product (RMSM-05071) targets both HRP2 and pf-pLDH on separate lines; 
for this product HRP2 and pf-pLDH based results are presented separately in table 4. 
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12.2.  phase 1: p. falciparum 
culture panel
All but one of the products consistently detected 100% of 
cultured P. falciparum parasites at high parasite density 
(2000 parasites/µL); the PDS of the exception was 95%. 
The PDS was more variable (75–100%) at low parasite density 
(200 parasites/µL) (Fig. 9). 
12.3. phase 2: wild -type p. falciparum 
and p. vivax- and plasmodium spp.-
negative samples. 
12.3.1 P. falciparum detection
All 46 products in round 7 were designed to detect P. falci-
parum. As in phase 1, all the tests had very high scores at 
the high parasite density, with a PDS ≥ 96%. Seventeen of 
the 19 products specific for P. falciparum alone achieved 
a PDS ≥ 75% against samples with low parasite density 
(Table 5, Fig. 10). 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































a 3 (3%) of the 100 P. falciparum high parasite density dilution samples were at 5000 parasites/μL rather than 2000    
b Phase 2 evaluation panel consisted of 100 clinical blood samples containing wild type P. falciparum. RDTs performed = 2 tests x 2 lots at 200 p/μL and 1 test x 2 lots 
at 2000 p/μL;  
c All but 2 RDTs target HRP2 for falciparum detection. Two products target only pf-pLDH for falciparum detection (RMLM-05071 and C60RHA25). Two products 
(RMAM-05071 and 05FK130-40-0) target both HRP2 and pf-pLDH on the same line. One product (RMSM-05071) targets both HRP2 and pf-pLDH on separate lines; 
for this product HRP2 and pf-pLDH based results are presented separately in table 5.  
d A sample is considered detected only if all RDTs from both lots read by the first technician, at the minimum specified reading time, are positive.
4544 Malaria rapid diagnostic test perforMance – results of WHo product testing of malaria rdts: round 7 (2015–2016)
Only one of two tests met WHO procurement criteria based 
on detection of P. falciparum with Pf-pLDH alone. This test 
achieved a PDS of 75%, a false-positive rate of 0% and an 
invalid rate of 0.6%. The PDS in other Pf-pLDH tests in which 
HRP2 was used to detect Pf on the same test line, ranged 
from 90% to 94%, however it cannot be distinguished if 
this performance results from detection of HRP2, Pf-pLDH 
or both. Tests that can detect pfhrp2 gene-deleted parasites 
are a high priority in malaria-endemic countries with a high 
prevalence of such parasites (12, 13, 33, 34). 
12.3.2 P. vivax detection 
Fig. 11 shows that 25 of 27 (93%) products designed to 
detect P. vivax consistently detected ≥ 75% at high parasite 
density (2000 parasites/µL), and 19 (70%) achieved the same 
threshold of PDS against samples with 200 parasites/µL. 
The overall detection rate in low-parasite density wild-type 
P. vivax samples was lower than that for P. falciparum. At a 
low parasite density (200 parasites/µL), 13 products had 
a PDS ≥ 90%, and 18 had a PDS < 75% (Table 5, Fig. 11), 
which is an improvement on round-5 results, in which only 
eight products had a PDS ≥ 90%, and 19 had a PDS < 75%.










































































































































































































































































































































































































































































































































































































































































































a Phase-2 evaluation panel consisted of 35 clinical blood samples containing wild type P. vivax; RDTs performed = 2 tests x 2 lots at 200 p/μL and 1 test x 2 lots at 2000 
p/μL; 
b All RDTs target pan-pLDH or pv-pLDH 






4544 Malaria rapid diagnostic test perforMance – results of WHo product testing of malaria rdts: round 7 (2015–2016)
12.3.3 combined detection of P. falciparum 
and P. vivax 
Of the 27 pan-specific and combination tests, 19 (70%) had 
a PDS ≥ 75% for both P. falciparum and P. vivax at a low 
parasite density (200 parasites/µL) (Table 5). Most products 
performed well at a high parasite density. 
12.3.4 P. falciparum and P. vivax 
positivity rate 
The positivity rate was calculated in addition to the PDS. 
As expected, the positivity rates were higher than the PDS 
but mirrored the PDS against wild-type P. falciparum and 
P. vivax samples (Figs 12 and 13). 
12.3.5 band intensity 
Although RDTs do not provide quantitative results, the techni-
cians graded positive results according to a standard colour 
chart and calculated the mean band intensity for positive 
results (Annex 4, Tables A3.2 (for phase 1), A4.2 and A4.3 
(for phase 2)). A positive correlation was found between the 
PDS and band intensity (Spearman rank correlation, r = 0.75, 
p < 0.001 for the P. falciparum phase-2 panel and r = 0.82, 
p < 0.001 for the P. vivax panel).
Of the combination RDT products containing a pan test band 
that gave a positive indication for P. falciparum against 
low-density P. falciparum samples, 51.6% (2473/4796) gave 
positive results on both the P. falciparum and pan test 




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Positivity rate (HRP2) 
Positivity rate (pLDH)
Panel detection score (HRP2) 
Panel detection score (pLDH)
a Phase-2 evaluation panel consisted of 100 clinical blood samples containing wild-type P. falciparum. RDTs performed = 2 tests x 2 lots at 200 p/μL and 1 test x 2 lots 
at 2000 p/μL; 
b A sample is considered detected only if all RDTs from both lots read by the first technician, at minimum specified reading time, are positive;  
c The total number of times a test returned a positive result divided by the total number of times it should have (x100).
4746 Malaria rapid diagnostic test perforMance – results of WHo product testing of malaria rdts: round 7 (2015–2016)
bands, and 47.8% (2292/4796) were positive only on the 
P. falciparum test band. A small proportion (0.6%, 31/4796) 
were positive only on the pan test band.
When the pan test band in the combination products was 
positive, the intensity of the band was the same as the 
P. falciparum test band in 11.2% of tests, while 33.0%, 39.1% 
and 16.7% of the pan tests bands were one, two and three 
intensities lower than the corresponding P. falciparum test 
bands, respectively. Only 0.1% of tests had a pan band inten-
sity larger than the corresponding P. falciparum test band. 
When tested at low parasite density, none of the tests 
achieved 75% with a band intensity > 2 for P. falciparum 
or P. vivax, although 12 achieved at least 50% with this 
intensity for P. falciparum and 1 for P. vivax. 


























































































































































































































































































































































































































































































































































































































































































































Positivity rate (pLDH) 
Positivity rate (Aldolase)
Panel detection score (pLDH) 
Panel detection score (Aldolase)
a Phase-2 evaluation panel consisted of 35 clinical blood samples containing wild type P. vivax; . RDTs performed = 2 tests x 2 lots at 200 p/μL and 1 test x 2 lots at 
2000 p/μL;  
b A sample is considered detected only if all RDTs from both lots read by the first technician, at the minimum specified reading time, are positive;  
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12.3.6 false-positive rates 
None of the products had a false-positive rate > 10% with 52 
clean-negative samples of the P. falciparum test line (Fig. 14); 
three products had false-positive rates > 10% with pan or 
P. vivax test lines (Fig. 15). Fifteen products had false-positive 
rates > 5.6% (for one or both lots), against samples containing 
immunological factors. The rates of 9 of these were 5.6–7.4%, 
and those of a further six were 11.1–24.1% in both lots. These 
rates are worse than those in round 6 but similar to those 
in previous rounds. False positivity was seen predominantly 
for samples containing immunological factors (seven of the 
eight instances of false positivity > 10%). 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































a Phase-2 evaluation panel included 100 Plasmodium spp.-negative samples, of which 52 were clean negatives  from healthy volunteers with no known  
current illness or blood abnormality.
4948 Malaria rapid diagnostic test perforMance – results of WHo product testing of malaria rdts: round 7 (2015–2016)
The false-positivity rates for samples containing non-
Plasmodium spp. agents were similar to those in round 6. In 
only four products was the false-positivity rate > 3.3%, and 
only one had a false positivity rate > 10% (10% and 13% 
in each of the two lots); three products had false-positivity 
rates of 6.7% for one or both lots. False positivity was seen 
against all four of the samples of infections pathogens used: 
schistosoma, leishmaniasis, Chagas disease and dengue.


















































































































































































































































































































































































































































































































































































































































































































a Phase-2 evaluation panel included 100 Plasmodium spp.-negative samples of which 52 were clean negatives, from healthy volunteers  
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Only 21 samples contained non-Plasmodium infectious 
agents and 27 samples contained immunological factors. 
For detailed information on the blood abnormalities and 
pathogens that generated false-positive results in specific 
products, see Annex 4 (Tables A4.6–A4.9). 
Products were assessed for false-positivity rates for species 
that they were not designed to detect (Tables A4.4 and A4.5). 
Overall, the rates were low; only two combination products 
showed > 10% false positivity for a non-P. falciparum 
infection when tested against samples of P. falciparum at 
200 or 2000 parasites/µL. 
There was no clear trend of higher false-positive rates in tests 
with higher PDS, indicating no clear association between 
the sensitivity and specificity of the tests at these detection 
thresholds (Figs 16 and 17).
Figure 16: Phase-2 P. falciparum false-positive ratea versus P. falciparum panel detection scoreb  















0 25 50 75 100
P. falciparum PDS at 200 parasites/μL
a False-positive rate is for clean-negatives, only; 
b A sample is considered detected only if all RDTs from both lots read by the first technician, at the minimum specified reading time, are positive.
Figure 17: Phase-2 P. vivax false-positive ratea versus P. vivax panel detection scoreb  



















0 25 50 75 100
a False-positive rate is for clean negatives only.
b A sample is considered detected only if all RDTs from both lots read by the first technician, at the minimum specified reading time, are positive.
5150 Malaria rapid diagnostic test perforMance – results of WHo product testing of malaria rdts: round 7 (2015–2016)
12.4.  performance of resubmitted products 
Of the 46 products in round 7, 15 (33%) had been evaluated 
previously. For six of the resubmissions, this was the second 
testing, and nine had been tested more than twice. Figs 18 
and 19 show the performance in the current and previous 
testing of products against wild-type P. falciparum and 
P. vivax at 200 parasites/µL and clean-negative samples that 
had been resubmitted compulsorily and voluntarily. 
The change in PDS between the two rounds varied for the five 
products that had not been tested since round 3 (compulsory 
resubmissions): two had improved performance against 
P. falciparum (increases of 6 and 7 percentage points), and 
three showed worse performance (decreases of 7, 8 and 11 
percentage points). The changes in the two pan-detecting 
products in their ability to detect P. vivax differed from 
those in round 3: the PDS of one increased by 5 percentage 
points, while that of the other dropped from 91% in round 
3 to 0 in round 7. 
Figure 18: Phase-2 P. falciparum panel detection scorea at low parasite density (200 parasites/μL) during initial and 





















































Panel detection score (prior submission)
Panel detection score (Rd 7)
False-positive (prior submission)
False-positive (Rd 7)
a Panel detection score - A sample is considered detected only if all RDTs from both lots read by the first technician, at the minimum specified reading time, are positive.
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For the 10 products that were voluntarily resubmitted for 
testing, no significant correlation was found between the 
PDS for P. falciparum at lower parasite density in consecu-
tive submissions (Spearman rank correlation, r = – 0.30, P 
= 0.405). The median change in detection of P. falciparum was 
+7.5% (range, –8.0 to 40.0%), which was almost significantly 
different from zero (Wilcoxon signed rank test, P = 0.052). 
Most of the products (8/10) detected P. vivax, and detection of 
this parasite improved overall (median change, 28.6%; range, 
–8.6 to 65.7%), which was almost statistically significant 
(Wilcoxon signed rank test, P = 0.058). No statistically 
significant correlation was found between the PDS of 
consecutive submissions against P. vivax at lower parasite 
density (Spearman rank correlation, r = 0.503, P = 0.20). 
On re-testing, approximately half of the resubmitted products 
(7/15) showed no change or an improvement in their false-
positivity rate against clean negative samples; the median 
change in false-positivity rate was +0.4%. Most of the 
changes on re-testing were small (< 2.5%), except for two 
products, in which the false-positivity rate decreased by 
7.3% for one product and increased by 22.9% for another. 
Both of these products were voluntarily resubmitted for 
testing in Round 7. 
Figure 19: Phase-2 P. vivax panel detection scorea at low parasite density (200 parasites/μL) during initial and subsequent 
testing of compulsorily and voluntarily resubmitted malaria RDTs  
Panel detection score (prior submission)








































































a Panel detection score - A sample is considered detected only if all RDTs from both lots read by the first technician, at the minimum specified reading time, are positive. 
b  Clean-negative blood samples from healthy volunteers with no known current illness or blood abnormality.
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13. HeAt stAbIlIty 
13.1.  summary
A single P. falciparum culture sample and single wild-type 
P. vivax sample were used as the reference samples to test 
heat stability. Continuous in vitro culture of a wild-type 
P. vivax sample is difficult, largely because of selective 
invasion of reticulocytes by the parasite. Round 7 was 
the second in which the stability of test lines to detect 
non-P. falciparum parasites was tested. Because of the 
large number of aliquots used to assess heat stability, fewer 
replicate RDTs were tested against P. vivax, with four assessed 
against the 200 parasites/µL sample and two against the 
2000 parasites/µL sample, for each of the two lots. The results 
of heat stability testing are summarized in Tables 6a and 6b, 
and detailed results are presented in Annex 4 (Tables A4.10–
A4.18) and in Figs. 20–29, which show the results for the two 
lots combined. The maximum obtainable scores were 30 (15 
tests per lot) against P. falciparum for 200 parasites/µL and 10 
for 2000 parasites/µL (five tests per lot). The maximum score 
obtainable against P. vivax was 8 for 200 parasites/µL (four 
tests per lot) and 4 for 2000 parasites/µL (two tests per lot).
Confirmatory data on the stability of recent production 
lots of all tests can be obtained from the manufacturers 
and through the WHO–FIND lot-testing programme during 
product selection for procurement of RDTs.
13.2.  Plasmodium falciparum 
All of the 19 P. falciparum-only RDTs with an HRP2 test line 
were heat stable. Thus, they detected a cultured P. falciparum 
sample the same number of times when stored at room 
temperature (< 25°C) or at 35°C or 45°C (with 75% humidity) 
for 2 months (Fig. 20) as at baseline. One P. falciparum-only 
detecting product had a line that detected P. falciparum pLDH 
(in addition to an HRP2 line). Both lines were heat stable.
Of the 27 combination tests, 25 had an HRP2-detecting 
line. Of these, 24 tests were heat stable against a cultured 
P. falciparum sample. The 25th showed slight deterioration 
after 2 months’ storage at 45 °C. One of the 24 heat-stable 
products showed a slight loss in detection when stored at 
35 °C but not at 45 °C. The two combination tests with only 
pLDH-detecting lines for P. falciparum both showed some 
heat instability: one with a slight decline in performance at 
35 °C and then again at 45 °C, and the second with a major 
decrease in performance at 35 °C and then again at 45 °C.
Many combination test products had pan lines that poorly 
detected low-density P. falciparum samples at baseline. 
Furthermore, tests with a baseline positivity < 100% showed 
unpredictable variation in positivity rates on subsequent 
testing, indicating that they were on the borderline of 
visibility. Two of the three combination tests with good (i.e. 
scoring at least 28/30) baseline pan line reactivity to the 
low-density sample showed good detection throughout, 
while one showed a marked reduction in performance after 
2 months at 45 °C. The stability of pan-pLDH-detecting test 
lines was much poorer than that of HRP2-detecting test 
lines (Figs 20–25). 
13.3.  Plasmodium vivax
Testing of the heat stability of P. vivax-detecting lines using 
a P. vivax clinical sample was introduced in round 6. Many 
(11/14) of the combination RDTs with a pan-LDH test line 
were heat stable after 2 months’ storage at 45 °C when 
tested against a wild-type P. vivax sample. Two of the 11, 
however, showed some variation in performance under other 
conditions: one had slightly poorer performance at baseline 
and after storage at room temperature, and the other had 
very poor performance after storage at 35 °C. Of the three 
tests that did not detect 100% of samples after storage at 
45 °C, two showed 100% detection at baseline but some 
decrease after storage at 35 °C and 45 °C (one with only 
a slight decrease and the other with a more significant 
decrease). The third of the three tests performed very poorly 
at baseline (only 2 of 8 samples detected) and did not detect 
any samples after storage at any temperature. 
The P. vivax pLDH line appeared to be more stable, 11 of 13 
being heat stable under all testing conditions and a further 
one showing only a slight decrease in detection at 35 °C and 
100% detection at 45 °C. The exception was a product in 
which the P. vivax pLDH line did not detect any of the P. vivax 
samples at baseline or after storage at room temperature and 
only slightly better performance after incubation with one of 
eight samples detected after storage at 35 °C and three of 
eight samples detected after storage at 45 °C (Figs 26–29).
Overall, both P. falciparum and P. vivax detecting prod-
ucts appeared more stable against samples with high 
(2000 parasites/µL) rather than low (200 parasites/µL) 
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Figure 20: Heat stability of P. falciparum-specific test line of P. falciparum-only tests against a low-density  
P. falciparum sample (200 parasites/μL). Positivity rate at baseline and after 60 days’ incubation 
DIAQUICK Malaria P.f. Cassette - W06200
Adv Dx™  Malaria Pf Rapid Malaria Antigen Detection Test - RKMAL017
ADVANCED QUALITY™ ONE STEP Malaria (p.f) Test - ITP11002-TC25
Aspen© Malaria Ag Pf - AS0015
BioTracer™  Malaria P.f Rapid Card - 17912
CareStart™ Malaria Pf (HRP2) Ag RDT - RMOM-03091
CareStart™  Malaria Pf (HRP2/pLDH) Ag Combo 3-Line - RMSM-05071
careUS™  Malaria Pf (HRP2) Ag - RMO-M05082
ICT MALARIA P.F. CASSETTE TEST - ML01
KHB© Malaria Ag (HRP2) Pf Rapid Test - R-409-50-C
GMD Malaria Pf test - GMDMALPF001
One Step MalariaHRP2 (P.f) Test - W37-C
One Step Test for Malaria Pf HRP-II Ag MERISCREEN Malaria Pf HRP-II Ag - MPHRPD-01
PALUTOP + pf© - 5531
Parahit f© Ver 1.0 - Dipstick - 55IC103-50
Parahit© f Ver 1.0 - Device - 55IC104-50
SD BIOLINE Malaria Ag P.f. (HRP2/pLDH) 2 Lines - 05FK130-40-0
Malaria Pf Rapid Test - GCMAL(pf)-402a






















a Maximum score is 30 (15 tests x 2 lots)
Figure 21: Heat stability of P. falciparum-specific test line of P. falciparum-only tests against a high-density  







BioTracer™ Malaria P.f Rapid Card - 17912
Adv Dx™ Malaria Pf Rapid Malaria Antigen Detection Test - RKMAL017
ICT MALARIA P.F. CASSETTE TEST - ML01
DIAQUICK Malaria P.f. Cassette - W06200
ADVANCED QUALITY™ ONE STEP Malaria (p.f) Test - ITP11002-TC25
Aspen© Malaria Ag Pf - AS0015
CareStart™ Malaria Pf (HRP2) - RMOM-03091
CareStart™ Malaria Pf (HRP2/pLDH) Ag Combo 3-Line - RMSM-05071
careUS™ Malaria Pf (HRP2) Ag - RMO-M05082
One Step MalariaHRP2 (P.f) Test - W37-C
GMD Malaria Pf test - MDMALPF001
Malaria Pf Rapid Test - GCMAL(pf)-402a
KHB© Malaria Ag (HRP2) Pf Rapid Test - R-409-50-C
One Step Test for Malaria Pf HRP-II Ag MERISCREEN Malaria Pf HRP-II Ag - MPHRPD-01
PALUTOP + pf© - 5531
Parahit f© Ver 1.0 - Dipstick - 55IC103-50
Parahit© f Ver 1.0 - Device - 55IC104-50
SD BIOLINE Malaria Ag P.f. (HRP2/pLDH) 2 Lines - 05FK130-40-0

















Baseline RT 35 °C 45 °C
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Figure 22:  Heat stability of P. falciparum-specific test line in combination tests against a low-density  
P. falciparum sample (200 parasites/μL). Positivity rate at baseline and after 60 days’ incubation. 
BIOCREDIT Malaria Ag Pf/Pan (HRPII/pLDH) - C32RHA25
Alere Trueline™ - Rapid test kit for Malaria Ag Pf/Pan (HRP-II/pLDH) - 05FK60AI-40
PALUTOP +4 optima® - 5499
QuickProfile™ Malaria Pf/Pv Antigen Test - 71050
One Step Test for Malaria Pf/Pv Ag MERISCREEN Malaria Pf/Pv Ag - MFLRPD-02
One Step Malaria HRP2/pLDH (P.f/P.v) Test - W056-C
Malaria Pf/PAN Test - PROMALPFV001
Malaria Pf/Pv Rapid Test - GCMAL(pf/pv)-402a
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag Combo RDT - RMVM-03091
Is It... Malaria Pf PAN - MPFPAN050
CareStart™ Malaria Screen RDT - RMAM-05071
ICT MALARIA DUAL TEST - ML03
CareStart™ Malaria Pf/PAN (pLDH) Ag RDT - RMLM-05071
Biosynex® Malaria Pf/Pan - 0584_K25
Rapid 1-2-3 HEMA® CASSETTE MALARIA PF/PAN - MAL-PF/Pan-CAS/25
Rapid Test Kit for Malaria Ag Pf/Pv-Alere Trueline Malaria Ag Pf/Pv - 11108191040
BioTracer™ Malaria P.f/PAN Rapid Card - 17012
BIOCREDIT Malaria Ag Pf/Pv (pLDH/pLDH) - C60RHA25
Biosynex® Malaria Pf/Pv - 0581_K25
Asan Easy Test® Malaria Pf/Pan Ag - AM4650-K
Adv Dx™ Malaria Pan/Pf Rapid Test Detection Kit - RKMAL016
AllTest™ Malaria P.f./Pan Rapid Test Cassette - IMPN-402
NG-Test MALARIA Pf/Pan (pLDH) - NGB-MAL-W23-005
Aspen® Malaria Ag Pf/Pv - AS0060
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag Combo RDT - RMVM-05072
careUS™ Malaria Combo Pf/Pv (HRP2/pLDH) Ag - RMV-M05082





















Baseline RT 35 °C 45 °C
a Maximum score is 30 (15 tests x 2 lots)
Figure 23: Heat stability of P. falciparum-specific test line in combination tests against a high-density  
P. falciparum sample (2000 parasites/μL). Positivity rate at baseline and after 60 days’ incubation. 
CareStart™ Malaria Screen RDT - RMAM-05071
QuickProfile™ Malaria Pf/Pv Antigen Test - 71050
Alere Trueline™ - Rapid test kit for Malaria Ag Pf/Pan (HRP-II/pLDH) - 05FK60AI-40
BioTracer™ Malaria P.f/PAN Rapid Card - 17012
BIOCREDIT Malaria Ag Pf/Pan (HRPII/pLDH) - C32RHA25
ICT MALARIA DUAL TEST - ML03
Rapid Test Kit for Malaria Ag Pf/Pv-Alere Trueline Malaria Ag Pf/Pv - 11108191040
NG-Test MALARIA Pf/Pan (pLDH) - NGB-MAL-W23-005
ADVANCED QUALITY™ ONE STEP Malaria (p.f/p.v.) Tri-line Test - ITP11003-TC25
Adv Dx™ Malaria Pan/Pf Rapid Test Detection Kit - RKMAL016
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag Combo RDT - RMVM-05072
careUS™ Malaria Combo Pf/Pv (HRP2/pLDH) Ag - RMV-M05082
AllTest™ Malaria P.f./Pan Rapid Test Cassette - IMPN-402
Asan Easy Test® Malaria Pf/Pan Ag - AM4650-K
Malaria Pf/PAN Test - PROMALPFV001
Malaria Pf/Pv Rapid Test - GCMAL(pf/pv)-402a
One Step Malaria HRP2/pLDH (P.f/P.v) Test - W056-C
One Step Test for Malaria Pf/Pv Ag MERISCREEN Malaria Pf/Pv Ag - MFLRPD-02
Is It... Malaria Pf PAN - MPFPAN050
PALUTOP +4 optima® - 5499
Rapid 1-2-3 HEMA® CASSETTE MALARIA PF/PAN - MAL-PF/Pan-CAS/25
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag Combo RDT - RMVM-03091
Biosynex® Malaria Pf/Pv - 0581_K25
Biosynex® Malaria Pf/Pan - 0584_K25
Aspen® Malaria Ag Pf/Pv - AS0060
BIOCREDIT Malaria Ag Pf/Pv (pLDH/pLDH) - C60RHA25























Baseline RT 35 °C 45 °C
a Maximum score is 10 (5 tests x 2 lots)
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Figure 24: Heat stability of pan line of combination tests against a low-density P. falciparum sample (200 parasites/μL). 





















30 Parascreen® - Rapid Test for Malaria Pan/Pf - 503030025
First Response® Malaria Ag. pLDH/HRP2 Combo Card - PI16FRC
QuickProfileTM Malaria Pf/Pan Test - 71063
RapiGEN BIOCREDIT Malaria Ag Pf/Pan (HRPII/pLDH) - C30RHA25
EzDxTM Malaria Pan/Pf Rapid Test Detection kit - RK MAL 001
OnSite Malaria Pf/Pan Ag Rapid Test - R0113C
BioTracerTM Malaria Pf/PAN Rapid Card - 17012
Meriscreen Malaria Pf/Pan Ag - MHLRPD-01
BIONOTE MALARIA P.f.& Pan Ag Rapid Test Kit - RG19-08
Humasis Malaria P.f/Pan Antigen Test - ANMAL-7025
ATOMORAPIDTM Malaria (PF/PAN) - MMAL01
One Step Malaria P.f/Pan Whole Blood Test - W62-C
Is It… Malaria Pf/Pv Device - AL030
a Maximum score is 30 (15 tests x 2 lots)
Figure 25: Heat stability of pan line of combination tests against a high-density P. falciparum sample (2000 parasites/μL). 
Positivity rate at baseline and after 60 days’ incubation. 
AllTest™ Malaria P.f./Pan Rapid Test Cassette - IMPN-402
BIOCREDIT Malaria Ag Pf/Pan (HRPII/pLDH) - C32RHA25
Biosynex® Malaria Pf/Pan - 0584_K25
CareStart™ Malaria Pf/PAN (pLDH) Ag RDT - RMLM-05071
Rapid 1-2-3 HEMA® CASSETTE MALARIA PF/PAN - MAL-PF/Pan-CAS/25
BioTracer™ Malaria P.f/PAN Rapid Card - 17012
Asan Easy Test® Malaria Pf/Pan Ag - AM4650-K
ICT MALARIA DUAL TEST - ML03
Alere Trueline™ - Rapid test kit for Mala ria Ag Pf/Pan (HRP-II/pLDH) - 05FK60AI-40
Adv Dx™ Malaria Pan/Pf Rapid Test Detection Kit - RKMAL016
Is It... Malaria Pf PAN - MPFPAN050
NG-Test MALARIA Pf/Pan (pLDH) - NGB-MAL-W23-005
PALUTOP +4 optima® - 5499
CareStart™ Malaria Screen RDT - RMAM-05071























Baseline RT 35 °C 45 °C
a Maximum score is 10 (5 tests x 2 lots)
Figure 26: Heat stability of pan line of combination tests against a low-density P. vivax sample (200 parasites/μL). 
Positivity rate at baseline and after 60 days’ incubation. 
Adv Dx™ Malaria Pan/Pf Rapid Test Detection Kit - RKMAL016
AllTest™ Malaria P.f./Pan Rapid Test Cassette - IMPN-402
Asan Easy Test® Malaria Pf/Pan Ag - AM4650-K
BIOCREDIT Malaria Ag Pf/Pan (HRPII/pLDH) - C32RHA25
Biosynex® Malaria Pf/Pan - 0584_K25
BioTracer™ Malaria P.f/PAN Rapid Card - 17012
CareStart™ Malaria Pf/PAN (pLDH) Ag RDT - RMLM-05071
CareStart™ Malaria Screen RDT - RMAM-05071
ICT MALARIA DUAL TEST - ML03
Is It... Malaria Pf PAN - MPFPAN050
NG-Test MALARIA Pf/Pan (pLDH) - NGB-MAL-W23-005
Rapid 1-2-3 HEMA® CASSETTE MALARIA PF/PAN - MAL-PF/Pan-CAS/25
PALUTOP +4 optima® - 5499
Alere Trueline™ - Rapid test kit for Mala ria Ag Pf/Pan (HRP-II/pLDH) - 05FK60AI-40
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Figure 28: Heat stability of P. vivax-specific test line in combination tests against a low-density P. vivax sample 






















CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag Combo RDT - RMVM-03091
Malaria Pf/Pv Rapid Test - GCMAL(pf/pv)-402a
PALUTOP +4 optima® - 5499
Rapid Test Kit for Malaria Ag Pf/Pv-Alere Trueline Malaria Ag Pf/Pv - 11108191040
ADVANCED QUALITY™ ONE STEP Malaria (p.f/p.v.) Tri-line Test - ITP11003-TC25
BIOCREDIT Malaria Ag Pf/Pv (pLDH/pLDH) - C60RHA25
Biosynex® Malaria Pf/Pv - 0581_K25
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag Combo RDT - RMVM-05072
careUS™ Malaria Combo Pf/Pv (HRP2/pLDH) Ag - RMV-M05082
Malaria Pf/PAN Test - PROMALPFV001
One Step Malaria HRP2/pLDH (P.f/P.v) Test - W056-C
One Step Test for Malaria Pf/Pv Ag MERISCREEN Malaria Pf/Pv Ag - MFLRPD-02
QuickProfile™ Malaria Pf/Pv Antigen Test - 71050
a Maximum score is 8 (4 tests x 2 lots)
Figure 29: Heat stability of P. vivax-specific test line in combination tests against a high-density P. vivax sample  























ADVANCED QUALITY™ ONE STEP Malaria (p.f/p.v.) Tri-line Test - ITP11003-TC25
BIOCREDIT Malaria Ag Pf/Pv (pLDH/pLDH) - C60RHA25
Biosynex© Malaria Pf/Pv - 0581_K25
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag Combo RDT - RMVM-03091
CareStart™ Malaria Pf/Pv (HRP2/pLDH) Ag Combo RDT - RMVM-05072
careUS™ Malaria Combo Pf/Pv (HRP2/pLDH) Ag - RMV-M05082
Malaria Pf/Pv Rapid Test - GCMAL(pf/pv)-402a
One Step Malaria HRP2/pLDH (P.f/P.v) Test - W056-C
One Step Test for Malaria Pf/Pv Ag MERISCREEN Malaria Pf/Pv Ag - MFLRPD-02
QuickProfile™ Malaria Pf/Pv Antigen Test - 71050
Rapid Test Kit for Malaria Ag Pf/Pv-Alere Trueline Malaria Ag Pf/Pv - 11108191040
PALUTOP +4 optima© - 5499
Malaria Pf/PAN Test - PROMALPFV001
a Maximum score is 4 (2 tests x 2 lots)
Figure 27: Heat stability of pan line of combination tests against a high-density P. vivax sample (2000 parasites/μL). 
Positivity rate at baseline and after 60 days’ incubation 
Adv Dx™ Malaria Pan/Pf Rapid Test Detection Kit - RKMAL016
Alere Trueline™ - Rapid test kit for Mala ria Ag Pf/Pan (HRP-II/pLDH) - 05FK60AI-40
AllTest™ Malaria P.f./Pan Rapid Test Cassette - IMPN-402
Asan Easy Test® Malaria Pf/Pan Ag - AM4650-K
BIOCREDIT Malaria Ag Pf/Pan (HRPII/pLDH) - C32RHA25
Biosynex® Malaria Pf/Pan - 0584_K25
BioTracer™ Malaria P.f/PAN Rapid Card - 17012
CareStart™ Malaria Pf/PAN (pLDH) Ag RDT - RMLM-05071
CareStart™ Malaria Screen RDT - RMAM-05071
ICT MALARIA DUAL TEST - ML03
Is It... Malaria Pf PAN - MPFPAN050
NG-Test MALARIA Pf/Pan (pLDH) - NGB-MAL-W23-005
Rapid 1-2-3 HEMA® CASSETTE MALARIA PF/PAN - MAL-PF/Pan-CAS/25
PALUTOP +4 optima® - 5499






















Baseline RT 35 °C 45 °C
a Maximum score is 4 (2 tests x 2 lots)
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14. descrIptIon of eAse of 
use, AnomAlIes, lAbellIng And 
InstructIons for use
14.1.  ease of use
After becoming proficient in using a product, two technicians 
submitted a joint agreed assessment of its usability. The 
results, which are a description of the product with emphasis 
on aspects considered important for ease of use in the field, 
are presented in Table 7. The assessment did not include a 
comparison of blood transfer devices, which are critical to 
both the safety and the accuracy of the testing procedure 
and pose a significant challenge to many users. These may 
vary by manufacturer in many products. Procurement deci-
sions should be based on which transfer devices are best 
suited for the intended users, which should be discussed 
with the manufacturer before procurement. It is strongly 
recommended that RDT packaging, contents, safety and ease 
of use be assessed in the field as part of product selection 
(Annex S2, Table AS2.1). 
14.2.  Anomalies
In round 7, technicians regularly recorded anomalies from 
a list of problems encountered with some production lots 
evaluated in past rounds of testing and at WHO–FIND lot-
testing laboratories. Since March 2012, these observations 
have been included in all WHO–FIND lot testing reports 
and were recorded as part of product testing for the first 
time in round 5. Table 8 shows the percentage of tests per 
product in which specific anomalies were observed and 
the frequency of tests with an anomaly in each product. 
Generally, users should be aware of major anomalies that 
may be encountered in production lots (Fig. AS2.1), as they 
can affect interpretation of RDT results. In round 7, 33 
of the 46 products had between one and five different 
types of anomaly; in 13 products, no anomaly was seen 
(Table 8, Fig. 30). Incomplete clearing and red background 
(not obscuring test lines) were the most common anomalies, 
seen in 48% and 24% of products, respectively. Incomplete 
migration, failed migration and a red background obscuring 
the test lines were seen next most often, in 15%, 11% and 
11% of products, respectively. In most (31) of the 33 products 
with anomalies, they were found in < 1% of the tests; in two 
products, anomalies occurred in 1.4% of tests (Table 8). This 
rate is much lower than that in round 6, when all products 
had between one and six anomalies and approximately half 
had a frequency > 2%.
14.3.  labelling and instructions 
for use
Adherence to a list of recommendations for instructions for 
use and product labelling were assessed for the first time 
in Round 7. Figs 31–38 show the percentages of products 
that adhered to the recommendations, grouped by theme.
Generally good adherence was found to the recommenda-
tions for labelling of the main package (Fig. 31) and the 
device (Fig. 32), with exceptions in the guidance on storage 
conditions and the inclusion of appropriate warning labels. 
Labelling of the buffer bottle (Fig. 33) and accessories (Figs 
34–36) met only a few recommendations (see below). The 
instructions for use were highly variable, and many recom-
mendations, including critical ones, were not met.
An important area of divergence from the recommendations 
was for laboratory safety. For example, none of the blood 
transfer devices carried labels indicating that they were for 
single use only, and 59% of lancet packages had no indication 
that those with damaged packaging should not be used (Fig. 
35). The instructions for use of less than 10% of products 
advised disposal of tests in biohazard waste containers, and 
those of less than 20% advised disposal of lancets in sharps 
containers (Fig. 38). Only 26% of the instructions advised that 
a new pair of gloves should be used at each step (Fig. 38).
Important omissions were also found in basic product 
information: 28% of instructions for use did not mention 
that some necessary materials were not included in the kit 
(Fig. 37), and 33% did not list limitations of product. In terms 
of product specifications, nearly all the instructions listed 
the diagnostic sensitivity and specificity of the product, but 
few mentioned analytical sensitivity or specificity or gave 
information on parasite densities and reference methods 
(Fig. 37). Adherence to recommendations for describing 
procedures was also variable. While all gave good guidance 
on the interpretation of line combinations for positive results, 
fewer than half advised that a faint line should be considered 
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a: Completeness of information displayed 
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Figure 33: Adherence to buffer bottle labelling recommendations 
















































































































































b: Completeness of information displayed 
















Figure 34: Accessory labelling – use of internationally recognized symbols 
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15. dIscussIon of key fIndIngs
This report describes the performance of many of the 
commercially available malaria antigen-detecting RDTs 
manufactured under the ISO 13485:2003 quality standard. 
For malaria RDTs to improve the management of febrile 
illness in malaria-endemic areas, they must have adequate:
• sensitivity, to detect nearly all clinically significant cases 
of malaria;
• specificity, to accurately discriminate non-malarial 
febrile illness from malaria in order to ensure appropriate 
management and accurate disease monitoring;
• stability, to maintain accuracy after transport and storage 
in ambient conditions; and
• ease-of-use, and adequate labelling and instructions 
for use to ensure safe, correct preparation and accurate 
interpretation of results.
Malaria RDTs were evaluated in terms of these four require-
ments in order to assist national malaria control programmes 
and other procurement agencies in selecting products appro-
priate for their needs. The evaluation constitutes the laboratory 
component of the WHO programme for prequalification of in 
vitro diagnostics. The panel used ensured successful discrimi-
nation between the RDTs evaluated. A number of products 
showed a high rate of antigen detection, a low false-positive 
rate and good heat stability. These attributes are essential for 
tests used as a basis for decisions about malaria treatment in 
the populations of most malaria-endemic countries. 
Overall, the mean PDS against low-density P. falciparum 
samples in round 7 was 87.2%, slightly higher than in round 
6 (83.6%) and continuing the pattern of improvements in 
each round.1 For P. vivax tests, the mean PDS of 76.8% is the 
highest achieved so far.2 The median false-positive rate was 
0%, which is lower than in round 6 (0.5%). Overall, a high level 
of performance has been maintained in P. falciparum-only 
tests, and improved performance has been seen in P. vivax-
detecting RDTs. As previously, too few Pf-pLDH-based RDTs 
were submitted for evaluation: only three were assessed 
in round 7. The mean PDS (at 200 parasites/µL) was 62% 
(range, 38–75%) in rounds 2–6 (17 products) and 2.0–88.9% 
in rounds 2–7.
Five products tested in round 3 of the programme were 
resubmitted for testing in round 7. Two performed better 5 
years after initial testing, but three performed less well, and 
two of these no longer met the WHO criteria for procurement. 
The evaluation is performed against a standardized panel of 
cultured P. falciparum and frozen blood samples by expe-
rienced technicians in a research laboratory and is not 
1  The PDS values for P. falciparum in rounds 1, 2, 3, 4 and 5 were 
67.2%, 69.9%, 75.5%, 81.6% and 81.0%, respectively.
2  The PDS values for P. vivax in rounds 1, 2, 3 , 4, 5 and 6 were 36.0%, 
58.9%, 47.1%, 51.3%, 61.3% and 70.7%, respectively.
therefore a field evaluation of the accuracy of RDTs in a 
specific epidemiological context in the hands of the intended 
users. The panel is designed to mimic fresh blood samples 
from actual cases as closely as possible, while allowing direct 
comparison of a large number of products simultaneously, 
with control for confounding factors, and is calibrated to a 
level likely to discriminate differences in the performance 
of various products. The discussion points below should 
therefore be taken into account in interpreting the results.
15.1.  panel detection score and its 
relation to sensitivity 
Evaluation of the RDTs against the phase-2 wild-type parasite 
panel with a parasite density of 200 parasites/µL (Figs 10 and 
11) revealed a range of frequency and consistency of antigen 
detection between products, recorded as the PDS. As expected, 
testing at higher parasite density (2000 parasites/µL) resulted 
in smaller differences in performance. As two tests from two 
different lots were tested at 200 parasites/µL and as all four 
tests had to be positive in order for a sample to be considered 
“detected” by an RDT, a positive result indicates the ability of 
a product to detect the target antigen in the sample and to do 
this consistently (both tests from both lots). A parasite density 
of about 200 parasites/µL should be detected to ensure high 
field sensitivity for clinically significant malaria infection in 
many malaria-endemic populations (11). 
The PDS in the panels used in this evaluation differs from 
the test sensitivity in clinical settings for five main reasons. 
(i) The performance of different lots or batches of the 
same product may vary. Variation in lot performance 
is an issue for all diagnostics; therefore, the results 
found in the evaluation may not predict the results for 
subsequent RDT lots. It is important to test lots before 
their distribution in the field to ensure that the expected 
performance is maintained (section 16.2). 
(ii) In clinical settings, patients show wide variation in 
parasite density, the range depending on the local 
epidemiology of the disease. The parasite density in the 
population tested affects the clinical sensitivity of a test. 
The PDS against a test panel of blood samples diluted to 
200 parasites/µL is likely to underestimate the clinical 
sensitivity of an RDT in areas where symptomatic patients 
have much higher parasite densities. Many tests that 
show only moderate detection of the 200-parasites/µL 
panel may perform well in such settings, as indicated 
by the better PDS of most products against the panel at 
2000 parasites/µL. The small differences in PDS seen in 
Figs S1, S2 and 9–11 and Tables 4 and 5 found among 
the better-performing RDTs in this evaluation are 
unlikely to result in noticeable differences in clinical 
sensitivity, and other issues, such as required storage 
conditions, stability, cost, experience and training 
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of the intended users, ease of use (Annex S2) and 
manufacturing capacity, may be equally important 
in test selection. Consideration of the parasite density 
in target populations and the probable sensitivity of 
RDTs in the field indicates that, even in areas with high 
transmission and strong malaria immunity, the popula-
tion may include individuals with a low parasite density 
but clinically significant infection (e.g. young children, 
pregnant women, people who regularly use bed nets, 
immigrants and people with reduced immunity). The 
ability to detect low parasite-density infections reliably, 
therefore, remains important. As some countries move 
towards elimination of malaria, population immunity 
will decrease and/or clinical cases may be detected 
earlier, and it could become increasingly important to 
use diagnostic tests that detect low parasite density (i.e. 
with a high PDS against samples with 200 parasites/µL). 
(iii) The performance of tests against the challenge panel 
may not always predict sensitivity in clinical testing, e.g. 
when antigen expression by certain parasite populations 
differs greatly from that in the panel. For example, 
P. falciparum strains in some areas of Africa (Eritrea (33), 
Democratic Republic of the Congo), India (13) and South 
America (34) do not express HRP2 antigens because of 
gene deletions (12–13). If a significant proportion of 
parasites in a given area do not express HRP2 and HRP3, 
leading to false negative results, tests to detect other 
target antigens (e.g. pLDH or aldolase) must be used. 
To date, parasite populations with a high frequency of 
non-expression of target antigens have been identified 
in several countries in South America (12) and in Eritrea 
(33, 34). The reactivity of the non-HRP2, Pf-specific 
test lines against phase 1 and 2 Pf (HRP2-containing) 
samples is currently the best predictor of how well these 
RDTs would detect pfhrp2-negative parasites. In most 
cases, the Pf panel detection score for products based 
on pf-pLDH-specific test lines is < 75, the cut-off for 
procurement. In round 7, one combination test met 
the procurement criterion, with a PDS of 75 against 
200 parasites/µL Pf samples. For a summary of options 
and test performance in round 7 and previous rounds, 
refer to the WHO interim guidance on investigating 
false-negative RDTs and pfhrp2/3 gene deletions.1
(iv) The conditions under which RDTs are transported and 
stored can alter their sensitivity in the field. The tests 
evaluated in round 7 were shipped and stored under 
conditions intended to safeguard them from degradation 
by high temperature or other extreme conditions. If such 
precautions are not taken with purchased RDTs, loss of 
performance could result. The ambient temperature of 
storage conditions varies widely in the settings in which 
these tests are commonly used, as does the temperature 
during transport; therefore, the requirements for the 
heat stability of a product will differ. Tests should be 
transported and stored well within the temperature 
range recommended by the manufacturer (see Annex 1) 
and extremes of temperature avoided (32, 35).
1 http://apps.who.int/iris/bitstream/10665/208819/1/WHO_HTM_
GMP_2016.4_eng.pdf (accessed 8 March 2017).
(v) Diagnostic sensitivity and specificity depend on the 
quality of preparation and interpretation of the tests. 
Highly trained technicians tested all the products in 
this evaluation. In clinical settings, malaria RDTs are 
often used by health workers with limited training 
and supervision; therefore, simple design and clearly 
interpretable results are required to ensure translation 
of the technical proficiency of a product into accurate 
diagnoses in the field (36). 
15.2.  false-positive rate and 
specificity 
False-positive rates are reported against a panel of 52 
clean-negative samples taken from blood donated in low-
transmission settings by people without symptoms of malaria. 
In addition, false-positive rates were calculated with a 
smaller number of samples with specific characteristics 
that affect the likelihood of a false-positive result from an 
immunodiagnostic test (e.g. rheumatoid factor, anti-nuclear 
antibody) or that may be significant in a specific population 
in a malaria-endemic area (e.g. leishmaniasis, dengue). The 
importance of these results depends on the intended area 
of use. High false-positive rates with samples of blood from 
dengue patients, for example, might not be a significant factor 
in regions in which dengue does not occur. In view of the small 
number of samples in each category in this evaluation, the 
results should be considered primarily a guide to potential 
cross-reactions, which should be closely monitored if they 
are relevant to the target population. 
In general, it is preferable to procure a product with a low 
rate of false-positive reactions. In the case of many diagnostic 
tests, a trade-off must be made between a preference for 
a high rate of antigen detection (sensitivity) and a low 
false-positive rate (specificity). The context in which the test 
will be used will guide the relative importance of these two 
factors in the choice of one product over another. Overall, 
in this evaluation, there was no correlation between a lower 
PDS (loss of sensitivity) and a low false-positive rate (high 
specificity). A number of products had both a high PDS and 
a low false-positive rate.
15.3.  reactivity of combination 
Hrp2 and pan-pldH test lines 
against p. falciparum samples
Instructions for the use of P. falciparum/pan and pan/P. falci-
parum combination tests classify P. falciparum infections 
as either HRP2 test line-positive alone or in combination 
with the pan-pLDH line. Combination tests that return only 
a positive HRP2 test line may be incorrectly interpreted as 
false positives for malaria infection secondary to persistent 
(HRP2) antigenaemia. The results in this report clearly indicate 
that most combination tests in which HPR2 is used for the 
detection of P. falciparum return positive results only on the 
HRP2 band at lower densities of P. falciparum (Table A4.2). 
When both the HRP2 and the pan test bands were positive, the 
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band than on the HRP2 test band. Therefore, it is important 
to reinforce adherence to the manufacturer’s instructions 
for use (Annex 2) and to emphasize that for combination 
HRP2/pan-pLDH tests, a HRP2 test line-positive alone may 
well be attributed to the poor reactivity of pan-pLDH lines.
15.4.  Heat (thermal) stability 
The RDTs evaluated were held for 2 months at room tempera-
ture (21–25°C) and at 35°C and 45°C at 75% humidity and 
tested to evaluate stability at these temperatures as compared 
with baseline detection. The importance of thermal stability 
depends on the conditions under which a product will be 
transported and stored. Thus, stability at high temperatures is 
vital if an RDT is to be stored at clinics in a country where the 
ambient temperature can reach 45°C in the hot season but is 
less critical in a high-altitude or cooler environment where 
the temperature rarely rises above 35°C. Many commercially 
available RDTs indicate 30°C or 40°C as the maximal storage 
temperature (Annex 1). Higher temperatures were tested in 
this evaluation because malaria-endemic countries often 
have maximum ambient temperatures of 35°C, although 
use of cool storage can allow storage of products below this 
temperature. When RDTs are likely to be transported and 
stored at high ambient temperatures, heat (thermal) stability 
must be considered a significant factor in ensuring sensitivity. 
High humidity accelerates the degradation of malaria RDTs 
and other lateral flow tests. All the products in this evaluation 
were packaged in individual envelopes containing desiccant 
and designed to be moisture-proof. This allows the user 
to open the envelope of a test at the time of use, limiting 
exposure to high humidity. During the stability-testing phase 
of this evaluation, the RDTs were stored at 75% humidity. The 
packaging should, if in good condition, protect the contents 
from exposure to high humidity during storage. The results 
presented here provide an assessment of both the stability 
of the RDT and the quality of its packaging.
Several P. falciparum-detecting products were highly stable 
at the temperatures and times used in the evaluation. In 
this round, as in previous ones, pan-specific lines (pLDH) 
performed less well at baseline and were less stable than 
HRP2 test lines, so that it was difficult to assess post-
incubation stability. When tested against P. vivax, many of 
the pan-pLDH lines were highly stable at all temperatures 
and times tested. In most products, the P. vivax pLDH lines 
were also highly stable. These results for P. vivax are an 
improvement over round 6. 
While the temperature and humidity were held constant in 
this evaluation, temperatures in the field fluctuate with the 
time of day and season. Two months’ storage at a set tempera-
ture cannot accurately predict long-term stability under field 
conditions, but loss of sensitivity for parasite detection over 
this period indicates that significant sensitivity will be lost 
if RDTs are stored at similar or higher temperatures for a 
significant period of their storage time and the likelihood of 
greater susceptibility to degradation during short exposure to 
much higher temperatures, such as during transport (37, 38). 
15.5.  ease-of-use description 
The sensitivity and specificity of RDTs depend on the quality 
of preparation and interpretation. In general, a simpler format 
with fewer steps or fewer required extraneous materials is 
likely to be prepared and interpreted more reliably. Thus, 
cassette-format RDTs are generally more reliably prepared 
and interpreted than products in dipstick format (39). The 
extra cost of this format may be offset by the advantages 
of greater accuracy and, in some cases, less additional 
equipment required to perform them.
The method by which blood is transferred from the patient 
to the test is important for the safety of the user and for 
the accuracy of the volume transferred. Devices for blood 
transfer are supplied with RDTs but vary widely in design and 
accuracy (31). The performance of blood transfer devices 
was not formally assessed in this evaluation, as blood was 
transferred from a tube with a micropipette to ensure 
that the volume specified by the manufacturer was used. 
Procurement programmes for RDTs should consider the 
adequacy of the blood transfer device supplied, including 
the experience of health workers and the cost and time 
required for retraining. It may be appropriate to discuss 
with manufacturers the possibility of changing the blood 
transfer device from that usually supplied. 
The clarity of results is important for interpreting tests. 
A clearly visible (intense) test line is less likely to be overlooked 
than a line that is barely visible. While reading proficiency 
and adequate workplaces should be ensured, some health 
workers might have suboptimal vision or work in inadequate 
lighting. Although the intensity of the test band was found 
to be correlated with the PDS of RDTs, PDS is determined 
only from a positive or negative result under ideal working 
conditions. Thus, it is important when selecting RDTs also 
to consider the relative intensity of the test bands, with a 
preference for intense bands (i.e. an intensity > 2). 
The importance of format and the simplicity of the test 
design depend on the intended users. Trained laboratory 
technicians can handle a complicated procedure more reli-
ably than village volunteers with limited supervision. In all 
cases, proficiency-based training and adequate supervision 
should be included in any RDT-based diagnostic programme, 
and clear instructions should be provided in a language and 
format appropriate for the user (40, 41). Annex S2 provides 
guidance on conducting a field-based ease-of-use assess-
ment (Table AS3.1). 
15.6.  labelling and instructions 
for use
The labelling on primary packaging (the box), device packaging 
and the device itself was generally consistent and adhered 
to most of the recommendations. A notable exception was 
that almost all products failed to include warning labels on 
the boxes and cassette packaging. Much poorer adherence to 
the recommendations and less consistency among products 
was seen in labelling of buffers and other accessories. 
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Adherence to the recommendations for instructions for use 
was variable. Product information and intended use were 
generally included, with notable exceptions, such as the 
failure to list all the materials required but not provided. 
Other aspects of the instructions often did not meet the 
recommendations; for example, the instructions for over one 
third of the products did not include precautionary notes on 
the use of damaged products or product limitations. With 
regard to performance, the instructions for most products 
covered diagnostic sensitivity and specificity, but very few 
included analytical sensitivity and specificity or issues of 
parasite density and reference methods. Adherence to the 
recommendations for information on procedures was gener-
ally poor, particularly for safety practices and interpretation: 
fewer than half the product instructions advised that a faint 
line should be considered a positive result.
Wide differences in how information is presented to users can 
affect the ease and consistency of use and potentially affect 
proper use. There is considerable scope for improvement in 
the instructions for use of currently recommended products.
15.7.  Anomalies in rdt production 
lots
Anomalies that affected interpretation of the results were 
encountered with variable frequency in the production lots 
submitted for evaluation. A glossary of RDT anomalies has 
been prepared (Fig. AS2.1) on the basis of the experience of 
several rounds of product testing, with 4095 lots tested in 
the WHO–FIND lot testing programme. This glossary may 
be used in RDT training programmes to illustrate potential 
problems with some production lots and how to report them 
accurately. As many of the anomalies are infrequent, they 
might not be picked up in manufacturers’ quality control or 
lot release procedures; therefore, this information is also 
useful for manufacturers that wish to improve their processes. 
15.8.  Inter-lot variation 
Only two production lots of each product were evaluated in 
the testing programme. Malaria RDTs are complex biological 
products made up of components that are commonly supplied 
from different sources and are subject to a variety of condi-
tions during manufacture that may affect the quality of the 
final product. All manufacturers that entered this evaluation 
provided at least one current ISO 13485:2003 certificate for 
a manufacturing facility. This standard is designed to ensure 
consistency in the quality of the final product, if correctly 
implemented. The results presented here indicate that inter-
lot variation does occur, and WHO strongly recommends that 
a sample of RDTs from each production lot be tested before 
their dissemination to the field, to ensure that they meet an 
appropriate standard. This can be facilitated by WHO through 
two WHO-recognized lot-testing facilities (section 16.2). 
Inter-test variation will be detected to some extent by 
routine lot testing. Ensuring that manufacturers follow good 
manufacturing standards should minimize the likelihood of 
inconsistencies due to poor practice in the manufacturing 
process. Culture-based panels that are subsets of the phase-1 
panel used in this evaluation are available as reference 
standards for manufacturers against which to set their 
lot-release criteria.1
15.9.  selecting rdts: target antigens, 
species and sensitivity 
target antigens
The malaria RDTs evaluated detect one or more of three 
parasite antigens, HRP2, pLDH and aldolase, in various 
combinations. HRP2 is present only in P. falciparum, whereas 
aldolase and pLDH are present in all four species and may 
be used as pan or all-species targets. Some tests use differ-
ences in pLDH sequences between species as a means to 
differentiate P. falciparum from P. vivax and other species. 
There is considerable overlap in the PDS of products that 
target the different antigens in this evaluation. While the 
products with the highest PDS for P. falciparum targeted 
HRP2, a number of pLDH-detecting products had high PDS 
against P. vivax. The thermal stability of tests that target 
these different antigens also overlapped for samples with 
high parasite density.
In choosing an RDT, account should be taken of the target 
antigen: HRP2-detecting RDTs should not be used in areas 
where false negative RDT rates due to non-expression of 
HRP2 is common (> 5%) (33, 34). Five P. falciparum RDT prod-
ucts were evaluated in round 7 that detected P. falciparum 
with Pf-pLDH, two combination tests had only Pf-pLDH, 
and three had HRP2 as well. Of the three with both HRP2 
and Pf-pLDH, two combined the two antigens on a single 
test line, and the other had two separate test lines to detect 
P. falciparum. Only one of the three products with separate 
pf-pLDH test lines met WHO procurement criteria with a 
P. falciparum PDS of 75% at 200p/µl. However, the pf-pLDH 
test lines on all three products performed well at 2000p/µl 
(PDS range: 92-100%). Detection of Pf-pLDH is known to be 
less sensitive than detection of HRP2 at low parasite densities, 
and low-density infections with HRP2-deleted P. falciparum 
parasites could therefore be missed. 
Tests that detect only HRP2 (without pLDH or aldolase 
lines) will be of limited use where non-falciparum malaria 
is common. pLDH (and possibly aldolase) RDTs may have 
further advantages when antigen persistence (common with 
HRP2) result in a high false-positive rate in areas where 
early retesting in the weeks immediately after treatment is 
common. As mentioned in section 2.3, however, combination 
tests with both HRP2 and pan test lines should not be used 
for discriminating between acute infection and persistent 
antigenaemia, as the overall reactivity of pan test lines is 
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species-specific vs non-species-specific rdts
RDTs are mainly tools for making clinical decisions, but their 
role in surveillance has grown dramatically. If all infections 
are managed in the same way, ie. with artemisinin-based 
combination therapy, there is no clinical advantage of having 
an RDT that can distinguish falciparum from non-falciparum 
infection: a pan-only test would suffice. If treatment of the 
two infections is different, however, distinguishing between 
falciparum and non-falciparum infection is a priority, and a 
combination test must be used (Pf/Pan). When the results 
of RDTs are used for species-specific monitoring, a species-
specific RDT is preferable (Pf/Pv). No currently available RDT 
can specifically identify P. malariae or P. ovale infections. 
Furthermore, pan-species and Pvom tests are not evaluated 
against these, as there is no source of suitable mono-species 
infections. Published data suggest, however, that the sensi-
tivity of RDTs for detecting these species is significantly 
poorer than that for detecting P. falciparum and P. vivax (42). 
rdt sensitivity and the role of highly 
sensitive diagnostic tools 
RDTs are considered to be tools to detect symptomatic malaria 
infections, with ≥ 200 parasites/µL (11); however, the threshold 
of parasitaemia associated with symptoms depends on both 
transmission intensity and individual immunity to malaria. 
In a review of parasite densities in various epidemiological 
settings (43), the best estimate of the proportion of sympto-
matic people with a parasite density >200 parasites/µL who 
seek care at a health facility was 90-95% for P. falciparum 
and approximately 85% (range, 78-92%) for P. vivax. The 
performance panels used in product testing challenge the RDTs 
to consistently detect samples with antigen concentrations 
at the 200 parasites/µL threshold, corresponding to minimal 
HRP2 antigen concentrations of 0.59-0.80ng/mL and expected 
to detect the majority of clinically symptomatic malaria 
infections in endemic settings. The individual and public 
health benefits of detecting and treating submicroscopic 
or very-low-density parasitaemia are poorly understood 
and would require rigorous risk-benefit analysis (44,45). 
Nonetheless, highly sensitive tests like PCR and LAMP have 
been used for surveillance and focus investigation in low-
transmission areas, and a highly sensitive HRP2-based RDT 
(Alere™ Malaria Ag Pf (05FK140), Standard Diagnostics) has 
been commercialized with claims of an analytical sensitivity 
of 0.05–0.08 ng/mL of HRP2 (46). This is approximately 10 
times the detection limit of the best conventional RDTs that 
detect the samples in the product testing panel. (Annex S1). 
The current performance panels cannot discriminate between 
products that can detect samples with antigen concentrations 
comparable to < 200 parasites/µL (considered to be highly 
sensitive) and those that detect only > 200 parasites/µL 
(conventional RDTs). Therefore, as expected, the performance 
of the highly sensitive RDT in round 7 was similar to that of 
other high-performing conventional RDT able to detect  the 
majority of clinically significant infections. As for other high 
sensitive tests, the use of the high-sensitive HRP2-based 
RDT evaluated in round 7 is not recommended for malaria 
clinical case management, as it is anticipated to lead to the 
problems listed below: 
I) Detection of low levels of HRP2 antigen concentrations 
associated with low density falciparum infections may 
be associated with decreased specificity of diagnosis 
of clinical malaria.   Since the association between 
antigenemia and parasitemia  and fever varies from place 
to place, season to season, their use may potentially lead 
to misdiagnosis and overtreatment of fever, as malaria. 
ii) Persistent HRP2 antigenemia over longer period following 
successful treatment may also cause more false positive 
clinical cases.  
iii) If highly sensitive diagnostic tests are used for clinical 
case management or surveys,  there is a potential threat 
of antimalarial stock outs due to increased test positivity 
caused  by low density, asymptomatic infections. 
iv) If end-users abruptly see an unexpected increase in the 
number of malaria cases following the introduction of a 
highly sensitive RDT, this may undermine their confidence 
in conventional malaria RDTs as case management tools 
for acute febrile illness. 
More research is needed to determine the clinical conse-
quences of submicroscopic infections, their contribution to 
onward disease transmission and the role of highly sensi-
tive diagnostic tests in surveillance for targeting malaria 
elimination. 
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16. usIng results to ensure HIgH-
QuAlIty dIAgnosIs In tHe fIeld
This report provides data to guide malaria control programmes 
in selecting products that are likely to perform to a high 
standard in the context in which the programme operates. 
The report does not provide a list for procurement but should 
aid potential buyers by providing comparative data on the 
performance of the available products. Final product selection 
requires that these data be considered systematically, taking 
into account the distribution of parasite density in the target 
population in whom the tests will be used, the experience 
and training of the intended users and other criteria such as 
climate and transport/storage conditions, price and supply 
aspects, and others. Box 3 lists WHO’s current minimum 
RDT selection criteria, as endorsed by the Malaria Policy 
Advisory Committee, and Tables S2, S3 and 5 are colour-
coded to reflect these minimum performance criteria for 
product selection. As WHO prequalification will become 
a requirement as of 1 January 2018, the prequalification 
status of each product is also indicated. A web-based tool 
for filtering product testing results by various parameters is 
available on the FIND website and has now been updated to 
allow rapid identification of products with the same blood 
volume, number of buffer drops and time until reading.1 
Annex 1 groups products according to similar procedure 
characteristics. Furthermore, an algorithm to guide selection 
is given in Annex S3, and detailed guidance was published 
by WHO in Recommended selection criteria for procurement 
of malaria rapid diagnostic tests, Good practices for selecting 
and procuring rapid diagnostic tests for malaria (16) and 
Universal access to malaria diagnostic testing (17). 
While malaria RDTs can be used in a number of settings, the 
greatest impact on public health will ensue from extending 
access to accurate, parasite-based diagnoses of malaria to 
regions and populations where good-quality microscopy-
based analysis is impractical to maintain. This will allow 
implementation of WHO recommendations on universal 
parasite-based diagnosis before antimalarial therapy (2) 
and currently applies to most people at risk for malaria in 
endemic countries (1). In many settings where RDTs have 
been introduced, the true rate of parasitaemia has been 
found to be considerably lower than expected, so that health 
systems can reduce wastage of antimalarial medicines and 
focus on appropriate management of non-malarial causes 
of fever, including early pneumonia and sepsis. In order for 
an RDT programme to have its full potential public health 
impact, it must therefore address not only malaria but also 
the management of other common and severe febrile illnesses 
that occur locally in the differential diagnosis of malaria (46).
1  An interactive guide designed to short-list tests according to 
programme needs, based on the performance of tests in rounds 3–6 
of the WHO product testing programme can be found at: https://
www.finddx.org/malaria/interactive-guide/ (accessed 8 March 2017).
16.1.  wHo prequalification  
The WHO programme for prequalification of in vitro diag-
nostics promotes access to good-quality in vitro diagnostic 
tests by applying the principles of a comprehensive regulatory 
assessment. This includes inspection of the manufacturer’s 
quality management system, assessment of technical docu-
mentation (dossier review) and an independent performance 
evaluation. 
The results of the WHO malaria product testing programme 
fulfill the performance evaluation component of the prequali-
fication process. Twelve malaria RDT products have been 
prequalified.2 Prequalification has not been a requirement 
for eligibility for United Nations procurement tenders for 
malaria RDTs, as it is for other RDTs, such as for HIV; however, 
WHO prequalification will determine the eligibility of malaria 
RDTs for procurement after 31 December 2017. WHO product 
testing will continue to be the independent performance labo-
ratory evaluation component of the prequalification process. 
Round 8 of product testing is under way All manufacturers 
who submit products to round 8 are required also to submit 
applications for WHO prequalification. 
16.2.  beyond procurement 
Diagnostic tests are usually used at the start of a health 
system intervention, and their use is based on the assumption 
that appropriate patient management, based on testing, will 
follow. Thus, successful introduction of RDTs requires careful 
planning beyond rational procurement to ensure consistent 
supplies of all the necessary materials (including gloves, 
sharps disposal containers and supplies required for further 
case management), training of users, community sensitization 
and monitoring of diagnostic quality and results. This extends 
malaria management to management of other febrile diseases 
and health service delivery systems and requires integration 
with other health programmes. 
While this report does not provide a list for procurement, it 
provides information to guide procurement of RDTs within this 
framework. Factors beyond the performance characteristics 
reported here, however, must influence procurement decisions. 
An example of an algorithm, including an ease-of-use assess-
ment, is provided in Annexes S2 and S3 to guide decisions. 
Details of implementation will vary widely between 
programmes, depending on local capacity and needs. Further 
recommendations on budgeting, planning and implementation 
can be found in Annex 5 and in the relevant WHO guidance 
document (17). 
2 http://www.who.int/diagnostics_laboratory/evaluations/pq-list/
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16.3.  post-market surveillance: 
lot verification 
Post-market surveillance confirms manufacturer compliance 
with quality expectations and is an important component of 
any quality assurance scheme. Specifically for malaria RDTs, 
post-market surveillance ensures that the quality reported in 
product testing is found in what is available on the market 
to the user. Post-market surveillance can be performed 
proactively through lot verification (described next), which is 
recommended to all procurers, or reactively through comple-
tion of a “WHO user complaint form for reporting problems 
and/or adverse events related to diagnostic products” and 
submitted to the following email address: diagnostics@
who.int. 
As a complement to product testing, WHO and FIND currently 
support laboratories that perform continued quality assur-
ance of RDTs in the form of lot testing. This programme 
responds to requests from all purchasers, including national 
malaria programmes, manufacturers and procurement bodies, 
to assess the quality of RDT lots before shipment from 
the production facility or, when they arrive in a country, 
before distribution to the field and for clinical use. Testing 
is performed against parasite-positive and -negative panels 
prepared and characterized in the same way as the panels 
used in this evaluation. A number of national institutions 
have also developed this capacity, and, more recently, several 
countries have begun pilot-testing malaria recombinant 
antigen panels to monitor trends in lot performance. Lot 
testing reassures countries that the product they have 
purchased performs to a high standard and helps to ensure 
that manufacturers produce consistently good lots and 
improve their products. The results support decisions for 
accepting or rejecting lots. Lot testing provides information 
about the adequacy of RDTs for clinical use, their stability 
over their shelf life and any anomalies observed during testing 
that may also be encountered in the field. 
Countries and manufacturers ship 100–150 RDTs to regional, 
WHO-recognized lot testing centres, where they are evaluated 
against a small panel of parasites at low density and against 
negative samples (Fig. 2). They are subsequently incubated at 
a temperature close to the manufacturer’s specified storage 
temperature and retested 6 months before expiry. Initial 
results are available after 5 days, and definitive results after 
subsequent confirmatory tesing, if required. Details of the 
protocol can be found in the methods manual for lot testing 
(27). As lot-to-lot variation has previously been noted in 
many products, purchasers are encouraged to participate 
in the lot-testing programme to confirm the quality of RDT 
lots prior to use. Certain anomalies resulting from defects 
in production lots or RDT degradation, or even defects of 
some kit accessories, may affect the running of the test or 
interpretation and may warrant a field safety notice and 
corrective action. In such instances, a special lot testing 
service can be provided, which is determined case by case.
Lot testing is free of charge, but the requester must cover 
shipping costs, including related tax and duties. To access 
lot testing through the WHO-FIND programme, contact 
christian.nsanzabana@finddx.org and cc: Malaria_rdt@
who.int at least 2 weeks before RDTs are ready for shipment. 
17. conclusIons 
This report adds to the large data set on malaria RDT 
performance published regularly since 2009 (3–8). The 
product testing programme continues to be an authoritative 
source in the field of malaria RDT evaluations in terms of 
the number of products evaluated, its independence and 
its comprehensiveness. New laboratory methods have been 
developed and validated to support parasite characteriza-
tion, and this work has generated new findings on variation 
in antigen content at similar parasite densities and in the 
structure and expression of histidine-rich proteins. Round 
7 introduced a new component of the product evaluation: 
examining the labelling and instructions for use associated 
with each product in a standardized manner, to demonstrate 
their performance against a set of standards for these 
components. Publication of the results of past WHO product 
testing rounds has affected the procurement practices of 
countries and procurement agencies and contributed to a 
shift in the malaria RDT market towards better-performing 
products (1, 48). The report of round 7 adds to the number of 
well-performing RDTs for which comprehensive performance 
data are now available including the first high-sensitive RDT 
and provides updated data on 15 product resubmissions. 
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Annex s1: characteristics of 
evaluation panels used in rounds 
1–7 of wHo malaria rdt product 
testing, 2008–2016
Currently, the basis for diagnosing malaria with antigen-
detecting RDTs is the detection in a patient’s blood of one 
or more target malaria antigens, including HRP2 (P. falci-
parum only), pLDH (Plasmodium spp.pan-pLDH), P. falciparum 
(Pf-pLDH), non-falciparum (Pv-pLDH, Pvom-pLDH) and 
aldolase (all Plasmodium spp). The antigen concentration in 
samples with the same parasite density varies. Therefore, 
the concentrations of malaria antigens in the samples that 
comprise evaluation panels must be consistent in successive 
rounds of WHO malaria RDT product testing to ensure that 
the results of each round are highly comparable (statistically 
equivalent). 
Therefore, antigen concentrations were quantified in triplicate 
in all panel samples, including dilution pairs of 200 and 
2000 parasites/µL, by quantitative ELISA. Only results that 
were consistent in the triplicate runs and showed a value 
factor between the 200 and the 2000 parasites/µL dilutions 
close to 10 were considered acceptable and eligible for the 
performance evaluation panel. In some instances, the antigen 
concentration was below the detection limit of the ELISA, 
particularly for aldolase, which is present in malaria parasite 
samples at much lower concentrations than the other two 
antigens. Samples that gave inconsistent results for more 
than one of the three antigens were excluded from the panel.
Despite careful standardization of procedures, the tables and 
figures below show a wide variation in antigen concentra-
tions for the same parasite density. There are a number of 
possible explanations, including differences in the level of 
antigen expression by isolates; different durations of infection 
(accumulating antigens); different parasite growth stages at 
the time of collection (expressing different levels of antigen); 
the presence of circulating HRP2 from previous growth 
cycles; and HRP2 produced by parasites sequestered in the 
host’s vascular tissues that cannot be accounted for in the 
estimate of parasite density on the blood slide.
Before each round of WHO malaria RDT product testing, the 
distribution of HRP2, pLDH and aldolase concentrations at 
200 parasites/µL dilution of the wild-type P. falciparum and 
wild-type P. vivax samples selected for the phase-2 panels 
were systematically compared with those in the previous 
round to ensure there was no statistically significant differ-
ence. The figures and tables below show the distribution of 
antigen concentrations in all six performance evaluation 
panels. No statistically significant differences were seen 
(Kruskal-Wallis test; p > 0.5), confirming that the results 
of each new round are additive (and comparable) to the 
previous ones. In the following box and whisker plots, the 
end of whiskers represent minimum and maximum values; 
the box represents middle 50% of data and the line through 
box represents median values; the crosses represent the 
mean values.
Figure AS1.1: Box-and-whisker plot of distribution of 
P. falciparum HRP2 concentration (ng/mL) in product 
testing phase 2 (wildtype) panels.








P. falciparum  HRP2 concentration (ng/ml)
Figure AS1.3: Box-and-whisker plot of distribution of 
P. vivax pLDH concentration (ng/mL) in product testing 
phase 2 (wild-type) panels.








P. vivax pLDH concentration (ng/ml)
Figure AS1.2: Box-and-whisker plot of distribution of 
P. falciparum pLDH concentration (ng/mL) in product 
testing phase 2 (wildtype) panels.








P. falciparum pLDH concentration (ng/ml)
Figure AS1.4: Box-and-whisker plot of distribution of 
P. falciparum aldolase concentration (ng/mL) in product 
testing phase 2 (wild-type) panels.
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Table AS1.1: Statistics for P. falciparum HRP2 concentration (ng/mL) in product testing phase 2 (wild-type) panels.   
Round 1 Round 2 Round 3 Round 4 Round 5 Round 6 Round 7
Number of valuesa 78 99 99 98 99 99 99
Minimum 0.80 0.62 0.62 0.62 0.59 0.67 0.67
25% percentile 2.90 1.90 2.10 2.97 2.15 2.48 2.15
Median 9.57 6.76 6.83 6.98 6.76 8.12 6.76
75% percentile 18.94 16.91 17.37 15.65 15.31 15.51 16.99
Maximum 73.70 73.70 66.70 62.48 62.48 62.48 62.48
Mean 15.28 12.70 12.77 12.72 11.65 12.15 11.83
Std. Deviation 16.98 15.75 15.19 14.72 13.25 13.29 13.01
a The number of values is the number of samples for which consistent ELISA results were obtained.
Table AS1.2: Statistics for P. falciparum pLDH concentration (ng/mL) in product testing phase 2 (wild-type) panels.   
Round 1 Round 2 Round 3 Round 4 Round 5 Round 6 Round 7
Number of valuesa 74 93 92 92 94 98 98
Minimum 0.71 0.19 0.19 0.19 0.19 0.19 0.19
25% percentile 6.68 6.27 6.23 6.20 6.90 7.04 7.20
Median 11.95 10.31 11.18 10.92 12.24 11.85 12.99
75% percentile 23.75 20.10 22.70 21.28 23.05 20.36 21.51
Maximum 47.15 47.15 47.15 53.53 43.02 53.53 53.53
Mean 15.31 13.71 15.08 14.97 15.53 15.61 15.93
Std. Deviation 11.47 10.90 11.72 11.98 11.43 12.00 11.60
a The number of values is the number of samples for which consistent ELISA results were obtained.
Table AS1.3: Statistics for P. vivax pLDH concentration (ng/mL) in product testing phase 2 (wild-type) panels.
Round 1 Round 2 Round 3 Round 4 Round 5 Round 6 Round 7
Number of valuesa 20 37 33 32 34 34 35
Minimum 5.10 1.64 1.64 1.64 1.64 1.64 1.64
25% percentile 8.10 8.40 7.30 6.96 6.26 6.72 6.86
Median 12.65 17.00 19.78 17.50 13.22 15.17 16.62
75% percentile 27.40 29.69 31.89 29.84 23.42 23.14 22.89
Maximum 44.40 47.90 47.90 47.90 47.90 44.79 44.79
Mean 17.38 20.24 20.99 20.00 16.84 16.90 16.87
Std. Deviation 11.57 13.27 13.55 13.00 12.59 11.78 11.17
a The number of values is the number of samples for which consistent ELISA results were obtained.
Figure AS1.5: Box-and-whisker plot of distribution 
of P. vivax aldolase concentration (ng/mL) in product 
testing phase 2 (wild-type) panels.
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Table AS1.4: Statistics for P. falciparum aldolase concentration (ng/mL) in product testing phase 2 (wild-type) panels. 
Round 1 Round 2 Round 3 Round 4 Round 5 Round 6 Round 7
Number of valuesa 77 98 99 97 98 99 99
Minimum 0.00 0.00 0.00 0.00 0.00 0.00 0.00
25% percentile 0.84 0.74 0.67 0.64 0.52 0.44 0.59
Median 1.58 1.49 1.40 1.25 1.17 1.18 1.25
75% percentile 2.25 2.25 2.23 2.25 2.07 2.02 1.88
Maximum 9.90 9.90 9.90 9.08 7.74 9.08 9.08
Mean 1.93 1.79 1.76 1.72 1.52 1.50 1.43
Std. Deviation 1.73 1.66 1.69 1.68 1.52 1.61 1.34
a The number of values is the number of samples for which consistent ELISA results were obtained.
Table AS1.5: Statistics for P. vivax aldolase concentration (ng/mL) in product testing phase 2 (wild-type) panels. 
Round 1 Round 2 Round 3 Round 4 Round 5 Round 6 Round 7
Number of valuesa 20 40 34 33 35 35 35
Minimum 3.21 1.70 1.70 1.70 3.21 1.70 3.21
25% percentile 4.02 4.11 4.07 4.41 5.55 4.94 5.27
Median 6.33 6.15 6.10 6.16 6.86 6.54 7.96
75% percentile 8.47 8.47 8.32 9.10 9.43 9.68 10.52
Maximum 13.15 13.40 13.30 15.00 15.00 15.08 15.08
Mean 6.73 6.81 6.45 6.86 7.78 7.74 8.22
Std. Deviation 2.89 3.15 2.90 3.23 3.30 3.69 3.61
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Annex s2: malaria rdt field assessment and anomalies
Fig. AS2.1 shows examples of observations and anomalies encountered and routinely recorded for RDTs in round 7 of WHO 
Malaria RDT Product Testing at the CDC. Most of these anomalies would not invalidate the results, as reactivity in the control 
and test line areas is still visible, but they may pose challenges to health workers in interpreting the results. Furthermore, 
they should be reported to manufacturers. 
An extended list of notable observations on RDT packaging, kit accessories (buffer vials, desiccants) and instructions for 
use is being prepared for use in both product testing and lot testing in the WHO-FIND Malaria RDT Evaluation Programme.
Table AS2.1: Field assessment of RDT packaging, safety and ease-of-use to guide product selection 




Yes No NA Problems /Comments
Packaging and accessories
The RDT box is in good condition
RDTs are in individual sealed package
The correctly indicated number of RDTs are in the box
Desiccant is included in each individual RDT package 
An expiry date is visible on each RDT package
All required accessories are included in the correct quantities 
(RDT, buffer, blood transfer device, alcohol swab, 
lancet, gloves, test tubes (for dipsticks, only) 
If no, what is not included: 
Instructions
Instructions are included 
Instructions are in the national language(s)
The instructions are for the correct product 
The instructions include figures displaying 
all possible interpretations of the RDT results
The text and figures are accurate and consistent 
(specifically order of test lines and results interpretation)
Preparation and procedure
The test package is easy to open
It is easy to write on the test device 
The test lines on the device are clearly labelled
It is easy to use the device for blood collection
It is easy to open the buffer bottle or vial
The buffer bottle or vial have sufficient volume 
for testing all RDTs in the box
The buffer bottle or vial dispenses even drops
It is easy to fill the sample well correctly with the provided blood 
transfer device
It is easy to fill the buffer well correctly (no overflow)
The buffer and sample flow well along the test strip 
Result interpretation
Control and test lines 
Control line is clear
Test line(s) are clear
Good clearance of blood by time of reading If no, number of tests in the box affected: 
Steps and reading time 
Reading time <30 min
Two or fewer timed steps 
Was one or more of the last 10 tests 
you performed invalid (no control line)?
If YES, how many?
Safety
Are there mixing wells (risk of blood splash)?
Retractable needle for finger prick?
Is the RDT in a cassette format (unexposed strip)?
Have waste disposal safety concerns been addressed? 
(If no, please describe)
NA, not applicable
8988 Malaria rapid diagnostic test perforMance – results of WHo product testing of malaria rdts: round 7 (2015–2016)
Figure AS2.1 illustrates examples of RDT observations/anomalies encountered and routinely recorded during round 6 of 
WHO Malaria RDT Product Testing at the CDC. In most cases, these anomalies do not invalidate the results, as reactivity 
in the control and test line areas are still visible, but they may pose challenges to health workers interpreting the results. 
Furthermore, they should be reported to manufacturers. 
An expanded list of notable observations concerning RDT packaging, kit accessories (buffer vials, desiccants) and instruc-
tions for use, is under development for use in both product testing and lot testing activities of the WHO-FIND Malaria RDT 
Evaluation Programme. 
Figure AS2.1: Malaria RDT anomalies encountered in production lots 
a) Observations on the test strip
Red background Background staining is relatively common. 
In this example, the result is positive as test 
lines are positive; however, a more intense 
red background may obscure weak positive 
test lines, giving false-negative results.
Incomplete clearing In this example, the result is positive as 
the test line is visible. 
Poor clearing of blood may obscure weak 
positive test lines, giving false-negative 
results. 
b) Observations of flow problems
Failed migration Blood and buffer did not run the length 
of the strip
Incomplete migration One portion of the nitrocellulose near the 
test band was not absorptive and remained 
dry during wicking, creating irregular migra-
tion of blood/buffer with red background. 
In this example, the result is positive, as the 
test line is clearly visible.
c) Observations on test lines
Ghost test lines White lines on a stained background. In this 
example, the result is negative, as the test 
line is not dark and is thus not visible.
Patchy broken test 
line(s)
The test line is visible but interrupted 
(broken). 
Diffuse test line(s) Test line wider than control, without 
clearly defined edge. 




C   T1  T2  T3
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d) RDT structural problems
Strip misplaced in the 
cassette (shift)
Strip can be seen only partially in the 
results window.
Specimen pad not seen 
in sample window
Normally, the colour of the conjugated 
antibody can be seen in the sample 
window (commonly purple, pink or blue). 
Buffer remains pooled in 
the buffer well
The buffer is not completely absorbed 
and this may result in failed migration or 
incomplete clearing.
C    T1  T2

9190 Malaria rapid diagnostic test perforMance – results of WHo product testing of malaria rdts: round 7 (2015–2016)
Figure AS3.1: How to select of an appropriate RDT
Step 1.1
Define setting of use
What? target parasite species and antigena




Pf and non-Pf infections (single species)b:
- HRP2, aldolase; HRP2, pLDH-pan
- HRP2, pLDH-Pv; HRP2, pLDH-Pvom
- HRP2, pLDH-pan; pLDH-Pv






**Pf without HRP2 – Do not use exclusively HRP2-based RDTsc
Where? Exposure to high temperature e.g. tropical environment 
                      OR
temperature-controlled environment, including during 
transport and storage
Who? Laboratory personnel
           OR




WHO RDT product testing resultsd and apply WHO recommended RDT selection 
criteriae
- Panel detection score 
- False-positivity rate 
- Invalid rate 
- Ease-of-use
- Thermal stability
Sensitivity and specificity based on high-quality 
field studies in relevant populations 
Generate short-list of RDTs
Step 1.3
Apply national guidelines  
and experience in use of RDTs 
National malaria treatment guidelines
In-country experience, ease-of-use assessments (Annex S2),  




- Manufacturer: production capacity, lead times, heat stability data and storage conditions
- Delivery schedules (e.g. staggered deliveries), box size, shelf life
- Registration requirements of national regulatory authorities
- Product lot testing results
- Overall budget requirements (Annex 5)
a Pf-only or mixed Pf/non-Pf infections: Most areas of sub-Saharan Africa and lowland Papua New Guinea; Pf and non-Pf infections (single species): Most endemic 
areas of Asia and the Americas and isolated areas of the Horn of Africa; Mainly P. vivax-only: areas of East Asia, central Asia, South America, and some highland areas 
elsewhere
b Tests with a P. falciparum-specific line and pan-specific line will not distinguish P. falciparum-only infections from mixed P. falciparum infections. Distinguishing 
P. falciparum from mixed P. falciparum-vivax infections is important only if a full course of primaquine is routinely given for infections due to P. vivax. This must 
be weighed against the loss of ability to detect P. malariae and P. ovale if a test has only P. falciparum- and P. vivax-specific lines. Inclusion of further test lines 
(e.g. Pf-Pv-pan-pLDH) to detect these increases the complexity of test interpretation. A programme should prioritize these various advantages and disadvantages 
according to local conditions in the initial stage of making procurement decisions.
c  P. falciparum parasites lacking HRP2 +/- HRP3 genes have been identified with high frequency in parts of South America, Africa (Eritrea, Democratic Republic of the 
Congo, Ghana) and India (1–6). 
d See references (7–12).
e WHO RDT procurement criteria (13) : http://www.who.int/malaria/publications/atoz/rdt_selection_criteria/en/ (accessed 14 June 2017).
For a comprehensive guide to procurement of malaria RDTs extending beyond selection to quantification, budgeting, technical 
specifications, management of tenders, contracts, supply management and monitoring of supplier performance and managing 
product variations, see reference in the full report (16).
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































9392 Malaria rapid diagnostic test perforMance – results of WHo product testing of malaria rdts: round 7 (2015–2016)
Annex 2: malaria rdts: guide to interpretation of results
type A: guide to results of generic pf malaria rdts
Results window: C=control line; T=test line with bound HRP2 or Pf-specific pLDH antibody.
C T
Negative results: One line ‘C’ appears in the results window.
C T
Positive results:  P. falciparum infection. Two lines ‘C’ and ‘T’ appear in the results window.  
Test is positive even if the test line is faint.
C T
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type b: guide to results of generic major Plasmodium species (pan) malaria rdts 
Results window: C=control line; T=test line with bound pan-specific pLDH or aldolase antibody.
C T
Negative results: One line ‘C’ appears in the results window.
C T
Positive results:  Plasmodium species (P. falciparum, P. vivax, P. malariae, P. ovale) infection. Two lines ‘C’ and ‘T’ appear in 
the results window. Test is positive even is the test line is faint.
C T
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type c: guide to results of generic pan-pf malaria rdts
Results window:  C=control line; T1=test line with bound pLDH or aldolase antibody; T2=test line with bound HRP2 
and/or Pf-specific pLDH antibody.
C T2T1
Negative results: Only one line ‘C’ appears in the results window.
C T1 T2
Positive results:
 P. falciparum: Two lines ‘C’ and ‘T2” appear in the results window.
C T1 T2
  Non-falciparum infection (P. vivax, P. ovale, P. malariae) or mixed infection:  
Two lines ‘C’ and ‘T1” appear in the results window.
C T1 T2
 P. falciparum or mixed infection. Three lines ‘C’, ‘T1’ and ‘T2’ appear in the results window.
C T1 T2
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type d: guide to results of generic pf-pan malaria rdts
Results window:  C=control line; T1=test line with bound HRP2 or Pf-specific LDH antibody;  
T2=test line with bound pLDH or aldolase antibody.
C T2T1
Negative results: Only one line ‘C’ appears in the results window.
C T1 T2
Positive results:
 P. falciparum infection. Two lines ‘C’ and ‘T1’ appear in the results window.
C T1 T2
 Non-falciparum infection (P. vivax, P. ovale, P. malariae) or mixed infection.  
Two lines ‘C’ and ‘T2’ appear in the results window.
C T1 T2
 P. falciparum or mixed infection. Three lines ‘C’, ‘T1’ and ‘T2’ appear in the results window. 
C T1 T2
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type e: guide to results of generic pv-pf malaria rdts
Results window:  C=control line; T1=test line with bound P. vivax-specific pLDH;  
T2=test line with bound HRP2 or Pf-specific pLDH antibody.
C T2T1
Negative results: Only one line ‘C’ appears in the results window.
C T1 T2
Positive results:
 P. falciparum infection. Two lines ‘C’ and ‘T2’ appear in the results window.
C T1 T2
 P. vivax infection. Two lines ‘C’ and ‘T1’ appear in the results window.
C T1 T2
 P. falciparum and P. vivax mixed infection. Three lines ‘C’, ‘T1’ and ‘T2’ appear in the results window. 
C T1 T2
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type f: guide to results of generic pf-pv malaria rdts
Results window:  C=control line; T1= test line with bound HRP2 or Pf-specific pLDH antibody;  
T2=test line with bound P. vivax-specific pLDH.
C T2T1
Negative results: Only one line ‘C’ appears in the results window.
C T1 T2
Positive results:
 P. falciparum infection. Two lines ‘C’ and ‘T1’ appear in the results window.
C T1 T2
 P. vivax infection. Two lines ‘C’ and ‘T2’ appear in the results window.
C T1 T2
 P. falciparum and P. vivax mixed infection. Three lines ‘C’, ‘T1’ and ‘T2’ appear in the results window. 
C T1 T2
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type g: guide to results of generic pan-pv-pf malaria rdts
Results window:  C=control line; T1=test line with bound pLDH or aldolase antibody; T2=test line with bound P. vivax-specific 
pLDH; T3=test line with bound HRP2 or Pf-specific pLDH antibody
C T2 T3T1
Negative results: Only one line ‘C’ appears in the results window.
C T1 T2 T3
Positive results:
 P. falciparum infection. Two lines ‘C’ and ‘T3’ appear in the results window.
C T1 T2 T3
 
 P. vivax infection. Two lines ‘C’ and ‘T2’ appear in the results window.
C T1 T2 T3
 P. falciparum with or without mixed infection with P. ovale or P. malariae. Three lines ‘C’, ‘T1’ and ‘T3’ appear in the results window. 
C T1 T2 T3
 P. falciparum and P. vivax mixed infection. Three lines ‘C’, ‘T2’ and ‘T3’ appear in the results window. 
C T1 T2 T3
 P. falciparum and P. vivax mixed infection with or without P. ovale and/or P. malariae infection.  
Four lines ‘C’, ‘T1’, ‘T2’ and ‘T3’ appear in the results window. 
C T1 T2 T3
101100 Malaria rapid diagnostic test perforMance – results of WHo product testing of malaria rdts: round 7 (2015–2016)
 
P. vivax with or without P. ovale and/or P. malariae infection. Three lines ‘C’, ‘T1’ and ‘T2’ appear in the results 
window. 
C T1 T2 T3
 P. malariae with or without P. ovale and/or P. vivax infection. Two lines ‘C’ and ‘T1’ appear in the results window. 
C T1 T2 T3
Invalid results:  No ‘C’ line appears in the results window. Repeat the test with a new RDT if no control line appears.
C T1 T2 T3
 
C T1 T2 T3
C T1 T2 T3
 
C T1 T2 T3
C T1 T2 T3
 
C T1 T2 T3
C T1 T2 T3
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type H: guide to results of generic vom1-pf malaria rdts
Results window:  C=control line; T1= test line with bound pLDH specific for non-P. falciparum (P. vivax, P. ovale and P. malariae); 
T2=test line with bound HRP2 or Pf-specific pLDH antibody
C T2T1
Negative results: Only one line ‘C’ appears in the results window.
C T1 T2
Positive results:
 P. falciparum infection. Two lines ‘C’ and ‘T2’ appear in the results window.
C T1 T2
 P. falciparum mixed infection (with P. vivax, P. ovale and/or P. malariae). Three lines ‘C’, ‘T1’ and ‘T2’ appear in the 
results window. 
C T1 T2
 Non-P. falciparum infection (P. vivax, P. ovale and P. malariae) or mixed infection. Two lines ‘C’ and ‘T1’ appear in the 
results window. 
C T1 T2







1 vom, P. vivax, P. ovale, P. malariae
103102 Malaria rapid diagnostic test perforMance – results of WHo product testing of malaria rdts: round 7 (2015–2016)
type I: guide to results of generic pv malaria rdts 
Results window: C=control line; T=test line with bound P. vivax-specific pLDH.
C T
Negative results: Only one line ‘C’ appears in the results window.
C T
Positive results:  P. vivax infection. Two lines ‘C’ and ‘T’ appear in the results window. 
C T
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type j: guide to results of generic pf-pf malaria rdts
Results window:  C=control line; T1= test line with bound pLDH specific for P. falciparum;  
T2=test line with bound HRP2.
C T2T1
Negative results: Only one line ‘C’ appears in the results window.
C T1 T2
Positive results:
 P. falciparum infection. Two lines ‘C’ and ‘T1’ appear in the results window.
C T1 T2
 P. falciparum  infection. Two lines ‘C’ and ‘T2’ appear in the results window.
C T1 T2
 P. falciparum infection. Three lines ‘C’, ‘T1’ and ‘T2’ appear in the results window. 
C T1 T2
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type k: guide to results of generic pv-pf-pf malaria rdts
Results window:  C=control line; T1= test line with bound P. vivax-specific pLDH; T2=test line with bound HRP2 or Pf-specific 
pLDH antibody; T3=test line with bound HRP2 or Pf-specific pLDH antibody. If an RDT has bound HRP2 
antibodies on T2, T3 will have bound Pf-specific pLDH and vice versa (T2 Pf antigen target ≠ T3 Pf antigen 
target).
C T2 T3T1
Negative results: Only one line ‘C’ appears in the results window.
C T1 T2 T3
Positive results:
 P. falciparum infection. Two lines ‘C’ and ‘T3’ appear in the results window. 
C T1 T2 T3
 
 P. falciparum infection. Two lines ‘C’ and ‘T2’ appear in the results window. 
C T1 T2 T3
 P. falciparum infection. Three lines ‘C’, ‘T2’ and ‘T3’ appear in the results window. 
C T1 T2 T3
 P. falciparum infection and P. vivax mixed infection. Three lines ‘C’, ‘T1’ and ‘T2’ appear in the results window. 
C T1 T2 T3
 P. falciparum infection and P. vivax mixed infection. Three lines ‘C’, ‘T1’ and ‘T3’ appear in the results window. 
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 P. falciparum infection and P. vivax mixed infection. Four lines ‘C’, ‘T1’, ‘T2’ and ‘T3’ appear in the results window. 
C T1 T2 T3
 P. vivax infection. Two lines ‘C’ and ‘T1’ appear in the results window. 
C T1 T2 T3
Invalid results:  No ‘C’ line appears in the results window. Repeat the test with a new RDT if no control line appears.
C T1 T2 T3
 
C T1 T2 T3
C T1 T2 T3
 
C T1 T2 T3
C T1 T2 T3
 
C T1 T2 T3
C T1 T2 T3
 
C T1 T2 T3
107106 Malaria rapid diagnostic test perforMance – results of WHo product testing of malaria rdts: round 7 (2015–2016)
type l: guide to results of generic pan-pf-pf malaria rdts
Results window:  C=control line; T1= test line with bound PAN-pLDH or aldolase antibody; T2=test line with bound HRP2 or 
Pf-specific pLDH antibody; T3=test line with bound HRP2 or Pf-specific pLDH antibody. If an RDT has bound 
HRP2 antibodies on T2, T3 will have bound Pf-specific pLDH and vice versa (T2 Pf antigen target ≠ T3 Pf 
antigen target)
C T2 T3T1
Negative results: Only one line ‘C’ appears in the results window.
C T1 T2 T3
Positive results:
 P. falciparum infection. Two lines ‘C’ and ‘T2’ appear in the results window. 
C T1 T2 T3
 P. falciparum infection. Two lines ‘C’ and ‘T3’ appear in the results window. 
C T1 T2 T3
 
 P. falciparum infection. Three lines ‘C’, ‘T2’ and ‘T3’ appear in the results window. 
C T1 T2 T3
 P. falciparum infection with or without mixed infection with P. vivax, P. ovale and/or P. malariae.  
Three lines ‘C’, ‘T1’ and ‘T2’ appear in the results window. 
C T1 T2 T3
 P. falciparum infection with or without mixed infection with P. vivax, P. ovale and/or P. malariae.  
Three lines ‘C’, ‘T1’ and ‘T3’ appear in the results window. 







107106 Malaria rapid diagnostic test perforMance – results of WHo product testing of malaria rdts: round 7 (2015–2016)
 P. falciparum infection with or without mixed infection with P. vivax, P. ovale and/or P. malariae.  
Four lines ‘C’, ‘T1’, ‘T2’ and ‘T3’ appear in the results window. 
C T1 T2 T3
 Non-P. falciparum infection (P. vivax, P. ovale, P. malariae) or mixed infection.  
Two lines ‘C’ and ‘T1’ appear in the results window. 
C T1 T2 T3
Invalid results:  No ‘C’ line appears in the results window. Repeat the test with a new RDT if no control line appears.
C T1 T2 T3
 
C T1 T2 T3
C T1 T2 T3
 
C T1 T2 T3
C T1 T2 T3
 
C T1 T2 T3
C T1 T2 T3
 
C T1 T2 T3
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145144 Malaria rapid diagnostic test perforMance – results of WHo product testing of malaria rdts: round 7 (2015–2016)
Annex 5: Introducing rdt-based malaria diagnosis  
into national programmes
Introduction of parasite-based diagnosis at small clinics and 
at village level for case management poses many challenges, 
not only of logistics but also in managing the health-seeking 
and health-providing behaviour of patients and health 
workers. These can be addressed by a clear, time-bound 
strategic plan covering planning, implementation, monitoring 
and evaluation of the diagnosis programme, which must begin 
well before RDTs are procured. Furthermore, funding for the 
programme must include a significant component for planning 
and coordination, sensitization, information, education and 
communication, training, quality assurance, monitoring, 
supervision and logistics, in addition to procurement. In 
the absence of such funding, much of the expenditure on 
RDTs will be wasted, and loss of confidence in RDT-based 
diagnosis can hinder strengthening of appropriate malaria 
case management. A focal person or persons should be 
available to coordinate the overall implementation plan and 
to ensure that the various agencies involved understand the 
process and their own roles.
Examples of successful wide-scale introduction of malaria 
RDTs by various national programmes and comprehensive 
technical guidance on achieving universal access to malaria 
diagnostic testing have been reported (14–15). Figures A5.1 
and A5.2 give examples of the steps and timelines for RDT 
implementation and budget components for a malaria diag-
nosis programme, respectively. These will have to be modified 
considerably for each programme.
Key challenges
Changing past thinking that “fever equals malaria  
unless proven otherwise”.
Introducing RDTs will disprove this statement. To have an impact on malaria 
diagnosis and treatment, RDTs must be seen to provide an accurate diagnosis 
by both health workers and patients, that is, they must be as good or better 
than those relied on previously. A health worker requires a good alternative 
to antimalarial medicines for the management of parasite-negative febrile 
patients. To achieve and maintain confidence in RDT-based diagnosis, a 
good quality assurance system must be in place. There must be satisfactory 
education of health workers and widespread community sensitization. 
Health workers should have understanding of other causes of fever in order 
to devise appropriate management algorithms for parasite-negative cases. 
Changing and enforcing regulatory requirements
At the national level, regulation might be required to control the importation 
and use of malaria RDTs, and new procedures for storage, distribution and 
inventory management, such as those used for medicines, might be necessary.






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































149148 Malaria rapid diagnostic test perforMance – results of WHo product testing of malaria rdts: round 7 (2015–2016)
Figure A5.2. Components of the budget for a malaria diagnosis programmea
Component Activities specific to microscopy
Activities specific to  
RDTs
Activities for  
management of malaria 
and non-malaria fevers
Preparation of technical guidelines, standard operating procedures and checklists
Guidelines Laboratory supervisionb RDT transport and storage Fever management algorithm
Standard operating procedures for 
diagnostic testing Microscopy performance RDT performance
Other tests used at primary 
care level
Other standard operating procedures Proficiency testing, validation of routine slide results RDT storage
Training material Training manual for microscopy Training manual for RDTs
Training manuals for 
integrated management of 
fevers
Checklists for supervision Laboratory visitsb Health facility visits
Procurement and supply of commodities
Diagnostic tests Microscopes and related supplies RDT kits
Urine dipsticks, haemoglobin 
meter, haematocrit meter, 
glucometer
Medicines Artemisinin-based combination therapy Antibiotics, zinc, inhaled salbutamol, rehydration salts
Other commodities Gloves, lancets, alcohol, cotton-wool, timers, sharps boxes
Distribution of commodities to the field All items listed above
Quality management system 
Pre-shipment testing Lot-testing
Training of focal people Quality management system for focal people
Monitoring the quality management 
system
Quality monitoring supervision visits and compilation of  
health information management data
Training of health workers
Training of tutors Expert microscopists Tutors for RDT performance outside laboratories and clinical management of fever cases
Training of health workers Microscopists Health workers Clinicians
Training of supervisors Laboratory supervisorsb Clinical supervisors
Supervision
Supervisory visits Laboratory visitsb Health facility visits
Advocacy, communication and social mobilization 
Design of strategies and material Communication on the need for malaria testing Communication on other causes of fever
Dissemination of key messages Through each delivery channel
Monitoring and evaluation
Updating the health information 
management system 
Add row for RDTs in laboratory report and column  
for malaria test results in clinicians’ book
Column for other test results 
in clinicians’ book
Train health workers in the new health 
information management system 
Training of person in charge or focal person for reporting on  
health information management in health facilities
a Adapted with permission (14)







149148 Malaria rapid diagnostic test perforMance – results of WHo product testing of malaria rdts: round 7 (2015–2016)
references
1. Gamboa D, Ho MF, Bendezu J, Torres K, Chiodini PL, Barnwell JW, et al. A large proportion of P. falciparum isolates in the 
Amazon region of Peru lack pfhrp2 and pfhrp3: implications for malaria rapid diagnostic tests. PLoS One, 2010:5:e8091.
2. Bharti PK, Chandel HS, Ahmad A, Krishna S, Udhayakumar V, Singh N. Prevalence of pfhrp2 and/or pfhrp3 gene deletion 
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